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ABSTRACT 
The purpose of this study was to discover antimalarial compounds from necrotropic plant 
pathogenic fungi. Various phytotoxins released by necrotropic plant pathogenic fungi may 
inhibit the plant-like metabolic pathways in the apicoplast, a chloroplast-like organelle, essential 
for the survival of apicomplexan parasites, such as Plasmodium which cause malaria in humans.  
This dissertation describes the isolation, characterization, and biological evaluation of secondary 
metabolites of eight fungal strains. In addition to the antiplasmodial assay, all the extracts were 
subjected to phytotoxic, antimicrobial, and cytotoxic bioassays. Isolation of metabolites was 
performed by chromatographic methods and identification was carried out by spectroscopic and 
spectrometric methods. Absolute configurations of the metabolites were determined by 
comparing specific rotation values, ECD spectra, or X ray crystallographic analysis.  
The dissertation consists of seven chapters. Chapter 1 describes the overview of the 
current malaria situation in the world and the rationale for using necrotropic plant pathogenic 
fungi to discover antimalarial leads. Protocols used for isolation and fermentation of endophytic 
fungi from infected plant parts, as well as those used for biological activities of fungal 
metabolites are described in Chapter 2. Chapters 3-6 describe the isolation and identification of 
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metabolites from the plant pathogenic fungi obtained from the American Type Culture 
Collection (ATCC) (Septoria pistaciarum, S. musiva, Phomopsis viticola, and Postia balsamea).  
Chapter 7 consists of four sections which describe the isolation and identification of 
active metabolites from four endophytic fungi (Xylaria sp., Alternaria sp., Botryosphaeria 
dothidea, and a new fungus, UM #10 M) isolated from the infected leaves and seeds of Torreya 
taxifolia.  
From these fungi, 40 compounds including 17 new natural products were isolated and identified. 
Thirteen compounds displayed antiplasmodial activity, 12 showed phytotoxicity, whereas all 13 
exhibited weak to moderate cytotoxicity towards mammalian cells. This indicates that 
cytotoxicity rather than inhibition of plant-like metabolic pathways in the apicoplast was 
probably responsible for the observed antiplasmodial activity.  
The antiplasmodial compounds with high selectivity indices, septoriamycin A and 19,20-
epoxycytochalasin C, were evaluated for antimalarial activity in a mouse model. Septoriamycin 
A showed no activity or toxicity, whereas 19,20-epoxycytochalasin C, exhibited toxicity and 
weak suppressive activity. 
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CHAPTER 1: INTRODUCTION 
ANTIMALARIALS FROM PLANT PATHOGENIC FUNGI 
 
1.1. Background and Significance 
 
Malaria is an infectious disease caused by apicomplexan parasites of the genus 
Plasmodium  that are transmitted to people through bites of infected Anopheles mosquitoes. This 
disease is endemic throughout the tropics, especially in sub-Saharan Africa and the developing 
world, threatening about 40% of the world’s population.1 More than  200 million cases of 
malaria and around 650,000 deaths, the majority of them African children, have been reported in 
2010.
1 
 
Human malaria is caused by Plasmodium falciparum, P. vivax, P. ovale, and P. malariae. 
P. falciparum and P. vivax are the most prevalent, and P. falciparum is responsible for the 
majority of mortality. P. vivax, P. ovale, and P. malariae cause a mild form of the disease, and P. 
knowlesi, a zoonosis, also rarely infects humans. Owing to the unavailability of effective 
vaccines, pharmacotherapy is still the only mode of therapy for malaria.
2
 Several drugs, synthetic 
and natural product-derived, are currently available for the treatment of malaria;
2, 3
 however, 
control of this disease is limited by drug resistance in the parasite and insecticide resistance in 
2 
 
the  mosquito vector.
3
 Resistance to all available drugs except artemisinin has been reported 
from many malaria endemic areas.  Recent studies indicate the emergence of strains in Cambodia 
also resistant to artemisinin derivatives.
4
 No new class of antimalarials has been approved since 
1996,
3
  therefore, there is an urgent need to develop drugs with new modes of action to counter 
this trend. 
 
1.2. The Apicoplast as an Antimalarial Drug Target 
 
The apicoplast is an organelle essential for the survival and viability of the apicomplexan 
parasites such as Plasmodium, Toxoplasma, Theileria, Babasia, and Eimeria (Figure 1.1). This 
organelle is similar to plastids found in the cells of photosynthetic organisms like algae and 
plants.
5
 Plastids are present in plants in several forms such as chloroplasts, leucoplasts, 
amyloplasts, and chromoplasts with the same genetic compliments.
6
 It is believed that 
apicomplexan parasites acquired the apicoplast by engulfment of an ancestral algae and retention 
of its plastid.
5
 Apicoplasts contain their own genome that encodes for prokaryotic protein 
synthesis (70 S ribosomes, tRNAs, RNA polymerase, and DNA gyrase) and a small number of 
proteins.
7
 Many biosynthetic pathways in apicoplasts, including heme and ion sulfur clusters, 
type II fatty acid synthase, and the non-mevalonate pathway for isoprenoids, are absent in the 
vertebrate hosts of parasites, but are similar to those present in the plastids of plants (Table 1.1).
5, 
6, 8
 Apicoplast function is essential for both erythrocytic and hepatic development of the 
plasmodia parasites in mammalian hosts;
7
 thus, metabolic pathways found in apicoplasts are 
good targets for antimalarial drug discovery.
5
 Research over the last decade has demonstrated a 
3 
 
number of validated targets in plant-like metabolic pathways in the apicoplast of malaria 
parasites.
5, 7, 9, 10
 
 
 
 
 
Figure 1.1. General features of apicomplexan cells
11
 
  
(Reprinted by permission from Nature Publishing Group) 
4 
 
Table 1.1.  Drugs and possible apicoplast targets
5, 10
 
 
Drug/herbicide Metabolic activity Putative target 
Ciprofloxacin DNA replication Plastid DNA topoisomerase II 
Clindamycin Protein translation Plastid 23S rRNA 
Erythromycin 
 
 
Azithromycin 
 
 
Spiramycin 
 
 
Thiostrepton 
 
 
Micrococcin 
 
 
Chloramphenicol 
 
 
Doxycycline 
 
Plastid 16S rRNA 
Tetracycline 
 
 
Amythiamicin 
 
Elongation factor Tu (thermo 
unstable) 
Rifampicin RNA transcription Plastid RNA polymerase β-subunit 
Fosmidomycin Isoprenoid biosynthesis DOXP reductoisomerase 
Thiolactomycin Fatty acid biosynthesis  Β-ketoacyl-ACP synthase (Fab H) 
Clodinafop Fatty acid biosynthesis Acetyl-CoA carboxylase (ACC) 
Triclosan Fatty acid biosynthesis  Enoyl-ACP reductase (Fab I) 
 
 
  
5 
 
 
Antibiotics such as azithromycin, doxycycline, clindamycin, tetracyclines, rifampicin, 
and fluoroquinolones which are used for prophylaxis and treatment of malaria in combination 
with other antimalarial drugs,
7
 have been reported to target apicoplast prokaryotic derived 
protein translation pathways.
5,7,12
 Isoprenoid biosynthesis of the apicoplast involves the non-
mevalonate pathway which is similar to that in bacteria, and is known as the 1-deoxy-D-
xylulose-5-phosphate (DOXP) or 2-C-methyl-D-erythritol-4-phosphate (MEP)pathway.
6
 Unlike 
in humans, these isoprenoids are prosthetic groups for many enzymes involved in apicoplast 
translation, synthesis of mitochondrial ubiquinones, protein prenylation, and the formation of 
dolichols which are also involved in membrane proteins of the parasite.
6
 Fosmidomycin, an 
inhibitor of DOXP reductoisomerase (IspC)  of isoprenoid biosynthesis in the apicoplast  has 
been reported to be effective in killing in the  intra-erythrocytic phase of the malaria parasite.
6
 
Tonhosolo et al.
13
 also reported the presence of carotenoid biosynthesis including the phytoene 
desaturase enzyme in the apicoplast of the intraerythrocytic stages of P. falciparum. Inhibition of 
parasite growth by the herbicide norflurazon, a phytoene desaturase inhibitor, and chemical 
rescue by lycopene clearly indicated that this pathway is also a potential target for antimalarial 
drug therapy.
13
 Recent findings of chemical rescue of blood stage P. falciparum lacking an 
apicoplast demonstrated that parasites also exclusively depend on the apicoplast for isoprenoid 
precursors, isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate  (DMAPP).14 In 
contrast to humans and other eukaryotes without plastids, the apicoplast of the malaria parasite 
uses bacterial type fatty acid II synthase for the synthesis of lipids required for its function and to 
form parasitoporous vacuoles (PV) for the invasion of host erythrocytes.
5
 Apicoplast fatty acid II 
synthase biosynthesis involves several distinct enzymes namely, acetyl-CoA carboxylase (ACC), 
6 
 
acyl carrier protein transacylase (FabD), β-ketoacyl-ACP synthase (FabH), β-ketoacyl-ACP 
synthase (FabB/F), β-ketoacyl-ACP reductase (FabG), β-hydroxyacyl-ACP dehydratase 
(FabZ/A) and trans-2-enoyl-ACP reductase (FabI).
15
 All these enzymes are potential targets for 
malaria drug discovery.
15, 16
 FabH inhibitors like cerulenin, platensimycin,
17
 thiolactomycin, and 
their analogues,
18
 and FabI inhibitors triclosan,
18
 and (E)-oroidin,
19
 many of these of natural 
origin, have been reported to have herbicidal and antimalarial activities.
5, 9
 Several attempts have 
also been made in designing and in silico screening of analogues of  triclosan,
16, 20
  and 
thiolactomycin,
18
 as well as flavonoid derivatives
21
 for the antimalarial FAS-II activity.  
The apicoplast of the malaria parasite also possesses a family of class II histone 
deacetylase (HDAC) proteins which are also present in other photosynthetic eukaryotes and 
primitive algae.
22
 The enzyme CpHDAC3 (Rpd3 super family classs II) catalyzes deacetylation 
of histone tails to promote epigenetic regulation and some cellular processes of the parasite.
22-24
 
Analogues of several known anticancer HDAC inhibitors, such as suberoylanilide hydroxamic 
acid (SAHA), SB 939, hydroxamic acid (TSA), and apicidin have shown activity against the 
malaria parasite, some at low nanomolar concentrations.
23, 25-30
  
It has been demonstrated that all these apicoplast specific pathways are important for its 
proper functioning. Plasmodium parasites exclusively depend on the apicoplast for isoprenoid 
precursors, and it is involved in establishing the parasitophorus vacuole in host cells and invasion 
of parasites in new host cells.
6, 9, 14
 Thus, plant-like metabolic pathways in the apicoplast are 
potential targets for malaria drug discovery. 
 
7 
 
 
1.3. Plant Pathogenic Fungi 
 
Fungi produce a variety of biologically active secondary metabolites with applications in 
agriculture and medicine.
31
  Endophytic fungi reside inter- and-/or intracellularly in  plants and 
their association can vary from latent pathogenesis to mutualistic symbiosis.
31,32
 Many 
endophytic fungi are inert phytopathogens which cause disease symptoms when the host plant is 
aged and/or stressed under various environmental conditions.
33
 Phytopathogenic fungi are 
ubiquitous in the plant kingdom and their diversity depends on the ecosystem and host species. 
Plant pathogenic fungi are grouped into three categories based on their mode of nutrition.
34, 35
 
Biotrophs derive their nutrients from the host plant without killing it, whereas necrotrophs  kill 
host plant cells to derive their nutrition.
34
 Hemi-biotrophs have an initial biotrophic phase and 
then gradually become necrotrophic.
35
 Some biotrophs have symbiotic as well as parasitic 
associations.
35
 Parasitic biotrophic fungi such as rusts, smuts, and mildew have a restricted host 
range.
35
 In general, necrotrophs have a broader host range than biotrophs.
36
 
 
The invasion of host cells by necrotrophic fungi with appressoria and haustoria is 
initiated by active penetration of the surface by germinating fungal spores in favorable 
environmental conditions.
37
 The fungi release degradative enzymes such as pectinases, 
cellulases, proteases, and toxins to kill host cells.
37
 Wood-rotting pathogenic fungi preferentially 
attack living trees and rapidly depolymerize the cell wall components of internal, vascular, and 
cambium tissues.
34
 Host cells activate plant defense mechanisms by releasing phytoalexins, 
antifungal pathogenesis related proteins (PR’s), and oxidative enzymes.38 The spread of the 
8 
 
pathogen is controlled by an effective host defense mechanism;
39
 however, most of the plant 
pathogenic fungi (necrotrophs) can overcome the host defense mechanisms and derive nutrition 
by killing the neighboring cells. According to Schulz and Boyle’s hypothesis39 (Figure 1.2), as 
long as fungal virulence and host defense are balanced, colonization remains asymptomatic.
39
 
When the balance is disturbed by environmental factors or by senescence in favor of the fungus, 
disease develops.
39
 Pathogenesis is associated with the amount of phytotoxin produced by the 
pathogen.   
 
Figure 1.2. Host-fungi interaction
39
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Degradative enzymes and/or toxins released into host cells by necrotrophic fungi cause 
necrotic lesions, chlorosis, wilting, and finally death of plant parts.
40
  Necrotrophic disease is 
recognized by patches of dead black tissues and identified by different names such as 
anthracnose, blight, canker, scab, leaf spot, fruit rot, heart rot, butt rot, root rot, and shot hole.
34
 
Unlike biotrophs, necrotrophs can survive in the absence of their host cells and thus can be 
cultivated in an artificial media to isolate the biologically active lead molecules. 
 Some natural and synthetic phytotoxic compounds have been shown to target the plant-
like metabolic pathways in the plastid of plants, indicating their potential as inhibitors of  
metabolic pathways in the apicoplast of malaria parasites.
41
   
 
1.4. Fungi as a Source of Antimalarials 
 
Natural products have been used as antimalarial drugs or pharmacophores in designing 
potent analogues. Quinine, artemisinin, doxycycline, clindamycin, and azithromycin are some of 
the currently used malaria drugs that have been isolated from plants or microorganism.
42
  Fungal 
metabolites have several advantages over plant secondary metabolites: large scale preparation of 
metabolites can be carried out without disturbing biodiversity; optimization can be done using 
genetic engineering approaches; and results can be obtained in a short time, in many cases in less 
than one month, reducing the cost and time of drug development processes. Endophytic fungi, 
including necrotrophic plant pathogenic fungi, have yielded a number of metabolites with a 
variety of biological activities including antimalarial activity;
31
 however, antimalarial fungal 
10 
 
metabolites may also act on targets other than those in the apicoplast such as cytosolic targets 
(dihydrofolate reductase inhibitors), food vacuole targets (haemozoin inhibitors), and membrane 
targets (biosynthesis and transport of phospholipids).
5, 43
 
Recently, several antimalarial compounds have been isolated and identified from fungi 
and some of these compounds can be considered potential therapeutic agents. A Scifinder 
Scholar
® 
survey on antimalarials reported from endophytic, insect pathogenic, and plant 
pathogenic fungi showed a number of active compounds. These compounds are chemically 
diverse and showed varying degrees of antiplasmodial and cytotoxic activities (Table 1.2 & 
Figure 1.3). Of these compounds, radicicol (30) was moderately active in vivo at 40 mg/kg and 
heptelidic acid (31) showed hemolysis at this dose. 
 
Table 1.2.  Antimalarials reported from fungi 
Fungi Compounds Activity/µM  Cytotoxicity Ref. 
Menisporopsis theobromae Menisporopsin A (1) 5.0 Cytotoxic 44 
Menisporopsis theobromae  Dithiodiketopiperazine (2) 2.95 Weak 45 
Cordyceps brunnearubra  Cordyformamide (3) 18 Weak 46 
Paecilomyces cinnamomeus  Paecilodepsipeptides (4) 4.9 Cytotoxic 47 
Hirsutella nivea  Hirsutatins B (5) 8.2 Not toxic 48 
Phomopsis sp. Phomoxanthones A (6) 
Phomoxanthones A (7) 
0.14 
0.44 
Cytotoxic 
Cytotoxic 
49 
Favolaschia tonkinensis 9-Methoxystrobilurin B (8) 
9-Methoxystrobilurin G (9) 
0.85 
0.06 
Weak to 
moderate 
50 
Cordyceps militaris Cordycepin (11) 17.8 Not reported 51 
11 
 
 
 
Geotrichum sp. Dihydroisocoumarin (12) 8.4 Not reported 52 
Hirsutella kobayasii  Hirsutellide A (13) 4.2 Non toxic to 
vero 
53 
Kionochaeta pughii  Pughiinin A (14) 
Picnidione (15) 
6.7 
0.5 
Not toxic 
Cytotoxic 
54,55 
 
Microsphaeropsis sp.  Preussomerins (16) 2.3 Cytotoxic 56 
Xylaria sp.  (-)-Depudecin (17) 
(+)-Phaseolinone (18) 
(+)-Phomenone (19) 
19,20-Epoxycytochalasin Q 
(20) 
4.7 
1.7 
1.2 
1.1 
Cytotoxic 
Cytotoxic 
Cytotoxic 
Cytotoxic 
 
 
57 
Sclerotinia homoeocarpa Tetranorditerpenoids (21) 0.1 Cytotoxic 58 
Rhizina sp.  Chromanone derivatives 
(22) 
14.7 Moderate 59 
Berkleasmium nigroapicale  Berkleasmin (23) 5.4 Cytotoxic 60 
Torrubiella luteorostrata  Pyrone diterpene (24) 8.1 Cytotoxic 61 
Penicillium sp.  Brefeldin A (25) 3.9 Cytotoxic 62 
Myrothecium verrucaria Macrocyclic trichothecenes 
 Roridin E acetate (26) 
 
0.0001 
 
Cytotoxic 
 
63 
Cordiceps nipponica  Cordypyridones A (27) 
Cordypyridones B (28) 
0.23   
0.13    
Weak 
 Weak 
64 
Streptomyces sp. 
Humicola  sp.  
Soil fungus- FO-4443 
Nanomycin A (29) 
Radicicol (30) 
Heptelidic acid (31) 
0.03 
0.02 
0.04 
Weak 
Weak 
Weak 
65, 66 
67 
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Figure 1.3: Antimalarial compounds reported from fungi 
 
15 
 
1.5. Aims and Objectives of the Thesis 
 
Malaria, an infectious disease caused by Plasmodium parasites, is a major cause of 
morbidity and mortality in tropical parts of the world. Control of this disease is hampered by 
drug resistance. No new class of antimalarial drug has been approved since 1996.  
The overall aim of this project is to search for antimalarial compounds from necrotrophic 
plant pathogenic fungi based on the rationale that certain phytotoxins biosynthesized by this 
class of fungi may inhibit plant-like metabolic pathways in the apicoplast, an essential organelle, 
of the apicomplexan parasites including Plasmodium. 
 
Main objectives were:  
1.5.1. Procurement of necrotrophic plant pathogenic fungi  
1.5.2. Culture and extraction of fungi  
1.5.3. Evaluation of fungal extracts for herbicidal and antiplasmodial activities 
1.5.4. Bioassay guided fractionation of active extracts and isolation of compounds responsible 
 for biological activity. 
1.5.5. Identification of actives compounds 
1.5.6. Evaluation of promising active compounds in animal models 
16 
 
 
 
 
 
CHAPTER 2: MATERIALS AND METHODS 
 
The overall approach of this research project as summarized in Figure 2.1 was to search for 
antimalarial actives from necrotrophic plant pathogenic fungi based on the rationale that some 
phytotoxins released by these fungi may inhibit plant-like metabolic pathways in the apicoplast, 
an essential organelle, of the apicomplexan parasites. 
 
2.1. Sources of Necrotrophic Plant Pathogenic Fungi 
 
ATCC (American Type Culture Collection): The ATCC database was searched for fungi 
which caused leaf spot, fruit rot, heart rot, butt rot, and root rot diseases in plants and the 
available organisms were purchased.  
Plant pathology labs: Identified plant pathogenic fungi were obtained from the Biological 
Control of Pests Research Unit, USDA-ARS, Stoneville, MS 38677, USA and the Center for 
Bottomland Hardwoods Research, USDA-Forest Service, Southern Hardwoods Laboratory, 
Stoneville, MS 38677, USA. 
17 
 
Fresh necrotropic plant-pathogenic fungal isolates from infected plant: Leaves which 
showed cell death (leaf spots) due to fungal infections were collected from cultivated plants and 
fungi were isolated from infected leaf areas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.  The overall design of the research approach 
Fermentation and extraction of metabolites 
Imidazo pyridine and pyrimidine derivatives   
 In vitro phytotoxicity assay In vitro antiplasmodial assay In vitro cytotoxicity assay 
Bioassay guided fractionation 
& structure elucidation 
 
 
         Phytopathogenic  fungi 
 
Imidazo pyridine and pyrimidine 
derivatives   
 
ATCC Plant pathology labs Fresh isolates  
New leads 
New targets 
In vivo antimalarial assay 
totoxicity assay 
New antimalarials 
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2.2. Isolation of Fungi from Infected Plant Materials 
 
Leaves of the infected plant, Torreya taxifolia Arnott, were obtained from Dr. Edward 
Croom. The plant species identity was determined by Dr. Croom following the taxonomic 
treatment in the Flora of North America 
(http://www.efloras.org/florataxon.aspx?flora_id=1&taxon_id=220013607).  
 
2.2.1. From Infected leaves 
 
The infected parts of leaves were surface-sterilized with 5% Clorox for 5 minutes and 
rinsed with sterile water (×3). Transverse sections from the dried leaf were cut aseptically into 
small portions and immersed into Potato Dextrose plates (PDA). Plates were incubated for two 
weeks and sub-cultured to PDA plates to isolate pure fungal strain. 
 
 2.2.2. From Infected seeds 
 
Infected seeds of T. taxifolia Arnott were furnished by Dr. Edward Croom,
 
Croomia, 
1509, Smallwood Dr., Oxford, MS, and isolation of fungi from those was performed by Dr. 
Luis Rosa, NCNPR, University of Mississippi. 
19 
 
 
2.3. Identification of Fungi 
 
DNA sequence analysis of fungi was carried out
68
 by Dr. N. Techen, NCNPR, 
University of Mississippi 
Preliminary identification of isolated fungi were mainly based on morphological features 
of colonies and DNA sequence analysis of internal transcribed spacer (ITS) regions of nuclear 
ribosomal DNA (nrDNA).  
  
2.4. In Vitro Culture and Extraction of Plant Pathogenic Fungi 
 
Pure fungal isolates were grown in PDA plates at 27 ºC for 5-7 days. For preliminary 
assays, fungi were cultured in 2 conical flasks (1 L) containing 500 mL of potato dextrose broth 
and incubated at 27 ºC for 2 weeks, 3 weeks, and 4 weeks respectively,  on an orbital shaker. 
Culture medium was separated by filtration and mycelium and broth were extracted with EtOAc 
(× 3). Fungi which showed antiplasmodial activity were cultured in large scale (20 L, 40 L) 
media to obtain sufficient amount of extracts. If a fungal extract showed no activity in the 
antimalarial bioassay, then the fungus was cultured in three additional media selected from the 
following: 
1. PDB 
2. Modified Czapex Dox Broth  
3. Solid media (Rice) 
20 
 
4. V – 8 (100% vegetable juice) 
 
2.5 Evaluation of In vitro Antimalarial and Phytotoxic Activities of the Extracts 
 
Mycelium and broth extracts were subjected to in vitro antiplasmodial (10.0 mg each) and 
phytotoxic (1.0 mg of each) assays. Metabolites which inhibit plant-like metabolic pathways in 
the apicoplast should exhibit both antimalarial and phytotoxic activities. However, cytotoxic 
compounds also may show positive results in both of these assays. In order to identify these 
compounds, extracts were also simultaneously evaluated for cytotoxicity and selectivity indices 
(IC50 cytotoxicity / IC50 antiplasmodial activity). Active extracts with good selectivity indices 
(>10) were selected for bioassay-guided fractionation.   
2.6. Bioassay Guided Fractionation of Antimalarial Extracts, Isolation, and Structural 
Elucidation of Bioactive Metabolites. 
 
Active extracts were fractionated using chromatographic methods. A suitable stationary 
phase was selected on the basis of the chemical profile of the extract. For preliminary 
fractionation, gel filtration, reversed-phase, or normal phase column chromatography was used. 
Further separation of active fractions was carried out by the same methods and also by 
preparative TLC and HPLC. Structure elucidation of active compounds was carried out by 
spectroscopic/spectrometric methods (UV/Visible, IR, 
1
H, 
13
C, NMR, COSY, NOESY/ROESY, 
HMQC, HMBC, and HRMS).  Absolute configuration was determined by comparing specific 
rotation values, ECD spectra, or X ray crystallography.  
21 
 
Out of the broth and mycelia extracts of 60 plant pathogenic and endophytic  fungi 
screened in different culture media, the extracts as shown in Table 2.1 showed good 
antiplasmodial and herbicidal activities. Among them the following fungal strains were selected 
for further isolation and characterization of bioactive metabolites 
1. Septoria pistaciarum (Chapter 3 & 4) 
2.  Septoria. musiva (Chapter 5) 
3. Phomopsis viticola (Chapter 5) 
4. Postia balsamea (Chapter 6) 
5. Xylaria sp. (Chapter 7 section 1) 
6. Alternaria sp. (Chapter 7 section 2) 
7.  UM #10 M (new isolate) (Chapter 7 section 3) 
8. Botryosphaeria dothidea (Chapter 7 section 4) 
These extracts were also screened for antimicrobial and antileishmanial activities. 
Among those, some of plant pathogenic fungal extracts (Sclerotinia homeocarpa, Gleosporium 
minus, Elsinoe corni, Resinium bicolor) and an unidentified endophytic fungus (# 1 A) isolated 
from cultivated Torreya taxifolia Arnott showed good antimicrobial activities.  
 
2.7. Preparation of Culture Media 
 
2.7.1. Potato Dextrose Broth (PDB) 
24.0 g of PDB powder (Difco
TM
) 
1.0 L of distilled water 
22 
 
PDB powder and a magnet was added to an Erlenmeyer flask (1L) containing 1 L of distilled 
water and heated at boiling point on a stirrer for about 15 minutes.  The solution was divided 
into two Erlenmeyer flasks (500 mL).  Flasks were covered with Aluminum foil and then 
autoclaved at 121 
ο
C for 15 minutes. 
 
2.7.2. Modified Czapex Dox Broth 
  
Czapex Dox 35 g 
Yeast 1.5 g 
Malt extract 1.5 g 
All ingredients were dissolved in 1 L of distilled water and autoclaved at 121 
0
C for 15 minutes.  
 
2.7.3. Solid Media (Rice) 
  
Rice (long grain) 100 g 
Distilled water 60 mL  
Rice was mixed with distilled water in an Erlenmeyer flask and was allowed to stand for 2 
hours. Then it was autoclaved at 121 
ο
C for 45 minutes.  After 24 hours, flasks were re-
autoclaved under the same conditions, and allowed to cool to room temperature.  Fungi 
inoculated into PDB media were used to inoculate these solid media.  
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2.7.4.   V-8 ( 100% vegetable juice) 
  
V-8 100 mL  
PDB 12 g 
CaCO3 1.5 g 
All ingredients were dissolved in 1 L of distilled water and autoclaved at 121 ºC for 15 minutes. 
 
2.7.5. Potato Dextrose Agar (PDA) plates 
 
39.0 g of PDA powder (Difco
TM
) 
1.0 L of double deionized (DDI) water 
PDA powder with a small magnet was added to an Erlenmeyer flask (2L) containing 1 L of 
distilled water and heated at boiling point on a stirrer for about 15 minutes.  The solution was 
divided into two Erlenmeyer flasks (500 mL). The flasks were covered with aluminium foil and 
then autoclaved at 121 
ο
C for 15 minutes. This media were used to pour into sterilized 
petridishes and allowed to solidify over 5 minutes. 
24 
 
 
 
Table 2.1. Antiplasmodial and herbicidal activity of plant pathogenic fungi extracts 
 
Fungi 
 
Medium 
  
Antiplasmodial activity IC 50 (ng/mL) Cytotoxicity 
(Vero)  
IC 50  (ng/mL) 
  
Phytotoxicity 
P. falciparum D6  SI P. falciparum W2  SI Lettuce Bentgrass 
Septoria pistaciarum  (Broth + 
mycelium) 
Czapex 
Dox 1200 3.1 1400 2.6 3700 5 5 
S. musiva  (Broth + Mycelium ) 
Czapex 
Dox 720 4.2 570 5.3 3000 5 5 
Postia balsamea (Broth) PDB 1800 25 1400 32.1 45000 5 5 
Phomopsis viticola (Broth ) PDB 11000 >4.3 10000 >4.8 NC NT NT 
Phomopsis viticola (Broth ) V8 1200 >39.7 1200 >39.7 NC NT NT 
Phomopsis viticola (Broth) 
Czapex 
Dox 570 83.5 400 119 47600 5 5 
Sclerotinia homoeocarpa (Broth) PDB 700 28.6 1300 15.4 20000 5 5 
Amylostereum ferreum (Broth) PDB 3000 >15.9 2300 >20.7 NC NT NT 
Amylostereum laevigatum (Broth) PDB 2400 >19.8 1700 >28 NC NT NT 
 
2
4
 
25 
 
 
 
Antiplasmodial assay:  NC = not cytotoxic , NT = not tested , S. I. (selectivity index) = IC50 for cytotoxicity /IC50 for 
antiplasmodial activity, IC50: concentration causing 50% growth inhibition, Phytotoxicity assay: Concentration (mM) = 1 
mg/mL, Ranking based on scale of 0 to 5, 0 = no effect, 5 = no growth 
 
 
 
Botryosphaeria dothidea (Broth) PDB 860 37.2 1300 24.6 32000 5 5 
 Xylaria sp  (Broth) PDB 62 3.3 87 2.3 200 5 5 
UM #10 M  (Broth) PDB 40 170 44 154.5 6800 5 5 
Alternaria sp. (Broth + 
Mycelium) PDB 6800 1.8 5800 2.1 12000 5 5 
2
5
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2.8. Preparation of Stock Solution (10 % RPMI Buffer Solution) for Long Term Storage of 
Fungi 
 
2.8.1. RPMI (Roswell Park Memorial Institute) Buffer Preparation 
 
Powdered medium of RPMI 1640 without sodium bicarbonate (10.4 g) was mixed with 
34.5 g of MOPS (3-(N-Morpholino)propanesulfonic acid) buffer in a beaker (1L) and dissolved 
in 750 mL of DDI water. The pH was adjusted to 7.0 with 0.1M NaOH and DDI water was 
added and stirred to bring the total volume to 1.0 L.  RPMI BUFFER was filtered using a 0.45 
micron filter unit to sterilize and stored at 4 ºC. 
 
2.8.2. 10% Glycerol/RPMI Buffer Stock Solution 
 
90 mL of RPMI buffer (Stock buffer stored at 4 
ο
C) and 10 mL of glycerol were vortexed 
for 2 minutes.  It was filtered using Nalgene
®
 (NYL) filter unit, (0.45 micrones, 250 mL), and 
stored at 4 
0
C. 
 
2.8.3. Inoculum Stock Solution 
 
50 µL of inoculum was added to 1 mL of 10% RPMI buffer/glycerol stock solution in a 5 
mL round bottom tube, vortexed and stored at 4 
ο
C. 
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2.8.4. Select Isolate for Storage 
 
Fungal spores were scraped from the PDA plates (4-5) with sterilized DDI water. Spore 
suspension was filtered through a mirror cloth and collected into a polypropylene conical tube, 
mixed with a vortex and stored at 4 
ο
C. After 24 hours, supernatant was removed.  5 mL of 10% 
glycerol/ RPMI buffer stock was added on to spores and vortexed for 2 minutes.  0.5 mL conidial 
suspension was added into each cryogenic vial and stored at -80 
ο
C.  
 
2.9. Evaluation of Pure Compounds for In Vitro Biological Activities 
 
Pure compounds (2.0 mg each) were submitted to the National Center for Natural 
Products Research (NCNPR) for screening of antimalarial, cytotoxic, antimicrobial (antifungal 
and antibacterial), and antileishmanial activities.   
2.9.1. In Vitro Antiplasmodial Screening  
 
This assay was performed by Dr. S. Khan, NCNPR. University of Mississippi 
The antiplasmodial activity of extracts, fractions, and pure compounds was performed against D6 
(chloroquine sensitive) and W2 (chloroquine resistant) strains of P.  falciparum using the in vitro 
assay as reported.
69
 The 96-well microplate assay was based on evaluation of the effect of 
compounds/extracts on growth of asynchronous cultures of P. falciparum, determined by the 
assay of parasite lactate dehydrogenase (pLDH) activity. The appropriate dilutions of the 
compounds /extracts were prepared in DMSO or RPMI-1640 medium and it was added to the 
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cultures of P. falciparum (2% hematocrit, 2% parasitemia) set up in clear flat bottomed 96 well 
plates. The plates were placed into the humidified chamber and flushed with a gas mixture of 
90% N2, 5% CO2, and 5% O2. The cultures were incubated at 37 
ο
C for 72 hours. The growth of 
the parasite in each well was determined by pLDH assay using Malsatat® reagent. The medium 
and RBC controls were also set-up in each plate. In addition to the P. falciparum strains, samples 
were tested against mammalian kidney cell line (Vero) as an indicator of general cytotoxicity.  
The selectivity indices (SI) – ratio of Vero IC50 to D6 or W2 IC50 – were calculated.   
Artemisinin and chloroquine were used as the positive controls while DMSO was the negative 
control. IC50 values were computed from the dose response curves using Microsoft Excel 
software. 
2.9.2. In Vitro Phytotoxicity Activity 
 
This assay was performed by Dr. S. Duke, USDA-ARS, University of Mississippi. 
Herbicidal or phytotoxic activity of extracts and test compounds was performed via the 
published procedure
70
 using bentgrass (Agrostis stolonifera) and lettuce (Lactuca sativa cv. L., 
Iceberg), in 24-well plates. Test compounds (1 mg each) were dissolved in 100 µL of acetone 
and a 20 µL aliquot of each solution was pipetted onto the filter paper and dried for 30 min under 
airflow in a sterile biohazard hood. Water (200 µL) was added after placing the dried and sample 
impregnated filter paper in the well. The solvent controls were treated identically, using the 
solvent described above. Phytotoxicity was ranked visually. The ranking of phytotoxic activity 
was based on a scale of 0 to 5 with 0 showing no effect and 5 no growth. 
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2.9.3. In Vitro Antimicrobial Activity 
 
This assay was performed by Dr.  M. Jacob, NCNPR, University of Mississippi. 
All organisms were obtained from the American Type Culture Collection (Manassas, 
VA) and include the fungi Candida albicans ATCC 90028, C. glabrata ATCC 90030, C. krusei 
ATCC 6258, Cryptococcus neoformans ATCC 90113 and Aspergillus fumigatus ATCC 90906 
and the bacteria Staphylococcus aureus ATCC 29213, methicillin-resistant Staphylococcus 
aureus ATCC 33591 (MRS), Escherichia coli ATCC 35218, Pseudomonas aeruginosa ATCC 
27853, and Mycobacterium intracellulare ATCC 23068. Susceptibility testing was performed 
using a modified version of the CLSI methods
71, 72
 as described.
73
 M. intracellulare and A. 
fumigatus growth were monitored using Alamar Blue
TM
 (Bio-Source International, Camarillo, 
CA). Samples dissolved in DMSO were serially diluted using 0.9% DMSO and transferred in 
duplicate to 96 well flat bottom microplates. Microbial inocula were prepared by diluting saline 
suspensions of colonies with assay broth to afford recommended colony forming units/mL. 
Growth (saline only), solvent and blank (media only) controls were included on each test plate. 
The drug controls ciprofloxacin (ICN Biomedicals, Ohio) for bacteria and amphotericin B (ICN 
Biomedicals, Ohio) for fungi were included in each assay.  All organisms were read at either 630 
nm using the EL-340 Biokinetics Reader (Bio-Tek Instruments, Vermont) or 544ex/590em (M. 
intracellulare,  A. fumigatus) using the Polarstar Galaxy Plate Reader (BMG Lab Technologies, 
Germany) prior to and after incubation. The MIC (minimum inhibitory concentration) was 
defined as the lowest test concentration that allowed no detectable growth. 
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2.9.4. In Vitro Antileishmanial Assay 
 
This assay was performed by Dr. B. L. Tekwani, NCNPR, University of Mississippi. 
The in vitro antileishmanial activity of the isolated compounds was carried out on a culture of 
Leishmania donovani promastigotes and axenic amastigotes by the Alamar Blue assay as 
described.
74
 In a 96 well microplate the samples with appropriate dilution were added to the 
leishmania promastigotes/axenic amastigote culture (2×10
6
 cell/mL). The compounds were 
tested at six concentrations ranging from 40 to 0.0128 µg/mL. The plates were incubated at 26 
C for 72 hours (37 C for amastigote) and growth of leishmania promastigotes/ amastigotes was 
determined. IC50 and IC90 values were computed from the dose response curves.  Pentamidine 
and amphotericin B were used as standard antileishmanial agents.  
 
2.9.5. In Vitro Macrophage Amastigote Assay 
 
This assay was performed by Dr. B. L. Tekwani, NCNPR, University of Mississippi. 
A recently developed
75
 promastigote rescue assay by  Jain et al. was used. The THPI 1 
cells (Human acute monocytic leukemia cell line) were maintained in RPMI1640 medium 
supplemented with 10% fetal bovine serum (FBS).  The cells were prepared prior to each assay 
and suspended in RPMI1640 medium with 10 % FBS at the cell density of 2.5 X10
5
 cells/mL. 
Phorbol 12-myristate 13-acetate (PMA) was added to the cell suspension to achieve final 
concentration of 25 ng/mL and cells were seeded onto a clear flat-bottom 96 well plate with 200 
µL (5×10
4
 cells) into each well.  The plate was incubated in a 5% CO2 incubator at 37 C for at 
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least 12 hours for differentiation of the THP1 cells to adherent macrophages. After overnight 
incubation the medium from each well was discarded and adherent cells were gently washed at 
least twice with serum free RPMI1640 medium. The Leishmania donovani promastigotes culture 
was harvested at the stationary phase (metacyclic infective stage) and suspended into RPMI1640 
medium with 2% FBS at the density of 2.5×10
6 
cells/mL. The 200 µL of promastigotes (5×10
5
) 
culture was added to each well. The plate was further incubated in a 5% CO2 incubator at 37 C 
for at least 24 hours to allow infection of macrophages with the Leishmania parasites. After 24 
hours the non-adherent macrophages and unattached Leishmania promastigotes were washed off 
with serum free RPMI1640 medium. The infected macrophages were further incubated at 37 C 
and 5% CO2 in 200 µL RMPI1640 medium and 2% FBS with different concentrations of 
standard antileishmanial drugs (pentamidine & amphotericin B) or the test compounds for 48 
hours. The control wells with medium, uninfected THP1 cells, infected cells without drugs or 
test compounds were set up simultaneously. The cultures were washed off with serum free 
RPMI1640 and treated for 30 seconds with 20 µL of 0.05% sodium dodecyl sulfate in 
RPMI1640 medium for the release of amastigotes from the infected macrophages. To each well 
180 µL of RPMI1640 medium with 10% FBS was added and the plate was further incubated at 
26 C for 48 hours to allow transformation of released amastigotes to promastigotes.  To each 
well 20 L of Alamar blue was added, the plates were incubated at 26 C for 24 hours and read 
on a BMG Fluostar microplate reader (BMG Lab Technologies) at excitation wavelength of 544 
nm and emission wavelength of 590 nm. Each compound was tested in duplicates at six 
concentrations, IC50 and IC90 values were computed from the dose response curves. 
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2.9.6. Assay for In Vitro Cytotoxicity  
 
This assay was performed by Dr. S. Khan, NCNPR, University of Mississippi. 
In vitro cytotoxicity was determined against a panel of mammalian cells that included 
kidney fibroblast (Vero), kidney epithelial (LLC-PK11), malignant melanoma (SK-MEL), oral 
epidermal carcinoma (KB), breast ductal carcinoma (BT-549), and ovary carcinoma (SK-OV-3) 
cells.
76
  The assay was performed in 96-well tissue culture-treated plates.  Cells were seeded to 
the wells of 96-well plate at a density of 25,000 cells/well and incubated for 24 h. Samples at 
different concentrations were added and plates were again incubated for 48 h. The number of 
viable cells was determined by using Neutral Red dye and IC50 values were obtained from dose 
response curves. Doxorubicin was used as a positive control. 
 
2.9.7. Evaluation of In Vivo Antimalarial Assay 
 
This assay was performed by Dr. B. L. Tekwani, NCNPR, University of Mississippi. 
Housing of the Animals-  The colony bred mice weighing 15 -20 g were used for maintaining 
the malaria parasite and also for screening of the test compounds for antimalarial activity.  The 
mice weighing 10-15 g were procured and kept under quarantine for one week. The animals were  
maintained on standard diet and water ad libitum and housed in solid bottom cages. Each cage 
had 6 mice and control and untreated mice were housed in separate cages in the same room. All 
the animal procedures were conducted under sterile conditions in the laminar flow hood.  
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Infection – A group of  three to five mice was  inoculated intraperitoneally or intravenously with 
the Plasmodium berghei infected mouse blood. The parasitemia was monitored from day 5 
onwards by preparation of blood smears  from a tail nick. These mice were  used as donor mice 
for infecting a larger batch of mice for in vivo testing. The mice with parasitemia >30%  were  
anesthetized by i.p. injection of ketamine/xylazine (8 mg and 1.2 mg/Kg). Blood was collected 
from the heart in sterile citrated saline. The blood counts were adjusted to 4×10
7
 infected 
erythroctes /500 µL by dilution with sterile normal saline. Each mouse  was inoculated 
intraparitoneally with 4×10
7
 P. berghei infected erythrocytes in 500 µL of sterile saline.    
 
Treatment –   The mice inoculated with P. berghei infected blood were divided into different 
groups with 6 animals in each group, housed in separate cages, were subjected to the treatment 
with the test compounds. For multiple dose studies three groups of mice were  administered with 
the test compounds at different dose levels (ranging between 1-100 mg/Kg) by oral route once 
daily for three days. The doses may be decided on the basis of prior information available with 
the compounds of similar class. In case of novel compounds in vitro cytotoxity data was used as 
the guide for dose selection. One group of postive control  was treated with chloroquine (30 
mg/Kg) while a group of 6 mice was treated with the vehicle.   
The mice were closely monitored for at least one hour after receiving the treatment and also at 
least once daily (for recording body weight, movement, and  behaviour) till their survival or up 
to 28 days post infection (the total duration of the experiment). Parasitemia was  monitored on 
day 5,7,10, 14, 21, and 28 post infection by preparing the blood smears from tail nick. The level 
of parasitemia and mean survival time were compared in treated and vehicle control groups. 
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Parasitemia was monitored by preparing the thin blood smears from the tail nick and staining 
with Geimsa stain. 
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CHAPTER 3: BIOACTIVE 1, 4-DIHYDROXY-5-PHENYL-2-PYRIDINONE 
ALKALOIDS FROM SEPTORIA PISTACIARUM   
 
Results presented in this chapter have been published in the following journal. 
 
Kumarihamy, M.; Fronczek, F. R.;  Ferreira, D.; Jacob, M.; Khan S. I.; Nanayakkara, N. P. D. 
Bioactive 1,4-dihydroxy-5-phenyl-2-pyridinone  alkaloids from Septoria pistaciarum  J. Nat. 
Prod. 2010, 73, 1250–1253 
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3.1. Summary 
 
Four new 1,4-dihydroxy-5-phenyl-2-pyridinone alkaloids (1-4) were isolated from an EtOAc 
extract of a culture medium of Septoria pistaciarum. The structures of these compounds were 
determined by spectroscopic methods, and the absolute configuration of the major compound (1) 
by X-ray crystallographic analysis. Compound 1 exhibited moderate in vitro antiplasmodial 
(antimalarial) activity against chloroquine-sensitive (D6) and -resistant (W2) strains of 
Plasmodium falciparum and cytotoxic activity to Vero cells. Compound 2 was moderately active 
against both methicillin-sensitive and methicillin-resistant strains of Staphylococcus aureus. 
 
3.2. Introduction 
 
Plant-like metabolic pathways found in the apicoplast,
10
 a chloroplast-like organelle of 
Plasmodium species, have been identified as suitable targets in malaria drug discovery.  A 
number of herbicides and phytotoxins with known molecular targets in the plastid have been 
evaluated for antimalarial activity.
77,78,41
 Various phytotoxins released by plant pathogenic fungi 
are known
79,80,81 
to
 
inhibit metabolic pathways in the apicoplast.
82
 As part of our ongoing search 
for potential sources of new antimalarial compounds, we have screened a number of plant 
pathogenic fungi for antiplasmodial activity.  
Septoria pistaciarum (Ascomycetes) is the causative agent of Septoria leaf and fruit spot 
disease in pistachio (Pistachia vera) in the US
83
 and Mediterranean countries.
84
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An EtOAc extract of this fungus showed potent herbicidal activity and moderate 
antiplasmodial activity against Plasmodium falciparum albeit with low selectivity index. No 
previous chemical work has been reported for this species. Structurally diversed chemical 
compounds namely, septorine,
85
 N-methoxyseptorine,
85
 N-methoxyseptorinol (substituted 
pyrazines),
86
 dihydroisocoumarins,
87
 mycophenolic acid,
87
 and mycosporins
88
 have been 
reported from the culture medium of the phytopathogenic fungus Septoria nodorum Berk., a 
parasite of wheat. Cordipyridones isolated from the insect pathogenic fungus Cordiceps 
nipponica have shown potent antimalarial activity with moderate selectivity.
64
  
Bioassay-guided fractionation of the EtOAc extract led to the isolation of a new 1,4-
dihydroxy-5-phenyl-2-pyridinone analogue as the active compound. Three additional new but 
inactive analogues of the same class were also isolated and identified. Several compounds of this 
class such as tenellin, bassianin, funiculosin, sambutoxin, oxysporidinones, cordipyridones, 
farinosones, and TMC-69  have been isolated from a number of fungal species and have shown 
antibacterial,
89,90
 antitumor,
90
 antifungal,
89,91
 and neurotrophic
92
 activities.  
 
3.3. Results and Discussion 
 
Compound 1 was isolated as the major active constituent of the EtOAc extract of S.  
pistaciarum.  The molecular formula of 1 was determined as C22H29NO4 by HRESIMS.  The 
1
H 
NMR (Figures 3.1 & 3.2) and COSY spectrum (Figure 3.3) displayed six hydrogens in the 
aromatic region consisting of a one-proton singlet and an A2B2C system due to a 
monosubstituted phenyl group. The 
13
C NMR spectra (Figures 3.4 & 3.5) confirmed the presence 
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of 22 carbon atoms, which comprised five quaternary, 11 methine, two methylene, and four 
methyl carbons. NMR signals in the aromatic region showed close resemblance to those of the 
1,4-dihydroxy-5-phenyl-2-pyridinone moiety of the antitumor agent, TMC-69-6H, and its 
analogues.
90
 IR absorptions (3109, 1642 and 1556 cm
-1
) and UV maxima (207.1, 241.0, and 
296.0 nm) of 1 were consistent with those reported for a compound with a 1,4-dihydroxy-2-
pyridinone moiety.
64
 In its HMBC spectrum (Figure 3.6), H-2′ and H-6′ (7.49) showed cross 
peaks with C-3′ and C-5′ (C128.6), C-4′ (C127.9), C-1′ (C133.4), and C-5 (C114.2), and 
H-6 (7.69) with C-2 (C158.0), C-4 (C161.4), C-5 (C114.2), and C-1′ (C133.4) 
supporting the partial structure of the substituted pyridinone ring moiety. In the aliphatic region, 
the 
1
H NMR spectrum showed two doublets representing two oxymethine hydrogens, and four 
methyl resonances, comprising three doublets and a triplet. The 
1
H NMR data additionally 
indicated the presence of a tetrahydropyrano ring attached to C-3 of the pyridinone ring similar 
to TMC-69-6H.
90
 The H-7 oxymethine doublet (4.72) showed cross peaks in the HMBC 
spectrum with C-4 (δC 161.4), C-2 (δC 158.0) C-3 (δC 110.4), C-11 (δC 89.9), C-9 (δC 42.2), C-8 
(δC 36.8), and C-15 (δC 17.5).  The H-11 oxymethine doublet at 3.07 similarly displayed 
HMBC correlations with C-7 (δC 81.4), C-9 (δC 42.2), C-12 (δC 35.6), C-13 (δC 22.1), C-16 (δC 
17.5), and C-17 (δC 17.2). The methyl triplet at 0.98 showed HMBC cross peaks with C-12 (δC 
35.5) and C-13 (δC 22.0) confirming its ω location in the chain. These correlations strongly 
suggested the gross structure 1 depicted for this compound. The HMBC correlations of other 
proton resonances and COSY correlations further supported this structure (Figure 3.7).   
 
The relative configuration of compound 1 was determined by the 
1
H NMR coupling 
constants and ROESY (Figure 3.9) data. A 
3
J7,8  value of 10.2 Hz suggested that H-7 and H-8 
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were trans-diaxially orientated. A 
3
J10,11 value of 10.2 Hz similarly indicated the trans-diaxial 
arrangement of H-10 and H-11. The lack of three-bond coupling of H-11 and H-12 may reflect a 
C-11 - C-12 conformation having H-11 and H-12 orthogonally oriented in order to minimize Van 
der Waals interaction between the C-10 and C-11 alkyl groups. In the ROESY spectrum H-7 
displayed interactions with H-11 and CH3-15 indicating the cofacial orientation of the three 
groups. Similarly, H-11 showed interactions with H-7 and CH3-16 (Figures 3.7 & 3.8).  
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Table 3.1. NMR Data for Compounds 1-4 in CDCl3- Methanol-d4 
 
 
 
Position 1 2 3 4 
δC
b
 δH 
a 
(J in Hz) δC
b
 δH
a 
(J in Hz) δC
b
 δH
a
 (J in Hz) δC
b
 δH
a
 (J in Hz) 
2 158.0  158.0  158.0  158.0  
3 110.4  111.8  111.7  111.7  
4 161.4  161.8  161.8  161.7  
5 114.2  114.3  114.4  114.3  
6 131.8 7.69, s 132.9 7.43, s 133.0 7.42, s 133.4 7.44, s 
7 81.4 4.72, d (10.2) 81.3 4.73, d (10.2) 81.4 4.72, d (10.2) 81.5 4.75, d (10.2)  
8 36.8 1.88, m 36.9 1.87, m 36.8 1.88, m 36.8 1.88, m 
9 42.2 1.82, dt (13.2, 
3.6) 
1.12, q (12.6) 
42.2 1.83, dt (13.2, 3.6) 
1.14, q (12.6) 
42.1 1.82, dt (13.2, 3.6) 
1.13, q  (12.6) 
42.0 1.85 
1.13, q (12.6) 
10 32.6 1.76, m 32.6 1.75, m 32.6 1.76, m 32.7 1.71, m 
11 89.9 3.07, d (10.2) 89.9 3.07, d (10.2) 89.8 3.08, d (9.6) 89.6 3.10, d (10.2) 
12 35.6 1.66, m 35.6 1.65, m 30.1 1.96, m 30.4 1.61, m 
13 22.1 1.02, m 
1.56, m 
22.1 1.00, m 
1.54, m 
32.3 1.23, m 
1.74, m 
28.4 1.21, m 
1.61, m 
14 12.8 0.90, t (7.2) 12.8 0.88, t (7.2) 61.0 3.56, brq (9.0) 
3.71, m 
63.0 4.02, m 
4.13, m 
15 17.5 0.73, d (6.6) 17.8 0.88, d (6.6) 17.7 0.86, d (6.6) 17.8 0.88, d (6.6) 
16 17.5 0.84, d (6.6) 17.5 0.83, d (6.6) 17.6 0.84, d (6.6) 17.3 0.85, d (6.6) 
17 17.2 0.98, d (6.6) 17.1 0.96, d (6.6) 17.4 0.97, d (7.2) 17.6 1.00, d (6.6) 
1′ 133.4  133.4  133.3  133.0  
4
0
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a1
H NMR spectra recorded at 600 MHz. 
b13
C NMR spectra recorded at 100 MHz. 
2′,6′ 129.3 7.49, d (7.8) 129.2 7.45, d (7.2) 129.2 7.42, d (7.8) 129.3 7.45, d (7.2) 
3′,5′ 128.6 7.43, t (7.8) 128.6 7.40, t (7.8) 128.5 7.38, t (7.8) 128.6 7.40, t (7.2) 
4′ 127.9 7.35, t (7.2) 127.8 7.33, t (7.8) 127.8 7.13, t (7.8) 128.0 7.34, t (7.2) 
OH  9.72, s  9.69, s  9.66, s  9.49, s 
OCH3   65.0 4.01, s 65.0 4.03, s 65.1 4.05 
COCH3       21.1 2.01, s 
COCH3       171.8  
4
1
 
 
3
9
 
 
42 
 
 
 
Figure 3.1.
 1
H NMR spectrum of 1  
 
 
 
Figure 3.2. Expansion of 
 1
H NMR spectra of 1  
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Figure 3.3. COSY spectrum of 1 
 
 
 
Figure 3.4. 
13
C NMR spectrum of 1  
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Figure 3.5. DEPT spectrum of 1  
 
 
Figure 3.6. HMBC spectrum of 1 
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Key COSY ( ) correlations 
 
 
Key HMBC ( ) correlations 
 
 
 
Key ROESY ( ) correlations 
 
Figure 3.7. COSY, HMBC, and ROESY correlations of 1 
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Figure 3.8. ROESY spectrum of 1 
 
This compound afforded crystals that were suitable for crystallographic analysis. On the 
basis of Cu K X-ray diffraction data, the absolute configuration of compound 1 was assigned as 
7R, 8R, 10S, 11R, and 12R. The solid-state structure contains four independent molecules, one of 
which is illustrated in Figure 3.9. All four have an intramolecular OH...O hydrogen bond to the 
tetrahydropyran oxygen, with O...O distances in the range 2.5771(19) to 2.5930 (19) Å. The four 
molecules differ only slightly in conformation, except for that about the bond joining the 
heterocyclic and phenyl rings, for which C-C-C-C torsion angles vary from -50.5(3)º to +44.(3)º. 
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Figure 3.9.  Single-crystal X-ray structure of 1, showing the absolute   
configuration of one of the four independent molecules 
 
Compound 2 had a molecular formula of C23H31NO4 as determined by HRESIMS. The 
1
H 
(Figure 3.10) and 
13
C NMR (Figure 3.11) spectra were similar to those of compound 1 except for 
the presence of an O-methyl resonance in the spectra of the former. This indicated that 
compound 2 was an O-methyl analogue of compound 1. The COSY (Figure 3.12), HMQC 
(Figure 3.13) and HMBC spectra (Figure 3.14) of compound 2 showed correlations identical to 
those observed for compound 1. Additionally, the O-methyl resonance showed no cross peaks in 
the HMBC spectrum whereas the OH proton (δH 9.69) correlated with C-3 (δC 118.8), C-4 (δC 
161.8) and C-5 (δC 114.2) suggesting that the O-methyl group was located on the nitrogen. The 
up-field shift of H-6 of compound 2 relative to that of compound 1 is consistent with the 
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structural modification. Identical coupling constants and ROESY correlations indicated that 
compounds 1 and 2 have the same relative configuration.  
 
 
Figure 3.10. 
1
H NMR spectrum of 2  
 
 
 
Figure 3.11.
 13
C NMR spectrum of 2  
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Figure 3.12. COSY spectrum of 2 
 
 
 
Figure 3.13. HMQC spectrum of 2 
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Figure 3.14. HMBC spectrum of 3 
 
The molecular formula of compound 3 was established as C23H31NO5 by HRESIMS. Its 
1
H-NMR spectrum (Figure 3.15) was similar to compound 2, the major differences being the 
replacement of the methyl triplet by two diastereotopic oxymethylene hydrogens in the spectrum 
of 3. This suggested that compound 3 was the C-14 oxygenated analogue of 2. Comparison of 
the 
13
C NMR data (Figure 3.16) of these compounds also confirmed the replacement of a methyl 
by an oxymethylene group in 3.  The COSY spectrum of compound 3 (Figure 3.17) displayed 
cross peaks between the C-14 oxymethylene (δH 3.58, 3.73) and C-13 methylene protons (δH 
1.23, 1.75). The COSY correlations for the rest of the hydrogen resonances were identical to 
those of compound 2. In the HMBC spectrum (Figure 3.18) the oxymethylene protons showed 
cross peaks with C-13 (δC 32.3) and C-12 (δC 30.1). The remaining HMBC correlations were 
identical to those observed for compound 2. These observations suggested that compound 3 was 
the C-14 hydroxy analogue of 2. ROESY correlations and coupling constants of H-7, H-9, and 
51 
 
H-11 of compound 3 were identical to those observed for compound 1 indicating that these two 
compounds had the same relative configuration. 
 
 
Figure 3.15. 
1
H NMR spectrum of 3 
 
  
 
Figure 3.16. 
13
C NMR spectrum of 3 
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Figure 3.17. COSY spectrum of 3 
 
 
Figure 3.18. HMBC spectrum of 3 
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The molecular formula of compound 4 was determined by HRESIMS as C25H33NO6. The 
1
H (Figure 3.19) and 
13
C NMR (Figure 3.20) spectra, COSY (Figure 3.21), and HMBC (Figure 
3.22) correlations of this compound were similar to those observed for compound 3. Major 
differences involved the presence of an additional methyl singlet (δH 2.01) and two carbon 
signals [δC 21.2 (CH3), 171.8 (CO)] in its 
1
H and 
13
C NMR spectra, respectively. The down-field 
shift of proton signals due to the C-14 oxymethylene group and HMBC correlations between 
these protons and the acetyl carbonyl carbon indicated that compound 4 was the 14-O-acetyl 
analogue of compound 3.  
 
 
 
Figure 3.19. 
1
H NMR spectrum of 4 
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Figure 3.20. 
 13
C NMR spectrum of 4  
 
Figure 3.21. COSY spectrum of 4 
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Figure 3.22. HMBC spectrum of 4 
 
Since the pyridinone analogues 1-4 presumably share a common biosynthetic origin 
involving an aromatic amino acid and an activated polyketide,
93
 analogues 2, 3, and 4 also 
possess 7R, 8R, 10S, 11R, 12R absolute configuration. Such an assumption is supported by the 
fact that all four compounds are strongly dextrorotatory. 
 The in vitro antiplasmodial activities of compounds 1-4 are summarized in Table 3.2. 
Compound 1 demonstrated strong antiplasmodial activity whereas compounds 2-4 were inactive. 
The selectivity index of antiplasmodial activity was calculated based on their cytotoxicity to 
mammalian kidney fibroblasts (Vero cells) determined in parallel experiments. Compound 1 was 
moderately cytotoxic to Vero cells.   
 Compound 2 exhibited moderate activity against both methicillin-sensitive and 
methicillin-resistant Staphylococcus aureus (Table 3.3). The cytotoxic potential of these 
compounds was further evaluated against a panel of solid tumor cell lines (SK-MEL, KB, BT-
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549, SK-OV-3) and kidney epithelial cells (LLC-PK11) (Table 3.4). Compound 1 showed 
moderate cytotoxicity against all the cell lines while compound 2 was inactive. The presence of 
an N-hydroxy group appears to be essential for the activity of these compounds. It is interesting 
to note that a free N-hydroxy group was also a prerequisite for the activity of cordypyridones, a 
group of 1,4-dihydroxy-2-pyridinone alkaloids, with moderate antiplasmodial activity previously 
reported from fungus Cordyceps nipponica.64  
 
3.4. Bioactivity Results 
 
Table 3.2.  Antiplasmodial activity of 1-4  
 
 
Compound  Chloroquine-sensitive 
(D6)-clone 
Chloroquine-resistant  
(W2)-clone 
Cytotoxicity 
to Vero cells 
 IC50 (nM)     S.I. IC50  (nM)     S. I. IC50 (nM) 
1 0.07    5.0 0.07     5.4 0.38 
2 NA  NA  NC 
3 NA  NA  NC 
4 NA  NA  NC 
chloroquine
a
 0.03  0.31  NC 
artemisinin
a
 0.02  0.01  NC 
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a 
Positive controls 
NC:  not cytotoxic  
NA:  not active  
S. I. (selectivity index) = IC50 for cytotoxicity/IC50 for antiplasmodial activity 
 
 
Table 3.3. Antifungal and antibacterial activity of 1-2. 
 
 
IC50 and MIC (minimum inhibitory concentration, the lowest test concentration that allows no 
growth) values are in µM. 
NA: not active. 
NT: not tested. 
 
 
 
 
Compound 
Candida 
albicans 
Aspergillus 
fumigatus 
Staphylococcus 
aureus 
MRSA 
 IC50 MIC IC50 MIC IC50 MIC IC50 MIC 
1 32.5 NT 23.5 NT NA NA NA NA 
2 NA NA NA NA 7.24 12.98 7.76 12.98 
amphotericin B 0.45 2.70 1.16 12.6 NT NT NT NT 
ciprofloxacin NT NT NT NT 0.27 0.75 0.15 0.75 
58 
 
 
Table 3.4. Cytotoxic activity [IC50 (µM)] of compounds 1-2 
 
 
NA: not active.  
a 
Positive control 
 
3.5. Experimental  
3.5.1. General  
 
  Melting points were measured with a Uni-melt, Thomas Hoover capillary melting point 
apparatus. Optical rotations were measured using a Rudolph Research Analytical Autopol IV 
automatic polarimeter model 589-546. UV and IR spectra were recorded on a Varian-50 Bio UV 
visible spectrophotometer and a Bruker-Tensor-27 infrared spectrophotometer, respectively.  
NMR spectra were recorded on a Varian-Mercury-plus-400 or Varian Unity-Inova-600 
spectrometer using CDCl3/methanol-d4 as the solvent unless otherwise stated. MS analyses were 
performed on an Agilent Series 1100 SL equipped with an ESI source (Agilent Technologies, 
Palo Alto, CA, USA). Column chromatography was carried out on Merck silica gel 60 (230-400 
Compound SK-MEL KB BT-549 SK-OV-3 LLC-PK11 Vero 
1 4.04 13.46 4.45 7.0 4.4 3.77 
2 NA NA NA NA NA NA 
doxorubicin
a
 11.03 2.48 1.47 2.2 1.1 >0.9 
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mesh). Preparative TLC was carried out using silica gel GF plates (20 X 20 cm, thickness 0.25 
mm). 
3.5.2. Fermentation, Extraction, and Isolation 
 
 Septoria pistaciarum Caracc. (ATCC 22201) was obtained from the American Type 
Culture Collection, Manassas, VA and grown in potato dextrose agar plates at 27 ºC for 12 days. 
An Erlenmeyer flask containing 100 mL of potato dextrose broth was inoculated with small agar 
pieces (0.25 in × 0.25 in) and were incubated at  27 ºC
 
 for 7 days on a shaker (RPM = 100). This 
seed culture was used to inoculate  20 × 1L Erlenmeyer flasks each containing 500 mL of M-2 
medium, (modified Czapex Dox medium : Czapex Dox 35.0 g, yeast extract 1.5 g, malt extract 
1.5 g in 1L of distilled H2O) and were incubated at 27 ºC 
 
 for 28 days on a shaker (RPM = 100). 
The culture broth and mycelia were extracted with EtOAc (×3) and the organic layer was 
evaporated under reduced pressure to give an oily residue (5.2 g).  
The oily extract (5.0 g) was chromatographed over Sephadex LH -20 and eluted with 
CHCl3/MeOH (20:80) to give 12 fractions. Fractions 3, 4, 5, 6, and 7 showed antiplasmodial 
activity (IC50 < 529 ng/mL). Fractions 3, 4, and 5 were combined and chromatographed over a 
reversed phase C18 column eluting with a gradient 10% to 100% MeOH / H2O to yield five 
fractions.  Subfraction 4 was further purified by crystallization from MeOH and CH2Cl2 to give 
compound 1 as white crystals (53.0 mg). Combined fractions 6 and 7 were chromatographed 
over a silica gel column using CH2Cl2/hexanes as the eluent to give 10 subfractions. Subfraction 
7 was further purified by Sephadex LH-20 (MeOH) followed by preparative TLC (2% MeOH in 
CH2Cl2) to give compound 2 (20.0 mg) and compound 3 (12.0 mg).  Subfraction 4 was 
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chromatographed over reversed phase C18 eluting with CH3CN / H2O (40:60) to give compound 
4 (3.0 mg).  
Compound 1: white crystals (CH2Cl2/MeOH);  mp 220 
0
C; [α]26D +201 (c, 0.4, CH3OH); 
UV (MeOH) λmax (log ε) 207.1 (3.78),  241.0 (3.75), 296.0 (3.03) nm; IR (CHCl3 ) max  3109, 
2963, 2927, 1642, 1556, 1454, 1225 cm
-1
;  
1
H and 
13
C NMR data (see Tables 1 and 2); 
HRESIMS [M - H]
-
 m/z 370.2012 (calcd for (C22H29NO4 - H)
-
, 370.2018 ). 
 Compound 2: amorphous; [α]26D +15 (c, 0.375, MeOH); UV (MeOH) λmax (log ε) 207.1 
(2.15),  241.0 (1.96), 297.0 (0.88) nm; IR (CHCl3 ) max  3318, 2917, 1686, 1047 cm
-1
;    
1
H and 
13
C NMR data (see Tables 1 and 2); HRESIMS [M + H]
+
 m/z 386.2423 (calcd for (C23H31NO4 + 
H)
 +
, 386.2331).  
 Compound 3: amorphous; [α]26D +190 (c, 0.6, MeOH); UV (MeOH) λmax (log ε) 205.0 
(3.61), 241.0 (3.46), 290.0 (2.72) nm;  IR (CHCl3 ) max  3212, 2929, 2341, 1647, 1557, 1456, 
1057  cm
-1
;  
1
H and 
13
C NMR data (see Tables 1 and 2); HRESIMS [M + H]
+
 m/z  402.236 (calcd 
for (C23H31NO5+H)
+
, 402.228) . 
 Compound 4: amorphous:  [α]26D +47 (c, 0.25, MeOH); UV (MeOH) λmax (log ε) 205.0 
(2.56), 241.0 (2.69) nm; IR (CHCl3 ) max   3331, 2925, 2853, 1736, 1647, 1227, 1053 cm
-1
;   
1
H 
and 
13
C NMR data (see Tables 1 and 2); HRESIMS [M + Na]
+
 m/z 466.2307 (calcd for 
(C25H33NO6 + Na)
+
, 466.2205). 
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3.5.3. Crystallographic Data for Compound 1 
 
 X-ray data were collected at low-temperature (90 K) on a Bruker Kappa Apex-II diffractometer 
equipped with graphite-monochromated CuK ( = 1.54178 Å) source, yielding 14,467 
independent data to max = 69.0º. Crystals were monoclinic, space group P21, with a = 
11.1427(9), b = 13.0004(10), c = 28.073(2) Å,  = 90.430(5)º, Z = 8. Refinement of the model 
containing four independent molecules resulted in R = 0.038 for 1015 parameters. Resonant 
scattering, principally from the O atoms, resulted in a Flack
94
 parameter X = 0.01(9) and a 
Hooft
95
 parameter Y = 0.09(5) for 6739 Bijvoet pairs. This corresponds to a probability of 1.000 
that the illustrated configuration is correct. 
 
3.5.4. Biological Assay 
 
3.5.4.1. Antimicrobial Assay 
 
All organisms were obtained from the American Type Culture Collection (Manassas, 
VA) and include the fungi Candida albicans ATCC 90028, C. glabrata ATCC 90030, C. krusei 
ATCC 6258, Cryptococcus neoformans ATCC 90113 and Aspergillus fumigatus ATCC 90906 
and the bacteria Staphylococcus aureus ATCC 29213, methicillin-resistant Staphylococcus 
aureus ATCC 33591 (MRS), Escherichia coli ATCC 35218, Pseudomonas aeruginosa ATCC 
27853, and Mycobacterium intracellulare ATCC 23068. Susceptibility testing was performed 
using a modified version of the CLSI methods
72,71
 as described by Samoylenko et al.
73
  The drug 
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controls ciprofloxacin (ICN Biomedicals, Ohio) for bacteria and amphotericin B (ICN 
Biomedicals, Ohio) for fungi were included in each assay. 
 
3.5.4.2. Antiplasmodial Assay  
 
In vitro antiplasmodial activity was determined against D6 (chloroquine sensitive) and 
W2 (chloroquine resistant) strains of Plasmodium falciparum as described earlier.
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3.5.4.3. Cytotoxicity Assay 
 
In vitro cytotoxicity was determined against a panel of mammalian cells that included 
kidney fibroblast (Vero), kidney epithelial (LLC-PK11), malignant melanoma (SK-MEL), oral 
epidermal carcinoma (KB), breast ductal carcinoma (BT-549), and ovary carcinoma (SK-OV-3) 
cells.
76
  The assay was performed in 96-well tissue culture-treated plates.  Cells were seeded to 
the wells of 96-well plate at a density of 25,000 cells/well and incubated for 24 h. Samples at 
different concentrations were added and plates were again incubated for 48 h. The number of 
viable cells was determined by using Neutral Red dye and IC50 values were obtained from dose 
response curves. Doxorubicin was used as a positive control. 
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CHAPTER 4: ANTIPROTOZOAL AND ANTIMICROBIAL COMPOUNDS FROM THE 
PLANT PATHOGEN SEPTORIA PISTACIARUM   
 
Some of the results presented in this chapter have been published in the following journal. 
 
Kumarihamy, M.; Khan, S. I.; Jacob,
 
M.; Tekwani, B. L.; Duke, S. O.; Ferreira,
 
D.; 
Nanayakkara, N. P. D.
 
Antiprotozoal and antimicrobial compounds from the plant pathogen 
Septoria pistaciarum, J. Nat. Prod. 2012, 75, 883-889. 
 
4.1. Summary 
 
Four new 1,4-dihydroxy-5-phenyl-2-pyridinone alkaloids, 17-hydroxy-N-(O-
methyl)septoriamycin A (1), 17-acetoxy-N-(O-methyl)septoriamycin  A (2), 13-(S)-hydroxy-N-
(O-methyl)septoriamycin A (3) and 13-(R)-hydroxy-N-(O-methyl)septoriamycin A  (4), together 
with the known compounds (+)-cercosporin (5), (+)-14-O-acetylcercosporin (6), and (+)-di-O-
acetylcercosporin (7), lumichrome, and brassicasterol were isolated from an ethyl acetate extract 
of a culture medium of Septoria pistaciarum. Methylation of septoriamycin A (8) with 
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diazomethane yielded three di-O-methyl analogues, two of which existed as mixtures of 
rotamers. We previously reported in vitro antimalarial activity of septoriamycin A. This 
compound also exhibited significant activity against Leishmania donovani promastigotes and 
amastigotes. Compounds 5-7 showed in vitro activity against L. donovani promastigotes, 
chloroquine-sensitive (D6) and -resistant (W2) strains of Plasmodium falciparum, methicillin-
sensitive and methicillin-resistant strains of Staphylococcus aureus, Mycobacterium 
intracellulare, Candida glabrata, and moderate cytotoxicity against a panel of cell lines. 
Compounds 5, 6, and 7 also exhibited moderate phytotoxic activity against both a dicot (lettuce, 
Lactuca sativa) and a monocot (bentgrass, Agrostis stolonifera).   
   
4.2. Introduction 
 
Phytotoxins from plant pathogenic fungi may act as inhibitors of plant-like metabolic 
pathways in the apicoplast, a chloroplast-like organelle, essential for  the survival of plasmodium 
species.
41
 Previously we reported
96
 the isolation and identification of the 2-pyridinone alkaloid, 
septoriamycin A
97
 (8) and three of its derivatives from the causative agent of septoria leaf spot 
disease in pistachio, Septoria pistaciarum (Ascomycetes), as part of our program to identify 
antimalarial compounds from plant pathogenic fungi. Although we detected several minor 
alkaloids of the same class in the original extract, their structural elucidation was not possible 
due to insufficient quantities. In order to isolate the minor compounds, we recultured the same 
fungus under the identical conditions at a larger scale. In the ethyl acetate extract of this 
fermentation culture broth, a series of pigments with 2-pyridinone alkaloidal architecture were 
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detected. The extract showed herbicidal, antimicrobial, antiplasmodial, and antileishmanial 
activities albeit with low selectivity indices. From this extract, four more new minor 
septoriamycin A analogues, 17-hydroxy-N-(O-methyl)septoriamycin A (1), 17-acetoxy-N-(O-
methyl)septoriamycin A (2), 13-(S)-hydroxy-N-(O-methyl)septoriamycin A (3), and 13-(R)- 
hydroxy-N-(O-methyl)septoriamycin A (4), in addition to the parent and its previously reported 
analogues were identified. Septoriamycin A (8), the major 2-pyridinone alkaloid in this extract 
showed significant antileishmanial activity in addition to its reported antiplasmodial activity. The 
pigments were identified as three known perylenequinones, (+)-cercosporin (5),
98
 (+)-14-O-
acetylcercosporin (6),
98
 and (+)-di-O-acetylcercosporin (7).
99
 These pigments have previously 
been identified as phytotoxins produced by a number of phytopathogenic Cercospora species 
and have been linked to their pathogenicity.
100
 Their biosynthesis appeared to be controlled by 
numerous environmental and physiological factors and the presence of even small amounts of 
certain compounds in the medium was found to have a strong stimulatory or inhibitory effect on 
their production.
100, 101
 Their ability to generate reactive oxygen species in the presence of light 
has been attributed to their phytotoxic activity.
100
 Cercosporin and its esters have also been 
reported to have antibacterial and antifungal
102
 activities as well as growth inhibitory effects on 
lettuce
98 
and tomato seeds.
102
 In this study, the perylenequinones showed antileishmanial, 
antiplasmodial, and cytotoxic activities in addition to antibacterial and antifungal activities. Two 
more known compounds, lumichrome (11),
103
 and brassicasterol (12)
104
 were also isolated and 
identified.  
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4.3. Results and Discussion 
 
Fractionation of an EtOAc extract of a culture medium of S. pistaciarum by Sephadex 
LH-20 gel column chromatography followed by purification using silica gel and RP C18 
chromatography afforded four minor 2-pyridinone alkaloids 1-4 in addition to the known 
septoriamycin A (8) and its three derivatives,
96
 three known perylenequinones (+)-cercosporin 
(5), (+)-14-O-acetylcercosporin (6), (+)-di-O-acetyl-cercosporin (7), lumichrome (11), and 
brassicasterol (12). 
The molecular formula of compound 1 was determined as C23H31NO5 by HRESIMS. UV 
maxima (205.0, 240.9, and 297.0 nm) and IR absorptions (3400, 3207, 1647, and 1555 cm
-1
) of 1 
were consistent with those of a 2-pyridinone moiety.
96
 The aromatic regions of the 
1
H NMR 
(Figure 4.2) and COSY (Figure 4.3) spectra were similar to those observed for 5-phenyl-2-
pyridinones previously isolated from this species, and  consisted of a one-proton singlet and an 
A2B2C spin system due to a monosubstituted phenyl group.
96
 The aliphatic region exhibited two 
oxymethine and two methyl doublets indicating the presence of a 2,4-dimethyltetrahydropyran 
moiety and an N-methoxy group (Figure 4.3). 
HMBC (Figure 4.4) correlations of H-2′ and H-6′ (H7.43) with C-3′ and C-5′ 
(C128.6), C-4′ (C127.8), C-1′ (C133.3), and C-5 (C114.5), and H-6 (H7.44) with C-2 
(C158.0), C-4 (C161.9), C-5 (C114.5), and C-1′ (C133.3) supported the partial structure of 
the substituted pyridinone ring moiety. HMBC correlations of the H-7 oxymethine doublet (H 
4.73) with C-4 (C161.9), C-2 (C158.0), C-3 (C111.6), C-11 (C86.3), C-9 (C36.4), C-8 
(C39.8), and C-15 (C17.8) supported the partial structure of the tetrahydropyran moiety. The 
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major difference in the rest of the 
1
H NMR resonances of compound 1 and the reported
96
 N-(O-
methyl)septoriamycin A (9) is the replacement of the methyl doublet in the chain attached to C-
11 of the tetrahydropyran ring by two diastereotopic oxymethylene hydrogens. This indicated 
that compound 1 was the C-17 oxygenated analogue of 9. The COSY spectrum of compound 1 
displayed cross peaks between the C-17 oxymethylene (H 3.60, 3.49) and C-12 methine proton 
(H1.87). In the HMBC spectrum the oxymethylene protons showed cross peaks with C-11 (C 
86.3), C-12 (C 36.5), and C-13 (C 22.3), and the H-11 oxymethine doublet at 3.36 with C-7 
(C81.2), C-9 (C36.4), C-12 (C), C-13 (C), C-16 (C), and C-17 (C63.6) 
further confirming that compound 1 was 17-hydroxy-N-(O-methyl)septoriamycin A. (Figure 4.1) 
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    Lumichrome (11)       brassicasterol (12) 
 
   Figure 4.1.  Structure of compounds 1 - 12 
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Figure 4.2.
 1
H NMR spectrum of 1  
 
 
Figure 4.3. COSY spectrum of 1 
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Figure 4.4. 
13
C NMR spectrum of 1  
 
 
 
Figure 4.5. HMBC spectrum of 1 
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Figure 4.6. ROESY spectrum of 1 
 
The HRESIMS data established the molecular formula of compound 2 as C25H33NO6. 
The 
1
H (Figure 4.7) and 
13
C NMR spectra (Figure 4.8) were similar to those of 1 except for the 
presence of additional resonances [( 2.06) C 21.1 (CH3), C 171.2 (CO)] originating from an 
O-acetyl group. HMBC (Figure 4.9) correlations between the C-12 oxymethylene group and the 
acetyl carbonyl carbon indicated that compound 2 was 17-O-acetyl-N-(O-methyl)septoriamycin 
A. The remaining HMBC and COSY (Figure 4.10) correlations were identical to those of 
compound 1.  Both 
3
J7,8  and 
3
J10,11 values were 10.2 Hz indicating that these protons are trans – 
diaxially oriented. ROESY correlations of compound 1 (Figures 4.6 & 4.11) and 2 were identical 
to those observed for septoriamycin A (8) suggesting that these two compounds had the same 
relative configurations. Since we have previously assigned the absolute configuration of 
septoriamycin A on the basis of X-ray diffraction data,
96
 and all these compounds presumably 
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share a common biosynthetic origin, compounds 1 and 2 also have 7R, 8R, 10S, 11R, and 12R 
absolute configuration.  It is further supported by their dextrorotatory specific rotations.   
 
Figure 4.7.
 1
H NMR spectrum of 2  
 
 
 
Figure 4.8.
 13
C NMR spectrum of 2  
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Figure 4.9. HMBC spectrum of 2 
 
Figure 4.10. COSY spectrum of 2 
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Key COSY ( ) correlations  
 
 
 
 
Key HMBC ( ) correlations 
 
 
 
Key ROESY ( ) correlations 
 
Figure 4.11. COSY, HMBC, and ROESY correlations of 1. 
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The HRESIMS data of 3 established its molecular formula as C23H31NO5. Comparison of 
1
H NMR (Figure 4.12), 
13
C NMR (Figure 4.13), COSY (Figure 4.14), and HMBC (Figure 4.15) 
data of 3 with those of 8 showed that the major difference was the replacement of a methyl triplet 
(H) of the latter by a methyl doublet (Hand an oxymethine doublet (
former. These changes could be attributable to the substitution of one of the C-13 diastereotopic 
methylene hydrogens  in 8 with a hydroxy group indicating that compound 3 is the 13-hydroxy 
analogue of N-(O-methyl)septoriamycin A (9). The methyl doublet at H (17-CH3) showed 
HMBC cross peaks with C-11 (C), C-12 (C), and C-13 (C) and the oxymethine 
multiplet at H with C-11 (C), C-12 (C), and C-17 (C15.9) confirming the C-13 
location of the secondary hydroxy group and, thus, compound 3 was 13-hydroxy-N-(O-
methyl)septoriamycin A.  
 ROESY (Figure 4.16) data
 
and
 1
H NMR coupling constants of compound 3 showed close 
correlations to those reported
96 
for septoriamycin A (8).  Our attempts to determine the absolute 
configuration at C-13 by Mosher analysis were unsuccessful. Treatment of compound 3 with the 
R- and S-Mosher’s acid chlorides afforded a mixture not worth resolving.  Methylation prior to 
acylation also yielded a mixture of products. The absolute configuration of compound 3 was 
proposed by a 
3
J12, 13   - based comparison of compounds 3 and 4 (Figure 4.17). 
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Figure 4.12. 
1
H NMR spectrum of 3  
 
 
Figure 4.13.
 13
C NMR spectrum of 3  
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Figure 4.14.
 
COSY spectrum of 3 
 
 
Figure 4.15. HMBC spectrum of 3 
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Figure 4.16. ROESY spectrum of 3 
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 Figure 4.17. Rotamer representation of 3 and 4 
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Compound 4 had the same molecular formula, C23H31NO5, as that of 3 based on 
HRESIMS data. The 
1
H NMR (Figure 4.18) and 
13
C NMR (Figure 4.19) spectra of these 
compounds were similar except for the down-field shift of the oxymethine proton (  4.20) and 
the up-field shift of a methyl doublet (H 1.00). The COSY (Figure 4.20) and HMBC (Figure 
4.21) spectra of 4 showed the same correlations as those observed for 3 suggesting that both 
compounds have the same gross structure. Identical coupling constants and ROESY (Figure 
4.22) correlations for the protons in the tetrahydropyran moiety indicated that they had the same 
relative configuration except at C-13. Since compounds 3, 4, and 8 presumably share a common 
biosynthetic origin, compounds 3 and 4 also have 7R, 8R, 10S, 11R, 12R absolute configuration.  
As described earlier for compound 3, our attempts to determine the absolute configuration of the 
C-13 stereogenic center by Mosher analysis were unsuccessful. Thus, we used a J-based 
approach relying on 
1
H NMR coupling constants combined with ROESY correlations, to assign 
the C-13 absolute configuration of compounds 3 and 4. An observed 
3
J12, 13 value of 7.2 Hz of 3, 
suggested a dihedral angle of ca 30
o
 or 150
o
 between H-12 and H-13. Eight rotamers are possible 
for 3 with these dihedral angles for the S (3a – 3d) and R (3e -3h) epimers (Figure 4.17). 
Observed ROESY correlations between H-12 and H-13, H-13 and CH3-17, and CH3-14 – CH3-
17 ruled out all conformers except 3a as the probable most abundant rotamer for compound 3 in 
solution indicating a 13S absolute configuration.  Similarly, an observed 
3
J12, 13 of 1.0 Hz for 4 
supported the fact that the dihedral angle between H-12 and H-13 was 90
0
 as shown in Figure 
4.17 for the 13R (4a - 4b) and S (4c – 4d) epimers.  In the ROESY spectrum, H-12 showed 
correlation with H-13 and CH3-14 and absence of interaction between CH3-14 and CH3 -17 
indicating 4a as the dominant rotamer and, hence, 13R as absolute configuration.   
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Figure 4.18. 
1
H NMR spectrum of 4  
 
 
   
Figure 4.19.
 13
C NMR spectrum of 4  
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Figure 4.20.
 
COSY spectrum of 4 
 
 
Figure 4.21. HMBC spectrum of 4 
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Figure 4.22. ROESY spectrum of 4 
 
Methylation of compounds 3 and 4 with diazomethane afforded several products. 
Treatment of septoriamycin A (8) with diazomethane as a model gave three products, whereas 
methylation with MeI and Cs2CO3 afforded a single compound which was identified as analogue 
9. The products of diazomethane methylation of septoriamycin A were separated by 
chromatography. All these products had the same molecular formula, C24H33NO4, by HRESIMS, 
suggesting that they were di-O-methyl derivatives. The 
1
H NMR (Figure 4.23) spectrum of the 
least polar compound (10a) was similar to that of 9 except for the presence of an additional O- 
methyl resonance in the former. The 
13
C NMR (Figure 4.24) spectrum of this compound showed 
changes in resonances in the pyridone ring. A down-field shift of C-4 (C indicated that the 
carbonyl group now resided at this carbon suggesting 10a was N,2-di-O-methylseptoriamycin A. 
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A hypsochromic shift of the UV absorption (max 278.9 nm) when compared to 9 (max 295 
nm)
105
 and COSY and HMBC correlations further supported this structure. 
 
Figure 4.23. 
1
H NMR spectrum of 10a  
 
 
Figure 4.24. 
13
C NMR spectrum of 10a  
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Table 4.1.  
1
H, and 
13
C, NMR data for compounds 1-4 in CDCl3/Methanol-d4. 
 1 2 3 4 
position δH
a
 (J in Hz) δC
b
 δH
a
 (J in Hz) δC
b
 δH
a
 (J in Hz) δC
b
 δH
a
 (J in Hz) δC
b
 
2  158.0  158.0  158.0  158.2 
3  111.6  111.4  112.0  112.0 
4  161.9  161.8  161.6  161.7 
5  114.5  114.3  114.5  114.8 
6 7.43, s 133.0 7.44, s 133.1 7.42, s 132.9 7.43, s 132.8 
7 4.73, d (10.2) 81.2 4.74, d (10.2) 81.3 4.70, d (10.2) 80.8 4.66, d (10.2) 80.9 
8 1.87, m 39.8 1.91, m 36.4 1.91, m 36.2 1.91, m 36.7 
9 1.34, q (12.6) 36.4 1.30, q (12.6) 36.5 1.06, q (12.6) 42.6 1.16, q (12.0) 42.2 
 1.98, brd (13.2)  2.00, (overlap)  1.80, dt (13.8, 3.6)  1.84, dt (13.2, 3.6)  
10 1.69, m 35.8 1.64, m 36.0 2.03, m 34.1 1.89, m 32.9 
11 3.36, d (10.2) 86.3 3.33, d (10.2) 86.2 3.14, d (10.2) 88.9 3.12, dd (10.2, 2.8) 88.5 
12 1.87, m 36.5 2.00, m 37.0 2.05, m 41.4 1.75, m 38.7 
13 1.02, m, 1.58, m 22.3 1.02, m, 1.55, m 22.3 3.78, m (7.2, 7.2) 68.9 4.20, m (6.6, 1.0) 66.0 
14 0.88, t (7.2) 12.6 0.89, t (7.2) 12.6 1.16, d (6.6) 23.1 1.16, d (6.3) 22.8 
15 0.91, d (6.6) 17.8 0.91, d (7.2) 17.7 0.85, d (6.6) 17.9 0.87, d (6.6) 17.9 
 
8
5
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a1
H NMR spectra recorded at 600 MHz, 
b13
C NMR spectra recorded at 100 MHz 
16 0.95, d (6.6) 17.1 0.97, d (7.2) 17.0 0.83, d (6.6) 17.7 0.84, d (6.6) 17.7 
17 3.49, dd (10.6, 3.6) 
3.60, dd (10.6, 3.6) 
63.6 3.91, dd (11.2, 5.4) 
3.98, dd (11.6, 4.5) 
65.3 0.93, d (7.2) 15.9 1.01, d (7.2) 10.5 
1′  133.3  133.4  133.4  133.7 
2′, 6′ 7.44, d (7.3) 129.2 7.44, d (7.3) 129.3 7.43, d (7.3) 129.2 7.43, d (7.3) 129.4 
3′, 5′ 7.39, t (7.2)  128.6 7.40, t (7.3) 128.6 7.38, t (7.8) 128.5 7.36, d (7.2) 128.6 
4′ 7.32, t (7.2) 127.8 7.34, t (7.3) 127.9 7.32, t (7.2) 127.7 7.30, t (7.2) 127.8 
OH 9.63, s  9.47, s  9.63, s  9.65, s  
OCH3 4.04, s 65.0 4.06, s 65.0 4.04, s 65.0 4.05, s 65.0 
COCH3   2.06, s 21.1     
COCH3    171.2     
 
84 
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Their 
1
H and 
13
C NMR spectra were similar to those of compound 9 but had an additional 
methoxy resonance. HMBC correlations showed that the additional methoxy group correlated to 
C-4 indicating that 10b was N,4-di-(O-methyl)septoriamycin A. At 100 
o
C in pyridine, 
duplicated 
1
H NMR (Figure 4.27) resonances coalesced but were restored to the original ratio 
when the temperature returned to ambient conditions (Figure 4.28). Atropisomers of 3-
cyclohexyl- or 3-cycloheptyl-N,4-dihydroxy-2-pyridone alkaloids have previously been isolated 
from several fungal species.
64, 105-108
 Even though a number of 3-pyrano-N,4-dihydroxy-2-
pyridone alkaloids similar to septoriamycin A analogues have been identified
109 
 from fungal 
sources, none have been reported to exist as rotamers.  The introduction of a 4-methoxy group 
appears to cause restricted rotation about the C-3-C-7 bond giving rise to rotamers. The most 
polar compound (10c) showed ionic characteristics. 
1
H (Figure 4.29) and 
13
C NMR (Figure 4.30) 
data indicated that the compound also existed as a 3:1 mixture of two diastereomeric rotamers. 
HMBC correlations showed that the methoxy resonance correlated to C-2 and C-4 suggesting 
that 10c is the 2,4-di-O-methylpyridinone-N-oxide analogue of septoriamycin A. The presence of 
the 4-methoxy group appears to cause restricted rotation about the C-3-C-7 bond. At 100 
o
C in 
pyridine duplicated 
1
H NMR (Figure 4.31) resonances coalesced. Even though the original ratio 
of rotamers reappeared at ambient temperature some decomposition of 10c was also observed 
(Figure 4.32). 
The known perylenequinones, (+)-cercosporin (5),
98
 (+)-14-O-acetylcercosporin (6),
98, 99
 and (+)-
di-O-acetylcercosporin (7),
99
 lumichrome (11),
103
 and brassicasterol (12),
104
 were identified by 
comparing their spectroscopic data with literature data. The absolute configurations of 5-7 were 
determined by comparing experimental and reported electronic circular dichroism data.
110, 111
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The helicity of compounds 5-7 was confirmed as M (aS) and the absolute configuration of both 
C-14 and C-17 as  R.
112
    
 
Figure 4.25. 
1
H NMR spectrum of 10b  
 
 
Figure 4.26.  
13
C NMR spectrum of 10b  
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Figure 4.27.  
1
H NMR spectrum of 10b (at 100 
o
C in pyridine)  
 
 
   
Figure 4.28.  
1
H NMR spectrum of 10b (at 25 
o
C in pyridine)  
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Figure 4.29.  
1
H NMR spectrum of 10c  
 
 
Figure 4.30. 
13
C NMR spectrum of 10c  
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Figure 4.31. 
1
H NMR spectrum of 10c (at 100 
o
C in pyridine)  
  
 
Figure 4.32. 
1
H NMR spectrum of 10c (at 25 
o
C in pyridine)  
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Table 4.2.  
1
H and 
13
C NMR data (methylated compounds 10a, 10b, and 10c) in CDCl3/Methanol-d4. 
 
position 10a 10b 10c 
δH
a
 (J in Hz) δC
b
 δH
a
 (J in Hz) δC
b
 δH
a
 (J in Hz) δC
b
 
2  155.0   159.2 157.2   158.0 156.0 
3  119.5   124.3 122.8   125.6 125.3 
4  177.0   164.9 164.8   155.7 157.0 
5  134.6   117.2 115.9   128.5 128.5 
6 7.51, s 132.7 7.44, s 7.49, s 133.4 134.0 8.15, s 8.14, s 139.6 139.7 
7 4.63, d (10.2) 78.4 4.56, d (10.2) 4.21, d (10.2) 79.4 79.5 4.33, d (10.4) 4.33, d (10.4) 79.4 80.7 
8 2.0, m 36.3 2.3, m 2.3, m 33.8 33.8 2.44, m 2.52, m 32.6 32.9 
9 1.78, m 
  1.02, m 
43.4 1.79, m 
1.04, m 
1.84, m 
1.06, m 
43.2 43.1 1.86, m 
0.96, m 
1.86, m 
0.96, m 
43.1 43.1 
10 1.69, m 33.7 1.72,  m 1.72, m 32.3 31.9 1.88, m 1.88, m 32.4 32.5 
11 2.92, d  (12.0) 89.2 2.97, d (12.0) 2.87, d (12.0) 89.0 88.9 2.92, d (10.0) 2.94, d (10.0) 89.8 90.0 
12 1.54, m 34.2 1.57, m 1.57, m 36.1 36.7 1.60, m 1.60, m 36.0 36.0 
13 1.54, m 
0.82, m 
22.8 1.53, m  
0.85, m 
1.53, m  
0.85, m 
22.6 21.9 1.5, m 
1.1, m 
1.5, m 
1.1, m 
22.5 22.5 
9
2
3
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14 0.84, t (7.2) 13.0 0.84, t (6.6) 0.84, t (6.6) 12.7 12.4 0.87, t (6.6) 0.87, t (6.6) 12.9 12.8 
15 0.68, d (6.6) 17.6 0.80, d (6.6) 0.80, d (6.6) 17.5 17.8 0.81, d (6.6) 0.81, d (6.6) 17.6 17.6 
16 0.77, d (6.6) 17.7 0.75, d (6.6) 0.68, d (6.6) 17.3 17.6 0.64, d (6.4) 0.67, d (6.6) 17.7 17.8 
17 0.89, d (6.6) 17.0 0.91, d (6.6) 0.91, d (6.6) 16.8 17.0 0.90, d (6.6) 0.90, d (6.6) 17.2 17.2 
1′  126.6   133.8 133.8   133.0 133.0 
2′, 6′ 7.56, d (7.2) 128.9 7.43, d (7.2) 7.43, d (7.2) 128.6 128.5 7.48, d (6.8) 7.48, d (7.5) 129.0 128.9 
3′, 5′ 7.33, t (7.2) 128.3 7.39, t (7.2) 7.39, t (7.2) 128.4 128.5 7.42, t (6.8) 7.42, d (7.5) 128.9 128.7 
4′ 7.25, t (7.2) 127.8 7.34, t (7.2) 7.34, t (7.2) 127.6 127.5 7.39, t (7.3) 7.39, t (7.3) 129.8 129.8 
OCH3 4.01, s 66.8 4.08, s 4.08, s 64.5 64.5 3.36, s 3.37, s 61.7 62.1 
OCH3 4.0, s 64.4 4.01, s 3.34, s 61.5 61.2 4.16, s 4.14, s 60.6 60.4 
 
 
a1
H NMR spectra recorded at 600 MHz, 
b13
C NMR spectra recorded at 100 MHz 
 
9
3
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Compounds 1-4 showed no antimicrobial, antifungal, antiprotozoal, phytotoxic, or 
cytotoxic activity in vitro. Compounds 5-7 showed moderate in vitro antiplasmodial activity 
(Table 4.3) but were cytotoxic to Vero cells. Their low selectivity indices (ratio of cytotoxicity 
vs. antiplasmodium activity) preclude them as antimalarial drug leads. Even though the plant 
pathogen S. pistaciarum is host-specific to pistachio, compounds 5-7 showed nonspecific 
moderate phytotoxic activity towards both bentgrass (A. stolonifera) and lettuce (L. sativa cv. L., 
Iceberg) in the presence of light (Table 4.4). General phytotoxicity of phytotoxins from host-
specific pathogens is very common. The biosynthesis of cercosporin (5) appeared to be 
controlled by numerous environmental and physiological factors and their production has been 
linked to the pathogenicity of fungi.
100, 101
 The possible mechanism of phytotoxic activity of this 
type of compounds has previously been attributed
 
to their ability to generate reactive oxygen 
species in the presence of light.
100 
This suggested that the selective inhibition of the plant-like 
metabolic pathways in the apicoplast of the malaria parasite
41 
is not responsible for the observed 
antimalarial activity of compounds 5-7. Compounds 5-7 also showed significant antileishmanial 
activity with IC50 values of 1.14 M, 1.7 M, and 3.1 M, respectively (Table 4.5). Compound 5 
was active against both methicillin-sensitive and methicillin-resistant Staph. aureus with IC50 
values of 2.2 and 2.3 M, respectively, and MIC values in the range of 4.7 – 9.4  µM (Table 4.6). 
This compound also showed weak activity against M. intracellulare. Compounds 6 and 7 
exhibited weak activity against C. glabrata, M. intracellulare, and methicillin-sensitive and 
methicillin-resistant Staph. aureus.  
Septoriamycin A (8), which demonstrated good antiplasmodial and antifungal activities,
96
 
exhibited significant antileishmanial activity against Leishmania donovani promastigotes with an 
IC50 of 0.11 M and an IC90 of 0.29 M (Table 4.5) and was more potent than the positive 
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controls pentamidine and amphotericin B. It also showed good activity against Leishmania 
donovani amastigotes with no toxicity to macrophages (Table 4.5). 
The cytotoxic potential of compounds 5-7 was further evaluated against a panel of human 
solid tumor cell lines (SK-MEL, KB, BT-549, and SK-OV-3) and pig kidney epithelial cells 
(LLC-PK11) (Table 4.7). Moderate cytotoxicity was observed against all the cell lines. The di-O-
methyl derivatives of septoriamycin A, 10a, 10b and 10c were also evaluated and compound 10c 
exhibited weak antibacterial and antiplasmodial activities whereas 10a and 10b were inactive in 
these assays.  
Structural features suggest that septoriamycin A may act as a hydroxamic acid analogue. 
Hydroxamic acid derivatives are also known
25, 113
 to target histone deacetylase of the parasites 
which cause malaria, schistosomiasis, trypanosomiasis, toxoplasmosis, and leishmaniasis. The 
apicoplast of the malaria parasite also possesses a family of class II histone deacetylase (HDAC) 
proteins which are also present in other photosynthetic eukaryotes and primitive algae.
22
 This 
unusual enzyme (CpHDAC3) catalyzes the deacetylation of histone tails to promote epigenetic 
regulation and some cellular processes of the parasite.
22, 23
  A number of hydroxamic acid 
analogues which inhibit histone deacetylase have been synthesized and their in vitro 
antiplasmodial and in vivo antimalarial activities have been evaluated.
114, 115
  Some of these 
compounds have shown selective potent in vitro activity but low in vivo activity in a mouse and  
a monkey model due to metabolic instability.
115
 Human and mouse liver microsomes rapidly 
converted the linear hydroxamic acids test compounds to carboxylic acids rendering them 
inactive.
115
  Septoriamycin A (8), a cyclic hydroxamic acid was evaluated in a P. berghei-
infected mouse model. At a dose of 100 mg/kg, the compound showed no toxicity and no 
96 
 
antimalarial activity (Table 4.8). This compound was also submitted for in vivo antileishmanial 
activity in a mouse model. The results have not yet been received.      
 
4.4. Bioactivity Results 
 
Table 4.3. Antiplasmodial activity of 5-7 and 10c 
 
  
 
 
 
 
 
 
 
 
 
a 
Positive controls 
NC not cytotoxic  
S. I. (selectivity index) = IC50 for cytotoxicity /IC50 for antiplasmodial activity  
IC50: concentration causing 50% growth inhibition 
IC90: concentration causing 90% growth inhibition 
Compound Chloroquine-sensitive  
(D6)-clone 
 Chloroquine-resistant 
(W2)-clone 
Cytotoxicity 
to Vero cells 
 IC50  nM S.I. IC50  nM S. I. IC50 nM 
5 1.08 4.8 1.62 3.2 5.24 
6 2.78 1.9 3.12 1.7 5.21 
7 2.75 1.6 1.94 2.3 4.53 
10c 6.76 >1.1 6.51 >1.2 NC 
chloroquine
a
 0.03  0.31  NC 
artemisinin
a
 0.02  0.01  NC 
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Table 4.4. Phytotoxic activity of 5-7 
 
Compound Concentration (mM)  Lettuce Bentgrass 
5 1.87 3  2 
6 1.73 2  4 
7 1.62 3  4 
Ranking based on scale of 0 to 5 
0 = no effect 
5 = no growth 
 
Table 4.5. Antileishmanial activity of 5-8 in µM 
 
Compound 
L.donovani 
promastigotes 
Macrophage 
amastigotes 
Cytotoxicity 
(Transformed THP1 cells) 
IC50     IC90    IC50     IC90    IC50     IC90    
Selectivit
y 
5 1.14 2.81 NT NT NT NT NT 
6 1.7 8.5 NT NT NT NT NT 
7 3.1 9.7 NT NT NT NT NT 
8 0.11 0.29 1.18 1.48 >26.9 >26.9 22.79 
pentamidine
a
 2.9 5.58 8.72 20.18 >58.75 >58.75 6.73 
amphotericin B
a
 0.18 0.38 0.15 1.88 3.62 8.72 24.13 
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a 
Positive controls 
IC50 concentration causing 50% growth inhibition  
IC90 concentration causing 90% growth inhibition 
Selectivity = IC50 for cytotoxicity /IC50 for macrophage amastigotes activity  
NT = Not tested  
 
Table 4.6: Antifungal and antibacterial activity of 5 -7 and  10c 
 
 
Compound 
Candida 
glabrata 
Staphylococcus 
aureus 
MRSA Mycobacterium 
intracellulare 
 IC50 MIC IC50 MIC IC50 MIC IC50  MIC 
5 NA NA 2.2 4.7 2.3 9.4 3.5 NA 
6 4.1 NA 6.9 17.3 5.9 34.7 7.1 NA 
7 7.9 NA 20.0 NA 26.4 NA 8.7 NA 
10c NA NA 23.1 NT 26.8 NT NA NA 
amphotericin B
a
 0.45 2.70 NT NT NT NT NT NT 
ciprofloxacin
a
 NT NT 0.27 1.17 0.27 1.11 0.72 1.5 
 
a 
Positive controls 
IC50 and MIC (concentration causing 50% growth inhibition and the lowest test concentration 
that allows no growth) values are in  
NA: not active  
NT: not tested  
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Table 4.7. Cytotoxic activity [IC50 ()] of 5-7 
 
 
 
 
 
 
SK-MEL = human malignant melanoma 
KB  = human epidermal carcinoma 
BT-549 = human breast carcinoma (ductal) 
SK-OV-3 = human ovary carcinoma 
LLC-PK11 = pig kidney epithelial 
 
Table 4.8. In vivo antimalarial activity of 8 
  
Compound SK-MEL KB BT-549 SK-OV-3 LLC-PK11 
5 3.6 7.1 10.8 3.7 3.9 
6 3.8 8.5 8.6 4.0 10.1 
7 4.9 8.7 8.7 4.8 9.4 
doxorubicin
a
 1.6 2.6 2.6 1.5 1.6 
Treatment 
 (PO) 
Dose 
(mg/kg × # 
days post 
infection) 
% Parasitemia 
suppression
1
 
Survival
2
 Day of 
 Death 
MST
3
 Cure
4
 
Day 5 Day 7 
vehicle        × 3 - - 0/5 17/19/17/19/17 17.8 0/5 
chloroquine
a
  100 × 3 100 100 5/5 28/28/28/28/28 28 0/5 
8  100 × 3 37.18 40.37 0/5 17/17/17/17/12 16 0/5 
100 
 
1
% Suppression in parasitemia is calculated by considering the mean parasitemia in the vehical 
control as 100%.  
Parasitemia suppression < 80% is considered as non-significant 
2
Number of animals that survived day 28/total animals in group (the day of the death-post 
infection) 
3
% MST – mean survival time (days) 
4
Number of mice without parasitemia (cured) till day 28 post-infection 
 
4.5. Experimental   
4.5.1. General  
 
Optical rotations were obtained using a Rudolph Research Analytical Autopol IV 
automatic polarimeter model 589-546. Melting points were measured with a Uni-melt, Thomas 
Hoover capillary melting point apparatus. UV and IR spectra were determined on a Varian-50 
Bio UV visible spectrophotometer and a Bruker-Tensor-27 infrared spectrophotometer, 
respectively. NMR spectra were recorded on a Varian-Mercury-plus-400 or Varian Unity-Inova-
600 spectrometer using CDCl3 and methanol-d4 unless otherwise stated. MS data were obtained 
from an Agilent Series 1100 SL equipped with an ESI source (Agilent Technologies, Palo Alto, 
CA, USA). Column chromatography and preparative TLC were carried out using Merck silica 
gel 60 (230-400 mesh) and silica gel GF plates (20 x 20 cm, thickness 0.25 mm), respectively. 
HPLC analysis was conducted on an Hewlett-Packard Agilent 1100 with diode array detector. 
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4.5.2. Fermentation, Extraction, and Isolation 
 
 The plant pathogenic fungus, Septoria pistaciarum Caracc. (ATCC 22201) was obtained 
from the American Type Culture Collection, Manassas, VA and it was grown as previously 
reported.
2
   
The oily extract (3.3 g) was chromatographed over Sephadex LH -20 and eluted with 
80% MeOH in CHCl3 to give 16 fractions. Fractions 2 -11 which showed antiplasmodial activity 
and were combined and chromatographed over a reversed phase C18 column eluting with a 
gradient of 10 to 100% MeOH-H2O to yield eight fractions. Subfractions 2, 3, and 4 were 
combined and separated on Sephadex LH-20 (MeOH) to give compounds 1 (5.0 mg) and 8 (35 
mg).  Subfraction 5 was chromatographed over a silica gel column using CH2Cl2-hexanes as the 
eluent to give compound 2 (8.0 mg).  Combined fractions 6, 7, and 8 were chromatographed over 
a silica gel column using CH2Cl2-hexanes as the eluent to give 10 subfractions.  Subfraction 2, 3, 
and 5  were combined and further separated using a C18 reversed phase HPLC column eluting 
with  MeCN:H2O, (1:1), flow rate 3.5 mL/min,  to give compounds 3 (3.5 mg) and 4 (8.0 mg). 
Subfractions 6, 7, and 8 were combined and purified on Sephadex LH-20 (MeOH) to give 
compounds 5 (14.0 mg), 6 (12.0 mg), and lumichrome (3.0 mg).  Subfractions 9 and 10 were 
combined and chromatographed over a silica gel column using CH2Cl2-hexanes as the eluent to 
give compound 7 (10.0 mg) and brassicasterol (8.0 mg).  
 
 Compound 1: amorphous powder: []26D +112 (c 0.05, MeOH); UV (MeOH); λmax (log 
ε) 205.0 (3.56), 240.9 (3.51), 297.0 (2.79) nm; IR (CHCl3 ) max 3400, 3207, 2967, 2929, 1647, 
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1555, 1454, 1049  cm
-1
; 
1
H and 
13
C NMR data (see Table 1); HRESIMS [M - H]
+
 m/z 400.2118 
(calcd for [C23H31NO5 - H]
+
, 400.2124) . 
  
Compound 2: amorphous powder: []26D +101 (c 0.05, MeOH); UV (MeOH); UV 
(MeOH) λmax (log ε) 204.0 (3.44), 240.0 (3.25), 295.9 (2.56)  nm; IR (CHCl3 ) max 3331, 2967, 
2925, 1740, 1651, 1230, 1045 cm
-1
; 
1
H and 
13
C NMR data (see Table 1); HRESIMS [M + H]
+
 
m/z 444.2370 (calcd for [C25H33NO6 + H]
+
, 444.2386). 
  
Compound 3: amorphous powder: []26D -38 (c 0.43, CH3OH); UV (MeOH); λmax (log ε) 
208.2 (3.94), 241.9 (3.92), 297.0 (3.19) nm; IR (CHCl3 ) max 3405, 3201, 2965, 2929, 1644, 
1551, 1455, 1219, 755 cm
-1
;  
1
H and 
13
C NMR data (see Table 1); HRESIMS [M + H + Na]
+
 m/z 
425.2172 (calcd for [C23H31NO5 + H + Na
 
]
+
, 425.2178).  
   
Compound 4: amorphous powder: []26D +130 (c 0.2, MeOH); UV (MeOH); λmax (log ε) 
207.1 (3.01), 241.0 (2.95), 295.1 (2.10) nm; IR (CHCl3 ) max 3422, 3159, 2926, 1641, 1541, 
1456 cm
-1
; 
1
H and 
13
C NMR data (see Table 1); HRESIMS [M + H + Na]
+
 m/z 425.2174 (calcd 
for [C23H31NO5 + H + Na
 
]
+
, 425.2178). 
 
Methylation of Septoriamycin A (8) with MeI:  
 
 A mixture of MeI (4 mL), Cs2CO3 (10.0 mg), and compound 8 (10.0 mg) in acetone was 
stirred at room temperature for 5 h. The reaction mixture was filtered, and the solvent was 
103 
 
evaporated.  The product was dissolved in CH2Cl2 and passed through a plug of florisil to give 
N-(O-methyl)septoriamycin A (9). 
 
Methylation of Septoriamycin A (8) with Diazomethane:  
 
A solution of 8 (60 mg) in MeOH was treated with excess diazomethane in Et2O at 0 
ο
C 
for 2 h. The solvent was evaporated and the mixture was separated by PTLC (40% EtOAc in 
hexanes) to yield compounds 10a (8 mg), 10b, and 10c. Compounds 10b and 10c were further 
purified by HPLC using a reversed phase Luna C18 column (1 × 25 cm) with MeOH: H2O (92:8) 
as the mobile phase at a flow rate of 4 mL/min, to give compounds 10b (5 mg) and 10c (6.0 mg). 
 
Compound 10a: amorphous powder:  []26D +14 (c 0.5, MeOH); UV (MeOH); λmax (log 
ε) 205.0 (3.75), 232.0 (3.68), 278.9 (3.41)  nm; IR (CHCl3 ) max 2959, 2929, 2873, 1627, 1547,  
1469, 1046 cm
-1
; 
1
H and 
13
C NMR data (see Table 2); HRESIMS [M + Na]
+
 m/z 422.2307 (calcd 
for [C24H33NO4  +  Na]
+
, 422.2307). 
 
Compound 10b: amorphous powder: UV (MeOH) λmax (log ε) 204.0 (3.39), 235.0 (3.18), 
308.0 (2.65) nm; IR (CHCl3) max 2958, 2929, 1740, 1656, 1524, 1457 cm
-1
; 
1
H and 
13
C NMR 
data (see Table 2); HRESIMS [M +H]
 +
 m/z 400.2472 (calcd for [C24H33NO4 + H]
 +
, 400.2487). 
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Compound 10c: amorphous powder: UV (MeOH) λmax (log ε) 207.0 (2.58), 240.9 (2.47), 
307.1 (1.70) nm; IR (CHCl3) max 2900, 2850, 1575, 1450 cm
-1
; 
1
H and 
13
C NMR data (see Table 
2); HRESIMS [M + Na]
 +
 m/z 422.2279 (calcd for [C24H33NO4 + Na]
 +
, 422.2307). 
 
Compound 5:  Red crystals (MeOH):  mp 239 
0
C  (lit.
110
 240-241.5 
0
C); UV (MeOH) 
λmax (log ε) 210.0 (3.71), 221.0 (3.72), 267.0 ( 3.55) , 470.0 (3.42) , 563.0 (2.98) nm; IR (CHCl3) 
max 3396, 2924, 1616, 1267 cm
-1
 
1
H and 
13
C NMR
 
and CD data 
 
were consistent with those 
reported.
98, 110, 112
  
 
Compound 6: Red crystals (MeOH): mp 135 
0
C  (lit.
99
 134 
0
C); UV (MeOH) λmax (log ε) 
222.0 (3.9), 269.0( 3.74) , 471.0 (3.62) , 563.0 (3.2) nm; IR (CHCl3) max 3338, 1735, 1616, 1266 
cm
-1
  
1
H and 
13
C NMR and CD data data were consistent with those reported.
98, 99
  
 
Compound 7: Red amorphous powder: UV (MeOH) λmax (log ε) 222.0 (3.9), 270.0 ( 
3.84) , 470.1 (4.0) , 563.3 (3.26) nm; IR (CHCl3) max  2921, 1736, 1617, 1211 cm
-1
  
1
H and 
13
C 
NMR and CD data were consistent with those reported.
99
  
 
4.5.3. Biological Assay 
 
4.5.3.1. Antiplasmodial Assay 
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The antiplasmodial activity was determined against D6 (chloroquine sensitive) and W2 
(chloroquine resistant) strains of Plasmodium falciparum in an in vitro assay as described 
earlier.
69
 Artemisinin and chloroquine were included as the drug controls and IC50 values were 
computed from the dose response curves using Microsoft Excel software. 
 
4.5.3.2. Phytotoxicity Assay 
 
The bioassay for phytotoxicity was carried out according to the procedure described by 
Dayan et al.
70
 using bentgrass (Agrostis stolonifera) and lettuce (Lactuca sativa cv. L., Iceberg), 
in 24-well plates.  
 
4.5.3.3. Antileishmanial Assay 
   
The in vitro antileishmanial activity of the compounds was carried out on a culture of 
Leishmania donovani promastigotes.
74
 Pentamidine and amphotericin B were used as standard 
antileishmanial agents. The IC50 values for each compound were computed from the growth 
inhibition curve using Microsoft Excel software. 
 
4.5.3.4. Macrophage Amastigote Assay 
 
A recently developed promastigote rescue assay by Jain et al. was used.
75
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4.5.3.5. Antimicrobial Assay 
 
All organisms were obtained from the American Type Culture Collection (Manassas, VA) and 
included the fungi Candida albicans ATCC 90028, Candida glabrata ATCC 90030, Candida 
krusei ATCC 6258, Cryptococcus neoformans ATCC 90113, and Aspergillus fumigatus ATCC 
90906, and the bacteria Staphylococcus aureus ATCC 29213, methicillin-resistant 
Staphylococcus aureus ATCC 33591 (MRSA), Escherichia coli ATCC 35218, Pseudomonas 
aeruginosa ATCC 27853, and Mycobacterium intracellulare ATCC 23068. Susceptibility testing 
was performed using a modified version of the CLSI methods
71,72 
as described
73
 by Samoylenko 
et al. The drug controls ciprofloxacin (ICN Biomedicals, Ohio) for bacteria and amphotericin B 
(ICN Biomedicals, Ohio) for fungi were included in each assay. 
 
4.5.3.6. Cytotoxicity Assay for Mammalian Cells 
 
In vitro cytotoxicity was determined against a panel of mammalian cells that included kidney 
fibroblast (Vero), kidney epithelial (LLC-PK11), malignant melanoma (SK-MEL), oral epidermal 
carcinoma (KB), breast ductal carcinoma (BT-549), and ovary carcinoma (SK-OV-3) cells as 
described earlier.
76
 The number of viable cells was determined by using Neutral Red dye and 
IC50 values were obtained from dose response curves. Doxorubicin was used as a positive 
control.  
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4.5.3.7. In Vivo Antimalarial Assay 
 
The in vivo antimalarial activity was determined in mice infected with P. berghei (NK-65 
strain), originally obtained from the Walter Read Army Institute of Research, Silver Spring, MD. 
Male mice (Swiss Webster strain) weighing 18-20 g were intraperitoneally inoculated with 2 x 
10
7 
parasitized red blood cells obtained from a highly infected donor mouse. Mice were divided 
into different groups with at least six mice in each group. Compounds stocks were prepared in 
DMSO. The mice infected with P. berghei were orally administered 100 μL of the compound. 
The animals were closely observed for at least 2 h after every dose for any apparent signs of 
toxicity. Blood smears were prepared on different days starting from 5 days post infection 
(through 28 days) by clipping the tail end, stained with Giemsa, and the slides were observed 
under microscope for determination of parasitemia. Mice without parasitemia through day 28 
postinfection were considered cured. 
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CHAPTER 5 
 PART-1: ANTIMALARIAL COMPOUNDS FROM SEPTORIA MUSIVA 
 
5.1.1. Summary 
 
An EtOAc extract of the culture medium of Septoria musiva showed antiplasmodial, 
antimicrobial, antileismanial, and phytotoxic activities. Bioassay-guided fractionation of this 
extract led to the isolation of septoriamycin A (1) and (+)-cercosporin (2) as the compounds 
responsible for antiplasmodial, antimicrobial, and antileishmanial activities. (+)-Cercosporin 
showed phytotoxic activity whereas both compounds exhibited moderate cytotoxic activity 
against mammalian cell lines. 
 
5.1.2. Introduction 
 
Septoria musiva is the causal agent of stem canker and leaf spot disease leading to 
defoliation in Populus sp (poplar tree). Chemical or biological investigation of S. musiva has not 
109 
 
been reported. An EtOAc extract of the culture medium S. musiva obtained from the American 
Type Culture Collection (ATCC 52800) showed antiplasmodial, phytotoxic, antimicrobial, and 
antileishmanial activities. This extract also exhibited moderate cytotoxicity towards Vero cells. 
Bioassay-guided fractionation of the EtOAc extract led to the isolation of septoriamycin A (1) 
and (+)-cercosporin (2) as the active constituents. 
 
5.1.3. Results and Discussion 
 
S. musiva was obtained from the American Type Culture Collection (ATCC 52800) and 
grown in potato dextrose agar (PDA) plates. Although the fermentation was carried out in 
several culture media such as PDB, Czapex Dox, V-8 (100% vegetable juice), and solid rice, 
only Czapex Dox medium afforded an extract with the antiplasmodial activity [720 ng/mL for 
chloroquine-sensitive (D6) and 570 ng/mL for chloroquine-resistant (W2) strains]. 
Chromatographic separation of this extract yielded septoriamycin A (1) and (+)-cercosporin (2) 
as the active compounds (Figure 5.1). These compounds showed identical physical, 
spectroscopic data, and biological activity profiles with those of the same compounds isolated 
from S. pistaciarum.
96, 117
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 septoriamycin A (1)     (+)-cercosporin (2) 
 
Figure 5.1.1.  Structure of compounds 1 and 2  
 
5.1.4. Experimental  
 
5.1.4.1. General 
 
Optical rotations were measured using a Rudolph Research Analytical Autopol IV 
automatic polarimeter model 589-546. NMR spectra were recorded on a Varian-Mercury-plus-
400 using CDCl3/methanol-d4 as the solvent. MS analyses were performed on an Agilent Series 
1100 SL equipped with an ESI source (Agilent Technologies, Palo Alto, CA, USA). Column 
chromatography was carried out on Merck silica gel 60 (230-400 mesh) and reversed phase C18. 
Preparative TLC was carried out using silica gel GF plates (20 X 20 cm, thickness 0.25 mm). 
111 
 
 
5.1.4.2. Fermentation, Extraction, and Isolation 
 
The fungus, S. musiva (ATCC 52800) was obtained from the American Type Culture 
Collection (Manassaas, VA, USA) and its fermentation was carried out as previously 
described.
96
 
The EtOAc extract (9.0 g) was chromatographed over a silica gel column using hexanes-CH2Cl2-
MeOH gradients as mobile phases to give 20 fractions.  Fractions 12 and 13 were combined and 
chromatographed over a reversed phase C18 column eluting with a gradient of 10 to 100% 
MeCN-H2O to yield nine fractions. Subfraction 4 was recrystallized with MeOH to obtain 
septoriamycin A (1, 100 mg) as the major active constituents.  Fractions 18-20 from the original 
extract were combined and purified on Sephadex LH-20 (MeOH) to give (+)-cercosporin (2, 10 
mg).  
 
Compound 1 : white crystals (MeOH);  mp 220 ºC; [α]26D +201 (c, 0.4, CH3OH) mp and 
[α]26D were consistent with reported
96
;  
1
H and 
13
C NMR data
96
 (see Chapter 3); HRESIMS [M - 
H]
-
 m/z 370.2012 (calcd for (C22H29NO4 - H)
-
, 370.2018 ). 
 
Compound 2 :  Red crystals (MeOH);  mp 239 ºC  (lit.
110
 240-241.5 ºC); 
1
H and 
13
C 
NMR
 
(see Chapter 4) were consistent with  reported.
98, 112
  HRESIMS [M + H]
 +
 m/z 535.1651 
(lit.
112
 [C24H33NO4 + H]
 +  
535.1604). 
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5.1.4.3. Biological Assays 
Antiplasmodial,
69
 phytotoxic,
70
 antimicrobial
71
,
72
 and cytotoxic
76
 assays were carried out as 
described.   
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PART 11:  MALFORMIN A1  AN ANTIMALARIAL COMPOUND FROM PHOMOPSIS 
VITICOLA (ASCOMYCOTA) 
5.2.1. Summary 
 
Malformin A1 was isolated as the active compound from an extract of Phomopsis viticola 
with antiplasmodial and phytotoxic activities. Even though this compound was not cytotoxic to 
Vero cells, it showed potent toxicity to a panel of mammalian cancer cell lines precluding it as a 
potential antimalarial drug lead. 
 
5.2.2. Introduction 
 
P. viticola (Ascomycetes), the agent responsible for Phomopsis cane and leaf spot disease 
in grapevines, causes serious yield loss. A variety of biologically active secondary metabolites 
have been reported
119-124
 from this genus.  
An EtOAc extract of P.viticola (ATCC 48153) in Czapex Dox medium showed potent herbicidal 
and antiplasmodial activities with good selectivity. Bioassay-guided fractionation of this extract 
led to the isolation of malformin A1 (3) as the active compound (Figure 6.2.1).  
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Figure 5.2.1. Structure of malformin A1 (3) 
5.2.3. Results and Discussion 
 
P.viticola, (ATCC 48153) was grown in PDB, V8, solid rice, and Czapex Dox culture 
media. Of those, an EtOAc extract of Czapex Dox culture broth showed potent herbicidal and 
antiplasmodial activity with good selectivity index (Table 2.1). Bioassay-guided fractionation of 
this extract by repeated column chromatography furnished malformin A1 (3) as the active 
compound. The structure of this compound was confirmed by spectroscopic methods.
125
 
Malformin A1, a cyclic pentapeptide (cyclo-D-Cys-D-Cys-L-Val-D-Leu-L-Ile) with a disulfide 
bond between two cysteine moieties,  has been isolated from plant pathogenic  Aspergillus 
species.
125, 126
 The phytotoxic activity of this compound has extensively been studied.
125, 127
 
Antiplasmodial and antitrypanosomal activities, and structure activity relationships of several 
synthetic malformin analogues have been reported.
128
 Based on these results, the presence of a 
disulfide bond is required for the biological activity of these compounds.
128
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Malformin A1 (3) showed potent antimalarial activity with IC50 values in the range of 
0.05-0.07 nM for W2 and D6 strains (Table 5.2.1) and strong phytotoxic (Table 5.2.3) activity. 
Although this compound exhibited no toxicity to Vero cells at the highest concentrations tested 
(4760 ng/mL), previous studies have shown it to be toxic to a panel of cancer cell lines.
129
 
Evaluation of activity  of malformin A1 (3) against a panel of human cancer cell lines (SK-MEL, 
KB, BT-549, and SK-OV-3)  and mammalian kidney epithelial cells (LLC-PK11) showed 
significant cytotoxicity to all the tested cell lines with IC50 values in the range of 2-4  except 
for KB cells (9.5 Malformin A1 has shown high intraperitonial toxicity in mice (LD50 3.1 
mg/kg); however, it had no oral toxicity at doses ≤ 50 mg/kg.126 This lack of oral toxicity may be 
due to poor oral bioavailability of peptides.
130
  
 
5.2.4. Bioactivity Results 
 
Table 5.2.1. Antimalarial activity of 3 
 
Compound 
 
         Chloroquine-
sensitive (D6)-clone 
     Chloroquine-
resistant (W2)-clone 
Cytotoxicity to 
Vero cells 
IC50 nM S.I. IC50 nM S. I. IC50 nM 
malformin A1(3) 0.07 >128.2 0.05 >178.0 NC 
chloroquine
a
 0.07  0.88  NC 
artimisinin
a
 0.06  0.04  NC 
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a 
Positive controls 
NC not cytotoxic  
S. I. (selectivity index) = IC50 for cytotoxicity /IC50 for antiplasmodial activity  
IC50: concentration causing 50% growth inhibition 
 
 Table 5.2.2. Cytotoxic activity [IC50 ()] of 3 
 
Compound SK-MEL KB BT-549 SK-OV-3 LLC-PK11 
malformin A1 
 
2.83 9.45 3.12 4.91 3.11 
doxorubicin
a
 1.65 1.65 1.51 3.49 1.13 
 
a 
Positive control. 
IC50 = concentration causing 50% growth inhibition  
SK-MEL = human malignant melanoma 
KB  = human epidermal carcinoma 
BT-549 = human breast carcinoma (ductal) 
SK-OV-3 = human ovary carcinoma 
LLC-PK11 = pig kidney epithelial 
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Table 5.2.3.  Phytotoxic activity of 3 
 
Compound Concentration (mM)  Lettuce Bentgrass 
Malformin A1 1.89 5 5 
0.18 3 4 
0.018 1 1 
 
Ranking based on scale of 0 to 5 
0 = no effect, 5 = no growth 
 
5.2.5. Experimental  
 
5.2.5.1. General  
 
 Melting points were measured with a Uni-melt, Thomas Hoover capillary melting point 
apparatus. Optical rotations were measured using a Rudolph Research Analytical Autopol IV 
automatic polarimeter model 589-546. NMR spectra were recorded on a Varian-Mercury-plus-
400 or Varian Unity-Inova-600 spectrometer using pyridine-d4 as the solvent unless otherwise 
stated. MS analyses were performed on an Agilent Series 1100 SL equipped with an ESI source 
(Agilent Technologies, Palo Alto, CA, USA). Column chromatography was carried out on Merck 
silica gel 60 (230-400 mesh) and reversed-phase C18 silica gel. Preparative TLC was carried out 
using silica gel GF plates (20 X 20 cm, thickness 0.25 mm). 
118 
 
 
5.2.5.2. Fermentation, Extraction, and Isolation 
 
P. viticola (ATCC 48153) was obtained from the American Type Culture Collection 
(Manassaas, VA, USA) and grown in PDA plates at 29 
ο
C for 14 days. A flask (1L) with100 mL 
of PDB was inoculated with agar pieces (0.25 in × 0.25 in) and incubated at  29 ºC
 
 for 8 days on 
a shaker (RPM = 100). Erlenmeyer flasks (38 × 1L) each containing 500 mL of M-2 medium, 
(modified Czapex Dox medium : Czapex Dox 35.0 g, yeast extract 1.5 g, malt extract 1.5 g in 1L 
of distilled H2O) were inoculated with this seed culture and incubated at 29 ºC for 28 days on a 
shaker (RPM = 100). The broth was separated by filtration and extracted with EtOAc (×3). The 
organic layer was evaporated under reduced pressure to give an oily residue (3.0 g).  
The oily extract (2.9 g) was chromatographed over Sephadex LH -20 and eluted with 
100% MeOH to give 12 fractions. Fractions 4 and 5 which showed antiplasmodial activity (≤ 
528 ng/ml) were combined and chromatographed over a reversed-phase C18 column eluting with 
a gradient of 10 to 100% MeCN-H2O to yield malformin A1 (7.0 mg).  
 
Compound 3 : white amorphous powder (MeOH);  mp 303 
0
C (lit.
110
 > 300 
ο
C); [α]26D  -
28 (c, 0.5, CH3OH) ([α]
26
D -39 lit.
128
);  
1
H and 
13
C NMR data were consistent with reported
128
 
values; HRESIMS [M + H]
+
m/z 530.2418 (lit.
128
 [C24H33NO4 + H]
 +   
530.2470) 
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5.2.5.3. Biological Assays 
 
Antiplasmodial,
69
 phytotoxic,
70
 and cytotoxic
76
 assays were carried out using the procedures as 
previously described.   
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CHAPTER 6: PHYTOTOXIC COMPOUNDS FROM THE WOOD ROTTING FUNGUS, 
POSTIA BALSAMEA (BASIDIOMYCETES) 
 
6.1. Summary 
 
Postia balsamea is one of the causal agents of root rot and butt rot in balsam fir (Abies balsamea, 
Pinaceae). Preliminary screening of the EtOAc extract of a fermentation broth of P. balsamea 
showed antiplasmodial and phytotoxic activities. Bioassay-guided fractionation of the EtOAc 
extract led to the isolation of four polyacetylenes, (2E,8E)-matricaria ester (1), (2E,8E)-
matricarianol (2), (2E,8E)-deca-2-8-diene-4,6-diyne-1,10-diol (3),  and (3S,8E)-methyl 3-
hydroxydeca-8-en-4,6-diynoate (4); one phenolic acid, (S)-3-(3,4-dihydroxyphenyl)lactic acid 
(5); three halogenated phenolic acid analogues, (S)-3-(3,5-dichloro-4-hydroxyphenyl)lactic acid 
(6), (S)-Methyl 3-(3,5-dichloro-4-methoxyphenyl)lactate (7), and (S)-methyl 3-(3,5-dichloro-4-
methoxyphenyl)lactate (8); and four triterpenes, eboricoic acid (9), acetyleboricoic acid (10), 
sulfurenic acid (11), dehydrosulfurenic acid (12), and a mixture of minor compounds which 
showed good antiplasmodial activity. The structures of the pure compounds were determined by 
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spectroscopic and spectrometric methods. Of these compounds, compounds 4 and 8 are new, and 
compounds 6 and 7 have been synthesized, but this is the first report of their isolation from a 
natural source. The conjugated polyacetylenes and halogenated phenolic compounds showed 
strong phytotoxic activity against monocots (Agrostis stolonifera cv. Pencross) and dicots 
(Lactuca sativa).  
 
6.2. Introduction 
 
Postia Fr (Aphyllophorales, Basidiomycota), a widespread genus of brown rot fungi in 
North America, Europe, and China, has variable morphological characteristics  and a wide range 
of tree hosts including both hardwoods and conifers. 
131-133
  Species of this genus are also known 
by several synonyms because of updates in nomenclature, among them Oligoporous, Postia, 
Rhodonia, Spongipellis, Tyromyces, Polyporous, Polysticus, and Poria. 
131-133
  
P. balsamea, an agent responsible for root rot and butt rot in balsam fir (Abies balsamea, 
family Pinaceae), causes considerable economic damage. Balsam fir which grows in the northern 
United States and Canada is extensively used for pulp and lumber and is also one of the most 
popular Christmas trees. P. balsamea can enter roots and the basal area of trees through wounds 
caused by insects or mechanical means and attack functional vascular and cambium tissues most 
likely by releasing phytotoxins first and then depolymerizing enzymes to hydrolyze cellulose and 
hemicelluloses.
40, 135
 Infected trees become susceptible to secondary attacks by insects and wind 
damage.
135
  Thus far, no work has been reported on the chemical constituents of genus under the 
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named “Postia”, although there is a possibility that Postia has been identified under another 
synonym. 
 
Preliminary screening of the EtOAc extract of the fermentation broth of P. balsamea 
showed potent antiplasmodial and phytotoxic activities. Bioassay-guided fractionation of this 
extract afforded a fraction with potent activity and good selectivity. Although the EtOAc extracts 
of the subsequent large-scale fermentation broths showed potent phytotoxic activity against 
monocots (Agrostis stolonifera cv. Pencross) and dicots (Lactuca sativa), they were devoid of 
antiplasmodial activity. Thin layer chromatographic analysis of the active fraction showed two 
major and four minor spots. By comparison with the inactive fractions all but one could be 
eliminated as the possible active constituent (Figure 6.1). Compounds in P. balsamea broth 
belong to three different chemical classes: C-10 polyacetylenes, phenyllactic acid analogues, and 
lanostane triterpenes. Spectroscopic analysis indicated that constituents only present in the active 
fraction by TLC analysis did not to belong to any of these classes. 
 
6.3. Results and Discussion 
 
Preliminary small-scale culture of P. balsamea (ATTC 64899) in PD broth produced an 
extract with high antiplasmodial activity but no cytotoxicity.  Although the EtOAc extracts of the 
large scale fermentation broth showed TLC profiles similar to the original extract, it was devoid 
of antiplasmodial activity. Re-culture of the fungus with the same and different culture media 
[Czapex dox, V-8 (100% vegetable juice), and rice] and a new sample of the fungus from the 
ATCC, cultured under original conditions, failed to produce an extract with antiplasmodial 
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activity. Attempts were also made to produce active metabolites by inoculating the culture 
medium with the bark and leaf parts of Abies balsamea as elicitors. Fractionation of the original 
active extract yielded a fraction (15 mg) with potent selective activity. TLC analysis revealed a 
spot in the active fraction which was only present in that fraction (Figure 6.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. TLC comparison of antimalarial active fraction with inactive fractions and 
compounds 
  
Since the compound or compounds corresponding to this spot could be derivatives of the 
other compounds present in the extracts, all constituents in the extracts were isolated and 
identified to facilitate the identification of the active compounds.  
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EtOAc extracts of broth and mycelia of P. balsamea were fractionated by repeated silica 
gel column chromatography, and the compounds were purified by PTLC to afford 
polyacetylenes (1-4), four phenolic compounds (5–8), and four triterpene acids (9-12) as shown 
in Figure 6.2. Compounds 4 and 8 are new, and compounds 6 and 7 have previously been 
synthesized.
136
 The known compounds, (2E,8E)-matricaria ester (1),
137
 (2E,8E)-matricarianol 
(2),
137
 (2E,8E)-deca-2-8-diene-4,6-diyne-1,10-diol (3),
137, 138
 (S)-3-(3,4-dihydroxyphenyl)lactic 
acid (5),
139
 (S)-3-(3,5-dichloro-4-hydroxyphenyl)lactic acid (6),
136
 (S)-methyl 3-(3,5-dichloro-4-
methoxyphenyl)lactic acid (7),
136
 eboricoic acid (9), 
140
 acetyl eboricoic acid (10),
140
 sulfurenic 
acid (11),
141
 and dehydrosulfurenic acid (12)
141
 were identified by comparing  observed and 
published spectroscopic data.  
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Figure 6.2.  Structure of compounds isolated from P. balsamea 
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Compound 4 was obtained as an amorphous powder. The IR spectrum of 4 showed 
absorption at 3435 cm
-1
 due to a hydroxy group and at 1728 cm
-1
 due to a carbonyl group. The 
UV spectrum showed characteristic absorptions at 206, 228, 253,  268, and 284 nm,  indicating 
the presence of an ene-diyne chromophore.
142
 The 
1
H NMR spectrum (Figure 6.3) showed spin 
systems for a methyl-substituted trans-olefinic bond [δH (1H) 6.34 dq J = 16.0, 7.2 Hz, δH 5.52 
(1H) brd J = 16.0 Hz, and δH 1.82 (CH3) dd 7.2, 1.6 Hz], similar to that observed for compound 
1,
137
 a hydroxymethine adjacent to a methylene [δH (1H) 4.85 t J = 6.0 Hz, δH (2H) 2.76 d, J = 
6.0 Hz], and a methoxy group (δH 3.76). The 
13
C NMR spectrum (Figure 6.4) of 4 showed 11 
resonances indicating four acetylenic carbons (δC 80.1, 78.4, 71.5, and 70.2), two olefinic 
carbons (δC 109.6, 144.7), one oxymethine carbon (δC 59.4), one methoxy carbon (δC 52.3), one 
ester carbonyl carbon (δC 171.6), and one methylene carbon (δC 41.6). In the HMBC spectrum 
(Figure 6.5), H-9 showed correlations with the methyl group, C-10, and C-7 (δC 78.4). The -CH3 
protons (δH 1.80) showed correlations with C-9 (δC 144.7), C-8 (δC 109.6), C-7 (δC 78.4), and C-6 
(δC 71.5). The oxymethine proton at C-3 showed long range correlations to the carbonyl group 
(δC 171.6), C-4 (δC 80.1), C-5 (δC 70.2), and C-2 (δC 41.6); whereas, the methylene doublet at δH 
2.76 correlated with the carbonyl (δC 171.6), C-3 (δC 59.4), and C-4 (δC 80.1). The methoxy 
group (δH 3.76) had an HMBC correlation with the carbonyl group. These correlations, as 
indicated in Figure 6.6, supported the proposed structure as methyl 3-hydroxydeca-8-en-4,6-
diynoate (4). The absolute configuration at C-3 was determined based on specific rotation. The 
reported specific rotations for (3R)- and (3S)-3-hydroxypent-4-ynoic acid  methyl esters are 
+24.5
143
 and -19.2,
144
 respectively. The specific rotation of compound 4 was -14.5; thus, the 
absolute configuration of C-3 was assigned as S. 
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Figure 6.3.  
1
H NMR spectrum of 4 
 
 
 
 
 
 
 
 
 
 
Figure 6.4.  
13
C NMR spectrum of 4 
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Figure 6.5.  HMBC spectrum of 4 
  
 
 
 
Figure 6.6. COSY (  ) and HMBC (  ) correlations of 4 
 
The NMR spectra of 8 were superimposable with those of 7 except for the presence of an 
additional resonance for a methoxy group in the spectra of the former (Figure 6.7). Methylation 
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of compound 7 with trimethylsilyldiazomethane yielded a product which had the same physical 
and spectroscopic data (Figures 6.7 and 6.8) as those for 8, confirming that the latter was (S)-
methyl 3-(3,5-dichloro-4-methoxyphenyl)lactate. 
The active fraction from the original extract was separated by column chromatography to 
afford a subfraction which appeared to be a single compound by TLC. The 
1
H NMR spectrum 
indicated that it was a mixture of closely related compounds. This subfraction was further 
separated by HPLC to yield four compounds in minute amounts. The 
1
H NMR data of these 
compounds indicated that they did not belong to any class of compound isolated from these 
extracts. Owing to lack of material, their structure elucidation was not feasible. 
Compounds 1, 2, and 3 showed significant phytotoxic activity against both dicots 
(lettuce, Lactuca sativa) and monocots (bentgrass, Agrostis stolonifera) (Table 6.1).  A number 
of conjugated polyyne compounds have been isolated from higher plants,
145-148
 and 
basidiomycetes,
137, 149
 and exhibited a variety of biological activities.
142, 145, 150, 151
 Geometric 
isomers of compound 1 have been isolated from Chrysoma pauciflosculosa and their 
phytotoxicity as well as allelopathic effects on some Florida sandhill scrub species have been 
reported.
148
  
Compounds 5, 6, and 8 exhibited good phytotoxic activity against both dicots (lettuce, 
Lactuca sativa) and monocots (bentgrass) (Table 6.1).  Compounds 1-8  showed no activity in 
antimicrobial and antiprotozoal assays.  
Compound 5, the S enantiomer, is a rare natural product. Its R enantiomer, salvianic acid 
A,  has been isolated from Salvia miltiorrhiza root, which is widely used in traditional medicine 
for the treatment of various cardiovascular diseases 
152
 and is also a biosynthetic precursor to a 
number of natural products including rosmarinic acid.
139
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Compounds 6 and 7 have not been isolated from natural sources.  They have been found 
as precursors to compounds isolated from a cyanobacterium
136
 and have been synthesized.  
 
 
 
 
Figure 6.7.  
1
H NMR spectrum of 8 
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Figure 6.8.  
13
C NMR spectrum of 8 
  
A number of chlorinated phenolic compounds have been isolated from 
basidiomycetes.
142, 153, 154
 Some of these compounds have shown antimicrobial
155
 and seed 
germination inhibitory
156
 activities.  They also have been reported
157, 158
 to be involved in lignin 
degradation
25,26
 and inhibition of the enzyme chitin synthase.
29
  
Lanostane triterpenes have been isolated from several fungal species of the Polyporaceae, 
and their antioxidant and cytotoxic activities have been reported.
140, 159-161
 Compounds 9-12 
showed no activity in antimicrobial, antiprotozoal, and phytotoxic assays.  
The variation in metabolite production in culture media and from one culture flask to 
another within the same media has been reported
45, 119
 from several fungi. The failure to produce 
the antiplasmodial metabolites in large-scale culture broths may be due to the loss of virulence 
factors and/or specific virulence genes involved in the synthesis of specific toxins, upon 
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continuous subculturing of the fungus. It may also be due to mutation of genes responsible for 
biosynthesis of the specific toxins.  
 
6.4. Experimental 
6.4.1. General  
 
Optical rotations were obtained using a Rudolph Research Analytical Autopol IV automatic 
polarimeter model 589-546. Melting points were measured with a Uni-melt, Thomas Hoover 
capillary melting point apparatus. UV and IR spectra were determined on a Varian-50 Bio UV 
visible spectrophotometer and a Bruker-Tensor-27 infrared spectrophotometer, respectively. 
NMR spectra were recorded on a Varian-Mercury-plus-400 or Varian Unity-Inova-600 
spectrometer using CDCl3/CD3OD as the solvent unless otherwise stated. MS analyses were 
obtained from an Agilent Series 1100 SL equipped with an ESI source (Agilent Technologies, 
Palo Alto, CA, USA) and GCMS (Hewlett-Packard 6890 series). Column chromatography and 
preparative TLC were carried out using Merck silica gel 60 (230-400 mesh) and silica gel GF 
plates (20 × 20 cm, thickness 0.25 mm), respectively. TLC spots were detected under UV 
irradiation and by heating on a hot plate after spraying anisaldehyde reagent.  HPLC analysis was 
conducted on a Hewlett-Packard Agilent 1100 with diode array detector.  Potato dextrose agar 
(PDA), potato dextrose broth (PDB), and Czapex dox were purchased from Difco
TM
. V-8 and 
rice were purchased from Walmart in Oxford, MS. Postia balsamea (ATCC 64899) was 
obtained from the American Type Culture Collection (ATCC). 
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6.4.2. Fermentation and Extraction 
 
 P. balsamea obtained from the ATCC was grown on PDA plates at 27 ºC for 12 days. 
Erlenmeyer flasks (2 × 1 L) containing 600 mL of PDB  were inoculated with three small agar 
pieces (5 × 5 mm) containing P. balsamea and were incubated at 27 ºC
 
 for 28 days on a shaker 
(RPM = 100). The culture broth and mycelia were filtered. The broth was extracted with EtOAc 
(× 3), and the organic layer was evaporated under reduced pressure to give an oily residue (189.0 
mg).  Mycelia were extracted with MeOH (× 3) and evaporated to give a brown oily residue (200 
mg). These extracts showed good phytotoxic and antimalarial activities.  
 Scale up of fermentation was carried out (× 3) by repeating the above procedure with 
identical conditions using Erlenmeyer flasks (40 × 1L) to obtain EtOAc broth extracts (3.8, 3.5, 
and 3.7 g) and mycelia extracts (4.1, 4.8, and 3.4 g). These extracts exhibited good phytotoxic 
activities but were inactive in the antimalarial assay. 
 Fermentation was carried out in several other culture media [V8 (100% vegetable juice), 
Czapex dox, and Rice] and under various conditions such as different volume of broth (100 , 250 
, and 500 mL), different Erlenmeyer flask sizes (250, 500 mL, and 1 L), and different 
fermentation time periods (2, 3, 4, and 5 weeks). Fermentations were also carried out in the 
presence of small amounts of the bark and leaf parts of a fir tree; however, the above 
experiments, as well as a fresh P. balsamea sample from the ATCC under the original culture 
conditions, failed to produce extracts with antimalarial activity.    
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6.4.3. Attempted Isolation of Antimalarial Compounds 
 
The original oily extract (189 mg) which showed good antiplasmodial activity (IC50 < 1 
µg/mL against P. falciparum) and good phytotoxic activity was chromatographed over a gravity 
column using hexanes, CH2Cl2, and MeOH as the eluents to give seven subfractions. Fraction 3 
(18.0 mg) showed potent antiplasmodial activity (IC50 < 120 ng/mL) with high selectivity. TLC 
analysis of this fraction showed the presence of two major and four minor spots (Figure 6.1). The 
active fraction was separated using a reversed-phase Luna C18 column (1 × 25 cm) and eluted 
with MeOH-H2O (65:35) as the mobile phase at a flow rate of 2.5 mL/min, with wave length set 
at 254 nm. The major compounds corresponding to the major spots were also present in 
substantial amounts in the large-scale extracts as well as in mycelia extracts. They were isolated 
from mycelium extract and identified as eboricoic acid (9) and sulfurenic acid (11) (vide infra).  
These compounds were inactive in the antiplasmodial assay. HPLC analysis revealed that the 
minor spot consisted of at least four related compounds, and their identification was not possible 
due to insufficient quantities.   
 
Polyacetylenes 
 
The EtOAc extract of the large scale fermentation broth (3.8 g) which showed potent 
phytotoxic activity against monocots (Agrostis stolonifera cv. Pencross) and dicots (Lactuca 
sativa) was fractionated by silica gel column chromatography using hexanes, CH2Cl2, and 
MeOH as eluents to give eighteen fractions. Fractions 1, 2, and 3 showed potent phytotoxic 
activity against both monocots and dicots. The compounds present in these fractions showed a 
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tendency to undergo decomposition. Fraction 1 (50.0 mg) was chromatographed over a gravity 
column using hexanes as the eluting solvent, and further separation was carried out by PTLC 
using 15% EtOAc in hexanes to yield (2E,8E)-matricaria ester (1)
137
 (8.0 mg). Fractions 2 and 3 
were combined and subjected to silica gel gravity column chromatography using hexanes and 
CH2Cl2 as the eluents to yield 9 fractions. Subfraction 8 (130 mg) was applied on Sephadex LH-
20 and eluted with 100% MeOH to give (2E,8E)-matricarianol (2)
137
 (5.0 mg).  Subfraction 9 
was applied on Sephadex LH-20 and eluted with 100% MeOH followed by PTLC using 30% 
EtOAc in hexanes as developing solvent to yield (2E,8E)-deca-2-8-diene-4,6-diyne1,10-diol 
(3)
137, 138
 (1.0 mg) and (3S,8E)-methyl 3-hydroxydeca-8-en-4,6-diynoate (4) (2.0 mg).  
 
Phenolic Compounds  
Fractions 4 and 5 were combined and chromatographed over a silica gel gravity column 
followed by PTLC using 35% EtOAc in hexanes as the developing solvent to give three simple 
phenolic compounds, 5 (S)-3-(3,4-dihydroxyphenyl)lactic acid (2.0 mg), 6 (S)-3-(3,5-dichloro-4-
hydroxyphenyl)lactic acid (7.0 mg), and 7 (S)-methyl 3-(3,5-dichloro-4-methoxyphenyl)lactate 
(10.0 mg). Compound 8 (S)-methyl 3-(3,5-dichloro-4-methoxyphenyl)lactate (10.0 mg) was 
isolated as white crystals from fraction 12 (CH2Cl2/MeOH).  
 
Triterpenes  
 
Fractions 13 and 14 were combined and chromatographed over a silica gel column using 
hexanes and EtOAc as eluents to give eboricoic acid (9, 1.0 mg) and acetyl eboricoic acid (10,  
2.0 mg) as  white amorphous powders.  The mycelia extract (12.0 g) was chromatographed over 
136 
 
a silica gel column using hexanes, CH2Cl2, and MeOH as the eluents to give nine fractions. 
Further purification of these fractions using repeated column chromatography furnished 
triterpenes 9 (5.0 mg) and 10 (10.0 mg) and a mixture of the two triterpenes 11 and 12. NMR and 
HRESIMS data of the mixture confirmed them to be sulfurenic acid (11) and dehydrosulfurenic 
acid (12).  
 
Compound 4 : amorphous,  [α]26D – 14.5 (c 0.1, CHCl3);  IR max  3435, 1728 cm
-1
; UV (CHCl3): 
λmax (log ε) 206 (3.20), 228 (3.33), 253 (3.22), 268 (3.20), and 284 (3.14) nm; ESIMS [M - H]
+
 : 
m/z = 174; 
1
H NMR: 1.82 (3H, dd, J = 7.2, 1.6 Hz, H-10), 2.77 (2H, d, 6.0 Hz, H-2)), 3.74 
(3H, s, OCH3), 4.85 (1H, t, J = 6.0 Hz, H-3), 5.52 (1H, d, J = 15.2 Hz, H-8), 6.34 (1H, dq, J = 
16.0, 7.2Hz, H-9),  
13
C NMR: 19.2 (C-10), 41.6 (C-2), 52.4 (-OCH3), 59.4 (C-3), 70.2 (C-5), 
71.5 (C-6), 78.4 (C-7), 80.1 (C-4), 109.6 (C-8), 144.8 (C-9), 171.6 (C-1) 
 
Compound 8 : White solid, mp 80
o
 C, [α]26D  -11 (c 0.1, CHCl3); IR max  3468, 1736 cm
-1
; UV 
(MeOH) λmax (log ε): 225 (3.91), 275 (3.19) nm; EIMS [M + H]
+
  m/z 279. HRESIMS [2M + H + 
Na]
+
 m/z 581.0403 (calcd for (C22H25Cl4O8Na) 580.0201); 
1
H NMR  2.7 (1H, dd, J = 14.0, 7.2 
Hz, H-3), 2.87 (1H, brd, J = 14.0 Hz, H-3), 3.31 (3H, s, OCH3), 3.64 (3H, s, COOCH3), 4.29 
(1H, brs, H-2), 7.00 (2H, s, H-2′ and H-6′); 13C NMR:  39.2 (C-3), 52.7 (OCH3), 60.7 
(COOCH3), 70.7 (C-2), 129.0 (C-1′), 129.9 (C-2′, 6′), 134.1 (C-3′ and C-5′), 151 (C-4′). 
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Methylation of Compound 7: 
 
Compound 7 (2 mg) in methanol (0.5 ml) was treated with trimethylsilyldiazomethane (50 L) at 
room temperature for 10 minutes.  Solvent was evaporated and the residue was dissolved in 
CH2Cl2, and filtered through a plug of celite
®
 to yield compound 8 (2.1 mg). 
 
6.4.4. Biological Assay 
 
6.4.4.1. Antiplasmodial Activity 
 
The antiplasmodial activity of extracts, fractions and pure compounds was performed 
against D6 (chloroquine sensitive) and W2 (chloroquine resistant) strains of P. falciparum using 
the in vitro assay as reported.
69
  
 
6.4.4.2. Phytotoxic Activity 
 
The herbicidal activity of extracts and test compounds was performed using the 
procedure described by Dayan et al.
111
 using bentgrass (Agrostis stolonifera) and lettuce 
(Lactuca sativa cv. L., Iceberg), in 24-well plates. The results are collated in Table 6.1. 
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Table 6.1. Phytotoxic activity of P. balsamea compounds 
 
Compound 
Concentration  
Lettuce Bentgrass (mM) 
1 5.7 5 4 
 
0.6 1 0 
2 6,8 5 5 
 
0.7 4 3 
3 5.2 5 5 
 
0.52 1 0 
4 - NT NT 
5 3.6 5 4 
 
0.36 0 0 
6 5.1 4 4 
 
0.5 0 0 
7 - NT NT 
8 4.0 5 5 
 
0.4 0 0 
9 2.1 NA NA 
10 1.9 NA NA 
11  2.1 NA NA 
12  2.1 NA NA 
 
Ranking based on scale of 0 to 5 
0 = no effect, 5 = no growth 
NT = Not tested 
NA = Not active 
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CHAPTER 7: ANTIMALARIALS FROM ENDOPHYTIC FUNGI ISOLATED FROM 
TORREYA TAXIFOLIA ARNOTT 
 
Torreya taxifolia Arn., an evergreen tree of the family Taxaceae, known as Florida 
torreya, stinking-cedar, or gopherwood, can grow to heights up to 20 meters.
162
 The native 
population decline during the last decades has been attributed to both abiotic and biotic causes 
including fungal diseases.
162
  T. taxifolia is considered the rarest conifer in North America and is 
one of the most endangered trees in the world.
162 
The symptoms of disease include needle spot, 
needle death, needle cankers, defoliation, and stem lesions.
163
 This tree is in the same plant 
family as Taxus brevifolia (Pacific yew) that produces taxol and taxane derivatives.
164
 Although 
several studies have been carried out to determine the causative agent responsible for the rapid 
decline of the plant, the identity of a single highly virulent pathogen remains an area of active 
research, with a Fusarium being the most recently reported causative agent.
162, 163
 Pathogenicity 
studies carried out in the past few years, concluded that several pathogens may be responsible for 
leaf spots, but not for the canker disease. These pathogens included
163, 165, 166
 Macrophoma sp., 
Rhizoctonia solani, Sphaeropsis sp., Sclerotium rolfsii, Fusarium lateritium, and Pestalotiopsis 
microspora. 
From T. taxifolia nine endophytic fungi were isolated from diseased leaves of cultivated 
plants (Figures 7.1 and 7.2), and six endophytic fungi were isolated from diseased seeds.  
140 
 
 
EtOAc extracts of fermentation cultures of these fungi were screened for phytoxic 
activity against both a dicot (lettuce, Lactuca sativa L.) and a monocot (bentgrass, Agrostis 
stolonifera L.) and antiplasmodial activity against chloroquine-sensitive (D6) and -resistant (W2) 
strains of P. falciparum. Of the endophytes screened, Xylaria sp. (Section 7.1), Alternaria sp. 
(Section 7.2), a new isolate, UM #10 M (Section 7.3), and Botryosphaeria dothidea (Section 7.4) 
showed good antiplasmodial and phytotoxic activities (Table 7.1).  
 
 
Figure 7.1. Symptoms of diseased needles of cultivated T. taxifolia 
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Figure7.2. Symptoms of diseased needles of cultivated T. taxifolia  
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Table 7.1: Antiplasmodial and herbicidal activity of endophytic fungi extracts 
 
Ranking based on scale of 0 to 5 
0 = no effect, 5 = no growth 
Fungi 
 
Medium 
  
Antiplasmodial activity 
IC 50 (ng/mL) 
Cytotoxicity 
(vero)  
IC 50  
(ng/mL) 
  
Phytotoxicity 
P. 
falciparum 
D6 clone SI 
P. 
falciparum 
W2 clone SI Lettuce Bentgrass 
Botryosphaeria dothidea 
(Broth) PDB 860 37.2 1300 24.6 32000 5 5 
 Xylaria sp  (Broth) PDB 62 3.3 87 2.3 200 5 5 
UM #10 M  (Broth) PDB 40 170 44 154.5 6800 5 5 
Alternaria sp. (Broth + 
Mycelium) PDB 6800 1.8 5800 2.1 12000 5 5 
1
4
2
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SECTION  7.1: ANTIMALARIALS FROM XYLARIA SP. 
 
7.1.1. Summary 
 
Bioassay-guided fractionation of the potato dextrose culture broth extract of Xylaria sp. isolated 
from a diseased leaf of Torreya. taxifolia afforded a known compound, heptelidic acid (1), as the 
active constituent. This compound showed good antiplasmodial activity and phytotoxicity, but 
was also cytotoxic to vero cells and a panel of solid tumor cell lines. 
 
 
 
Figure 7.1.1. PDA plate of Xylaria sp. 
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7.1.2. Introduction 
 
Xylaria sp. is also known as Stag's Horn and Candle-snuff. Its morphology (Figure 7.1.1) 
shows it contains antler-like ascocarps (fruit bodies) which are black at the base and, white and 
branched towards the top where the fruit bodies produce white conidia (asexual spores). This is a 
cosmopolitan fungal genus belonging to the family Xylariaceae and several members of this 
family have been reported
168-177
 to produce a number of chemically diverse, biologically active, 
and taxonomically significant constituents, including several antimalarial compounds.
57, 178, 179
  
An EtOAc extract of the fermentation culture broth of Xylaria sp. showed potent 
herbicidal and antiplasmodial activities. Bioassay-guided fractionation of this extract afforded 
heptelidic acid (1), as the active compound.  
 
7.1.3. Results and Discussion 
 
This fungus was identified to be a Xylaria sp. by its characteristic morphological features 
and the DNA sequencing profile of the fungal internal transcribed spacer (ITS) region.
68
 The 
active EtOAc extract was fractionated by repeated silica gel column chromatography, and 
compounds were further purified with Sephadex LH-20 to afford heptelidic acid (1) (Figure 
7.1.2) as the antiplasmodial and phytotoxic constituent. Its identity was confirmed by 
comparison of the physical and spectroscopic data with those reported.
180
 This sesquiterpene 
lactone has been isolated
180
 from Trichoderma viride, Chaetomium globsum, and Gliocladium 
virens, by Itoh et al., and  was demonstrated to possess antiplasmodial activity.
67
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Figure 7.1.2.  Heptelidic acid (1) 
  
Heptelidic acid (1) exhibited moderate antiplasmodial activity (Table 7.1.1) but also 
showed cytotoxicity against Vero cells (Table 7.1.1), kidney epithelial cells, and a panel of solid 
tumor cell lines (Table 7.1.3). This compound showed moderate phytotoxic activity against a 
dicot (Table 7.1.2). The observed general cytotoxicity precludes heptelidic acid as a viable 
antimalarial drug lead.  
7.1.4. Biological Activities  
 
Table 7.1.1.  Antiplasmodial activity of 1 
 
 
 
Compound 
 Chloroquine-
sensitive (D6)-clone  
Chloroquine-resistant 
(W2)-clone  
Cytotoxicity  
to Vero cells  
IC50 nM S. I. IC50 nM  S. I. IC50 nM  
heptelidic acid (1)  0.30  2.0  0.27  2.3  0.61  
chloroquine
a
  0.03 496.6 0.31 48.1 NC 
artemisinin
a
  0.02 845 0.01 1690 NC 
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a 
Positive controls  
NC, not cytotoxic  
S. I. (selectivity index) = IC50 for cytotoxicity/IC50 for antiplasmodial activity  
 
Table 7.1.2. Phytotoxic activity of 1 
 
 Compound Lettuce Bentgrass 
heptelidic acid (1)  4 1 
 
Ranking based on scale of ο to 5  
0 = no effect  
5 = no growth  
Solvent used, 10% acetone  
Concentration used, 1mg/mL 
 
Table 7.1.3. Cytotoxic activity [IC50 (µM)] of 1 
 
Compound SK-MEL KB BT-549 SK-OV-3 LLC-PK11 
heptelidic acid (1) 2.67 3.21 3.4 11.8 2.32 
doxorubicin
a
  1.29 2.12 1.83 1.47 1.28 
 
a 
Positive control.  
IC50 = concentration casusing 50% growth inhibition  
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SK-MEL = human malignant melanoma  
KB  = human epidermal carcinoma  
BT-549 = human breast carcinoma (ductal)  
SK-OV-3 = human ovary carcinoma  
LLC-PK11 =  pig kidney epithelial  
 
7.1.5. Experimental 
 
7.1.5.1. General 
 
Melting points were measured on a Unimelt, Thomas-Hoover capillary melting point 
apparatus. NMR spectra were recorded on a Bruker 400 MHz spectrometer using 
CDCl3/methanol-d4 as the solvent unless otherwise stated. MS analyses were performed on an 
Agilent Series 1100 SL equipped with an ESI source (Agilent Technologies, Palo Alto, CA). 
Column chromatography was carried out on Merck silica gel 60 (230-400 mesh) and Sephadex 
LH-20. Preparative TLC was carried out using silica gel GF plates (20 × 20 cm, thickness 0.25 
mm). HPLC analysis was conducted on a Hewlett-Packard Agilent 1100 with diode array 
detector.  
 
7.1.5.2. Isolation of Xylaria sp. from T. taxifolia  
 
Diseased leaves were collected from a cultivated T. taxifolia plant. Leaves were surface 
sterilized with 5% Chlorox for 5 minutes and rinsed with sterile water three times. Transverse 
 148 
 
sections from the dried leaf were cut aseptically into small portions and immersed in the potato 
dextrose plates. The plates were incubated for two weeks, and fungal colonies were subcultured 
to PDA plates to isolate pure fungal Xylaria sp.  
 
7.1.5.3. Fermentation, Extraction, and Purification 
 
Xylaria sp. was cultured in two conical flasks (1 L) containing 500 mL of Potato 
Dextrose Broth and incubated at 27 ºC for 18 days on an orbital shaker at 100 rpm. The media 
was separated by filtration. The culture broth was extracted with EtOAc (× 3), and the organic 
layer was evaporated to give an oily residue (410 mg).  
The oily extract (400 mg) was chromatographed over a silica gel gravity column using 
hexanes, CH2Cl2, and MeOH gradients as mobile phase to give 12 fractions. Fractions 5-9, which 
showed antiplasmodial activity, were combined, chromatographed over Sephadex LH-20, and 
washed with 100% MeOH to give heptelidic acid (1, 12.0 mg). 
 
Compound 1 : Heptelidic acid; white powder;  
1
H and 
13
C NMR
 
were consistent with 
those reported.
180
  [α]26D +2.5  (c 0.28, CHCl3) lit
180
 +7.7;  HRESIMS [M + H]
 +
 m/z 281.1422 
(calcd for [C24H33NO4 + H]
 +
 m/z 281.1389) 
 
7.1.5.4. Biological Assay 
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7.1.5.4.1. Antiplasmodial Assay  
 
In vitro antiplasmodial activity against D6 (chloroquine sensitive) and W2 (chloroquine 
resistant) strains of Plasmodium falciparum was determined as described earlier.
69
 
 
7.1.5.4.2. Phytotoxic Assay 
 
 The bioassay for phytotoxicity was carried out according to the procedure described by Dayan et 
al.
70
 using bentgrass (Agrostis stolonifera) and lettuce (Lactuca sativa L.cv. “Iceberg”), in 24-
well plates. 
 
 
7.1.5.4.3. Cytotoxicity Assay 
 
In vitro cytotoxicity was determined against a panel of mammalian cells as described earlier.
76
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SECTION 7.2: ANTIMALARIALS FROM ALTERNARIA SP. 
7.2.1. Summary 
 
An Alternaria strain isolated from a diseased leaf of T. taxifolia exhibited antiplasmodial 
and phytotoxic activities. Bioassay-guided fractionation of this extract afforded orsellinic acid 
(2), penicillic acid (3), and a diastereomeric mixture of two new compounds, 6-hydroxy-5,6-
dihydropenicillic acid (4). Penicillic and orsellinic acids showed strong phytotoxic activity and 
the former showed weak antiplasmodial activity.   
 
7.2.2. Introduction 
 
Figure 7.2.1. PDA plate of Alternaria sp. 
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The genus Alternaria is widely distributed and a number of its species are known as plant 
pathogens.
181
 Although several diverse secondary metabolites have been reported from 
terrestrial,
181
 marine,
182
 and endophytic Alternaria sp., no antimalarial compounds have yet been 
reported.  The EtOAc extract of the broth and mycelia of this fungus had similar chemical 
profiles and showed weak antiplasmodial activity against chloroquine-sensitive (D6) and -
resistant (W2) strains of P. falciparum and potent phytotoxic activity against both a dicot 
(lettuce, Lactuca sativa) and a monocot (bentgrass, Agrostis stolonifera). Bioactivity-guided 
fractionation of the combined extracts afforded orsellinic acid (2), penicillic acid (3), and a 
diastereomeric mixture of two new compounds, 6-hydroxy-5,6-dihydropenicillic acid (4) 
 
.  
 
 
 
 
 
 
 
 
 
 
Figure 7.2.2. Compounds isolated from Alternaria sp. 
 
 
orsellinic acid (2)        penicillic acid (3)   6-hydroxy-5,6-dihydropenicillic acid (4) 
 
4a        4b 
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7.2.3. Results and Discussion 
 
An Alternaria strain was isolated from a diseased leaf of T. taxifolia. Identification of this 
fungus was based on the DNA sequencing profile of the fungal internal transcribed spacer (ITS) 
region.
68
 The active extract was fractionated over silica gel and the active fractions were 
separated on Sephadex LH-20 to yield orsellinic acid (2), penicillic acids (3), and compound 4. 
The identities of orsellinic (2)
183
 and penicillic acids (3)
184
 were confirmed by comparing their 
physical and spectroscopic data with those reported. 
Compound 4 was obtained as a white semisolid, and its molecular formula was assigned 
as C8H12O5 by HRESIMS. The 
1
H (Figure 7.2.3) and 
13
C NMR (Figure 7.2.4) data of 4 clearly 
showed the presence of two related compounds in the ratio of approximately 1:2 (Table 7.2.1). 
Comparison of spectroscopic data of 4 with those of penicillic acid (3) indicated that they were 
closely related and that the vinyl group of the later has been replaced by a -CHCH2OH group 
creating an stereogenic center. As in the case of penicillic acid, this compound also forms 
epimeric lactols (Figure 7.2.5); however, due to the presence of the additional stereogenic center, 
compound 4 comprises two diastereomers. COSY (Figure 7.2.6), and HMBC correlations 
(Figure 7.2.7), were used to assign the resonances of both diastereomers, 4a and 4b (Figure 
7.2.8). In the COSY spectrum, both the oxygenated methylene (H-6) and the methyl doublet (H-
7) had crosspeaks with the upfield methine multiplet (H-5). In the HMBC spectrum, oxygenated 
methylene (H-6) showed correlations to C-4, C-5, and C-7 supporting the structure proposed for 
this compound. Additional correlations shown in Figure 7.2.8 further support this structure. A 
molecular mechanics energy minimization method showed 4a, as depicted in Figure 7.2.9, or its 
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enantiomer to be the more stable conformer. The absolute configuration at C-5 remains to be 
determined.  
Orsellinic acid has previously been isolated from lichens
183
 and several fungi species. 
185
 
This compound showed good phytotoxicity (Table 7.2.2).  Anti-oxidant,
183
 antibacterial,
186
 and 
growth inhibitory
187
 activities of orsellinic acid have been reported. Penicillic acid has been 
reported
188-190
 from several fungi and is known to be cytotoxic to mammalian cells. Penicillic 
acid showed weak in vitro antiplasmodial activity against chloroquine-sensitive (D6) and -
resistant (W2) strains of Plasmodium falciparum (Table 7.2.3) and good phytotoxic activity 
against both a monocot and a dicot (Table 7.2.2). Phytotoxic activity of penicillic acid against 
radical growth of Amaranthus hypochondriacus has been reported.
191
 Orsellinic acid is the 
intermediate for the biosynthesis of penicillic acid derivatives.
184
  
 
 
Figure 7.2.3. 
1
H NMR spectrum of 4  
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Figure 7.2.4. 
13
C NMR spectrum of 4  
 
 
   4a      4b 
6-Hydroxy-5,6-dihydropenicillic acid  
 
Figure 7.2.5. Formation of C-4 diastereomers (4a >4b, 2:1)  
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Figure 7.2.6. COSY spectrum of 4  
 
 
Figure 7.2.7. HMBC spectrum of 4 
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Figure 7.2.8.   COSY (  ) and HMBC ( ) correlations of 4 
 
 
 
    
4a       4b 
Figure 7.2.9. Energy minimized structures (4a > 4b; 2:1) 
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Table 7.2.1.   
1
H and 
13
C NMR of 3, 4a and, 4b in CDCl3- Methanol-d4 
 
Carbon penicillic acid (3) 4a 4b 
δC
b
 δH 
a 
(J in Hz) δC
b
 δH 
a 
(J in Hz) δC
b
 δH 
a 
(J in Hz) 
1 172.0 
 
171.6 
 
171.6 
 2 89.1 5.48, s 88.8 4.85, s 88.7 4.82, s 
3 179.4 
 
179.0 
 
180.2 
 4 116.5 
 
105.9 
 
104.8 
 5 139.3 
 
38.3 2.05, m 41.1 1.91, m 
6 116.5 5.12, s, 5.22, s 63.4 3.63, m 62.7 3.48, m 
7 17.1 1.77, s 10.6 0.5, d (8.0) 10.6 0.50, d (8.0) 
8 59.9 3.91, s 59.4 3.67, s 59.3 3.64, s 
 
a1
H NMR recorded at 400 MHz, 
b13
C NMR spectra recorded at 100 MHz 
7.2.4. Biological Activities   
 
Table 7.2.2. Phytotoxic activity of 2-4 
 
 
 
 
 
 
Ranking based on scale of ο to 5  
0 = no effect 5 = no growth  
Solvent used, 10% acetone 
Concentration used, 1mg/mL 
Compound Lettuce Bentgrass 
orsellinic acid (2) 5 5 
 penicillic acid (3) 4 5 
6-hydroxy-5,6-dihydropenicillic acid (4) 1 3 
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Table 7.2.3.  Antiplasmodial activity of 2-4 
 
 
a 
Positive controls  
NC, not cytotoxic 
NA, not active   
S. I. (selectivity index) = IC50 for cytotoxicity/IC50 for antiplasmodial activity  
 
 
 
Compound 
 Chloroquine-
sensitive (D6)-clone  
Chloroquine-
resistant (W2)-
clone  
Cytotoxicity  
to Vero cells  
IC50 nM S. I. IC50 nM  S. I. IC50 nM  
orsellinic acid (2) NA  NA  NC 
penicillic acid (3) 17.1 >1.6 15.9 >1.7 NC 
6-hydroxy-5,6-
dihydropenicillic acid (4a & 
4b) 
NA  NA  NC 
chloroquine
a
  0.03 496.6 0.31 48.1 NC 
artemisinin
a
  0.02 845 0.01 1690 NC 
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7.2.5. Experimental 
7.2.5.1. General 
 
Carried out as previously described in the section 7.1.4.1 
 
7.2.5.2. Isolation of Alternaria sp. 
 
Alternaria sp. was isolated as described in the Section 7.1.5.2 
 
7.2.5.3. Fermentation, Extraction, and Purification 
 
Alternaria sp. was cultured in four conical flasks (2 L) containing 500 mL of PDB and 
incubated at 27 
ο
C for 21 days on an orbital shaker at 100 rpm. The mycelium was separated by 
filtration, and then the broth was extracted with EtOAc (× 3) separately. The organic layer of the 
broth was evaporated to give a brown residue (1.85 g).  
The brown extract (1.8 g) was chromatographed over a silicagel column using hexanes, 
CH2Cl2, and MeOH gradients as mobile phase to yield nine fractions. Further separation of the 
active fractions (5-8) by Sephadex LH-20 gel filtration (100% MeOH) afforded orsellinic acid 
(2, 30.0.0 mg), penicillic acid (3, 15 mg), and a diastereomeric mixture of two new compounds, 
6-hydroxy-5,6-dihydropenicillic acid (4a and 4b, 6.0 mg).  
 
Compound 2 : Orsellinic acid; 
1
H ,
13
C NMR, and 
 
HRESIMS were consistent with reported 
data.
183
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Compound 3 :  Penicillic acid; colorless crystalline solid (MeOH); mp 80 
ο
C (lit
190
 82-85
 ο
C) 
1
H
190
 and 
13
C NMR
184 
were consistent with literature values. 
 
Compound 4 :  6-Hydroxy-5,6-dihydropenicillic acid; amorphous powder; 
1
H and 
13
C NMR (see 
Table 7.2.1) HRESIMS [M + H]
 +
 m/z 535.1651 (calcd for [C24H33NO4 + H]
 + 
 
 
535.1604). The 
most stable conformer was deduced using molecular mechanics (MM2) energy minimization 
program (ChemBio3D Ultra 12.0). 
 
7.2.5.4.  In Vitro Biological Assay 
 
7.2.5.4.1. Antiplasmodial Assay  
 
In vitro antiplasmodial activity was determined against D6 (chloroquine sensitive) and W2 
(chloroquine resistant) strains of Plasmodium falciparum as described earlier.
69
 
 
7.2.5.4.2. Phytotoxic Assay 
 
 The bioassay for phytotoxicity was carried out as described by Dayan et al.
70
 using bentgrass  
(Agrostis stolonifera) and lettuce (Lactuca sativa cv. L., Iceberg), in 24-well plates. 
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7.2.5.4.3. Cytotoxicity Assay 
 
In vitro cytotoxicity was determined against a panel of mammalian cells as described
76
 earlier.   
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SECTION 7.3: ANTIMALARIALS FROM A NEW ISOLATE, UM #10 M 
 
7.3.1. Summary 
 
Bioassay-guided fractionation of an EtOAc extract of the broth of the new fungus, UM 
#10 M, isolated from a diseased T. taxifloia leaf, afforded two known cytochalasins, 19,20-
epoxycytochalasin C (5), 19,20-epoxycytochalasin D (6),
 
and a new analogue, 18-deoxy-19,20-
epoxycytochalasin C (7). All three compounds showed potent in vitro antiplasmodial activity and 
phytotoxicity with no cytotoxicity to Vero cells. These compounds were also not cytotoxic 
against a panel of solid tumor cell lines (SK-MEL, KB, BT-549, and SK-OV-3) and kidney 
epithelial cells (LLC-PK11). Evaluation of in vivo antimalarial activity of 19,20-
epoxycytochalasin C (5)  in a mouse model showed that this compound was toxic to animals at 
subtherapeutic doses.  
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7.3.2. Introduction 
 
 
Figure 7.3.1.   PDA plate of the new fungus, UM #10 M 
 
Even though this fungus was conclusively identified as a new species, 18S rDNA 
analysis and morphology indicated that it most probably belongs to the family Xylariaceae. 
Some members of this family have been identified
192
 as endophytes and plant pathogens. A 
number of cytochalasins have been reported
192
 from Xylariaceae and several other plant 
pathogenic
193, 194
 and endophytic
192, 195, 196
 ascomycete and basidiomycete genera, namely, 
Penicillium, Aspergillus, Zygosporium, Phoma, Metarhizum, Rosellinia, Ascochyta, Phomopsis, 
Chaetomium, Hypoxylon, and Daldinia. The chemistry and biology of cytochalasins have 
extensively been studied by several research groups.
192
  Generally, the cytochalasin skeleton 
includes a macrocyclic ring, fused with a phenylsubstituted perhydroisoindolone group. 
Cytochalasins are known to be involved in fungal virulence, food spoilage, and symbiotic 
fungus-host relationships.
192
   Cytochalasin B
197, 198
 and D
199
 have been identified as 
microfilament-targeting molecules capable of blocking several cellular processes involving  
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cytokinesis, intracellular motility, and cytosis,
192, 200
 resulting in general cytotoxicity. 
Antiplasmodial
57
 and antitoxoplasma
199
 activities of cytochalasins have also been reported.  
The EtOAc extract of this fungal broth showed potent antiplasmodial activity and low 
cytotoxicity. Bioassay-guided fractionation yielded two known cytochalasins, 19,20-
epoxycytochalasin C (5),
201
 and 19,20-epoxycytochalasin D (6),
202
 and a new analogue, 18-
deoxy-19,20-epoxycytochalasin C (7) as active constituents.  
 
7.3.3 Results and Discussion 
 
Analysis of the 18S rDNA of this fungus indicated
68
 that it is related to both Xylariaceae 
sp., and Sordariomycetes sp., with 93 % sequence homology. Morphologically, (Figure 7.3.1) 
this fungus showed close similarities to Muscodor sp. of the family Xylariaceae originally 
isolated from Cinnamomum zeylanicum  by Strobel and coworkers.
203
 Since it does not show 
100% homologies to all the published sequences, this fungus was designated as a new isolate, 
UM # 10 M. 
An EtOAc extract of the culture broth of UM # 10 M, was fractionated over silica gel, 
followed by separation over Sephadex LH-20, and PTLC to afford compounds 5-7. Compounds 
5
201
 (19,20-epoxycytochalasin C) and 6
202
 (19,20-epoxycytochalasin D) (Figure 7.3.2) have been 
isolated from Xylaria obovata
201
 and X. hypoxylon,
202
 respectively, and were identified by 
comparing their spectroscopic and physical data with reported data. 
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  5     6               7 
 
Figure 7.3.2. Structure of cytochalasins (5-7)  
  
Compound 7 was obtained as a white amorphous powder, and HRESIMS determined its 
molecular formula to be C30H37NO6, one oxygen less than that of 5. Comparison of the 
1
H 
(Figure 7.3.4) and 
13
C NMR (Figure 7.3.5) resonances of 7 with those of 5 showed similarities 
except for the changes observed due to the absence of the hydroxy group at C-18 (Table 7.3.1). 
The 
1
H NMR spectrum of 7 showed a -CH3 doublet (δH 1.32) for 23-CH3 instead of a -CH3 
singlet (δH 1.54) as in 5 indicating the absence of the C-18 hydroxy group. HMBC correlation 
(Figures 7.3.6 and 7.3.7) of H-18 (δH 2.18) with C-20 (δC 57.6), C-19 (δC 58.6), and C-17 (δC 
216.9), in combination with COSY (Figure 7.3.8) cross peaks between the C-18 methine doublet 
(δH 2.18) and the C-19 oxymethine multiplet (δH 3.01) supported the gross structure of 7 to be 
the 18-deoxy analogue of 5, thus named as 18-deoxy-19,20-epoxycytochalasin C (7). Relative 
configuration at C-18 was assigned from ROESY correlations of 7 (Figure 7.3.9. and 7.3.10). In 
the ROESY spectrum H-18 displayed interactions with H-19 indicating the cofacial orientation 
of these protons. Since the analogues 5-7 presumably share a common biosynthetic origin, 
compound 7 also may possess 3S, 4R, 5Z, 7S, 8R, 9R, 13E, 16S, 18S, 19R, 20S, 21S absolute 
configuration. 
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Figure 7.3.3.  
1
H NMR spectrum of 7  
  
 
 
Figure 7.3.4.  
13
C NMR spectrum of 7  
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Figure 7.3.5.  HMBC spectrum of 7 
 
 
 
 
Figure 7.3.6.    HMBC (  ) correlations of 7 
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Figure 7.3.7.  COSY spectrum of 7 
 
Figure 7.3.8.  ROESY spectrum of 7 
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Figure 7.3.9.   COSY ( ) and ROESY ( ) correlations of 7 
 
 
 
 
Figure. 7.3.10. Gliding motility in apicomplexan parasites  
 
Reprinted by permission from Nature Publishing Group
11
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Table 7.3.1. 
1
H and 
13
C NMR data of 5-7 in CDCl3-Methanol-d4 
 
Carbon  
5 6 7 
δC
b
 δH 
a 
(J in Hz) δC
b
 δH 
a 
(J in Hz) δC
b
 δH 
a 
(J in Hz) 
1 175.0 
 
175.0 
 
175.1 
 3 61.0 3.35, m 54.1 3.28, s 61.1 3.32, m 
4 49.9 2.50, s 49.9 2.25, m 49.9 2.43, bs 
5 126.4   32.3 2.53, m 128.5 
 6 131.8   148.0 
 
131.7 
 7 68.1 3.76, d (12) 70.2 3.78, d, (12.0) 68.1 3.77, d  
8 48.7 2.25, t (12) 46.2 2.59, m 49.0 2.27, dd, (10, 10) 
9 52.0   53.0 
 
51.8 
 10 44.1 3.03, d (10) 44.1 2.84, d, (12.0) 44.4 3.04, bd, (7.5) 
11 16.7 1.19, s 13.7 13.1, d, (8.0) 14.1 1.26, s 
12 13.8 1.62, s 113.7 5.24, bs, 5.02, bs 13.9 1.65, s 
13 131.4 5.5, m 131.8 5.76, m 131.0 6.24, dd, (15.5, 10.4) 
14 132.9 5.99, dd (12, 8) 132.9 5.82, m 133.7 5.61, m 
15 37.5 2.63, q (12), 2.14, m 37.5 2.65, m 37.6 2.53, q (10.8), 2.14 (m) 
16 41.7 3.27, s 41.7 3.24, m 42.9 2.98, d (1.92) 
17 215.3   215.3 
 
216.9 
 18 76.3   76.2 
 
52.1 2.18, m (overlap) 
19 53.2 3.38, s 59.8 3.21, s 58.6 3.01, m (overlap) 
20 59.9 3.25, m 53.0 3.46, m 57.6 3.38, d (1.97)  
21 72.0 5.75, s 72.0 5.43, s 72.3 5.69, s 
22 18.9 1.21, d (12) 18.9 1.19, d, (6.6) 18.8 1.12, d (6.7) 
23 21.5 1.54, s 21.5 1.53, s 17.1 1.32, d (6.9) 
24 170.4   170.4 
 
170.5 
 
1
7
0
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25 20.5 2.18, s 20.5 2.17, s 20.7 2.15, s 
1' 137.3   137.3 
 
136.9 
 2',6' 129.2 7.28, m 129.2 7.29, m 129.4 7.26, m 
3',5' 128.6 7.33, m 128.6 7.34, m 128.7 7.33, m 
4' 126.8 7.25, m 126.9 7.25, m 126.9 7.25, m 
 
a1
H NMR spectra recorded at 400 MHz, 
b13
C NMR spectra recorded at 100 MHz 
1
7
1
 
 
 172 
 
Compounds 5-7 showed potent selective in vitro antiplasmodial activity against chloroquine-
sensitive (D6) and -resistant (W2) strains of P. falciparum (Table 7.3.2) and phytotoxic activity 
against both a monocot (bentgrass, Agrostis stolonifera) and a dicot (lettuce, Lactuca sativa) 
(Table 7.3.3).  These compounds showed no cytotoxicity against a panel of solid tumor cell lines 
(SK-MEL, KB, BT-549, and SK-OV-3) and kidney epithelial cells (LLC-PK11) (Table 7.3.4). 
Antiplasmodial
57
 and antitoxoplasma
199
 activities of cytochalasins have been reported. 
These compounds have been shown
11
 to inhibit the actin-based gliding motility (Figure 7.3.11) 
and impair host cell invasion of apicomplexan parasites of Toxoplasma gondii
199
 and P. 
falciparum.
204
 
 Evaluation of antimalarial activity of compound 5 in a mouse model showed that it was 
toxic to mice at subtherapeutic doses (Table 7.3.5), thus precluding it as an antimalarial lead.   
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7.4. Biological Activities 
 
Table 7.3.2.  Antiplasmodial activity of 5-7 
 
 
 
Compound 
 Chloroquine-
sensitive (D6)-
clone  
Chloroquine-resistant 
(W2)-clone  
Cytotoxicity  
to Vero cells  
IC50 nM S. I. IC50 nM  S. I. IC50 nM  
19,20-epoxycytochalasin C (5) 0.07 >129.8 0.05 >181.8 NC 
19,20-epoxycytochalasin D (6) 0.04 226.7 0.04 226.7 NC 
18-dehydroxy-19,20-
epoxycytochalasin C (7) 
0.56 >7 0.19 >49.6 NC 
chloroquine
a
  0.03 496.6 0.31 48.1 NC 
artemisinin
a
  0.02 845 0.01 1690 NC 
 
a 
Positive controls  
NC, not cytotoxic  
NA, not active  
S. I. (selectivity index) = IC50 for cytotoxicity/IC50 for antiplasmodial activity  
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Table 7.3.3. Phytotoxic activity of 5-7 
 
Compound Lettuce Bentgrass 
19,20-epoxycytochalasin C (5) 3 2 
19,20-epoxycytochalasin D (6) 3 3 
18-dehydroxy-19,20-epoxycytochalasin C (7) 3 4 
 
Ranking based on scale of ο to 5  
0 = no effect  
5 = no growth  
Solvent used, 10% acetone  
Concentration used, 1mg/mL 
 
Table 7.3.4. Cytotoxic activity [IC50 (µM)] of 5-7 
 
Compound SK-MEL KB BT-549 SK-OV-3 LLC-PK11 
19,20-epoxycytochalasin C (5)  8.02 NA NA NA NC 
19,20-epoxycytochalasin D (6) >19.1 NA 7.84 NA 8.4 
18-dehydroxy-19,20-
epoxycytochalasin C (7) 12.41 19.7 6.89 NA >19.7 
doxorubicin
a
  1.29 2.12 1.83 1.47 1.28 
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NA: not active at the highest test concentration of 10 µg/mL.  
a 
Positive control.  
IC50 = concentration casusing 50% growth inhibition  
SK-MEL = human malignant melanoma  
KB  = human epidermal carcinoma  
BT-549 = human breast carcinoma (ductal)  
SK-OV-3 = human ovary carcinoma  
LLC-PK11 =  pig kidney epithelial  
 
 
 Table 7.3.5. In vivo antimalarial activity of 5  
 
 
Treatment  
(PO) 
Dose 
(mg/kg × # 
days post 
infection) 
% Parasitemia 
suppression
1
 
Survival
2
 Day of 
Death 
MST
3
 Cure
4
 
Day 5 Day 7 
Vehicle  × 3 - - 0/5 13/5/13/14/14 11.8 0/5 
chloroquine
a
  100 × 3 100 100 5/5 28/28/28/28/28 28 2/5 
5   100 × 3 33.87 71.36 0/5 17/3/5/1/0 5.2 0/2 
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1
% suppression in parasitemia is calculated by considering the mean parasitemia in the vehical 
control as 100%.  
Parasitemia suppression < 80% is considered as non-significant 
2
Number of animals that survived day 28/total animals in group (the day of the death-post 
infection) 
3
% MST – mean survival time (days) 
4
Number of mice without parasitemia (cured) till day 28 post-infection 
 
7.5. Experimental 
7.5.1. General 
 
Carried out as previously described in Section 7.1.4.1. 
 
7.5.2. Isolation of the Fungus from T. taxifolia  
 
UM # 10 M was isolated as previously described in Section 7.1.5.2. 
 
7.5.3. Fermentation, Extraction, and Purification 
 
Fungus UM # 10 M was cultured in four conical flasks (2 L) containing 500 mL of PDB 
and incubated at 27 
ο
C for 30 days on an orbital shaker at 100 rpm. Mycelia and broth were 
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separated by filtration and extracted with EtOAc (×3). The organic layer from the broth was 
evaporated to give a brown/black residue (625 mg).  
This extract (600 mg) was chromatogtaphed on Sephadex LH-20 and eluted with 80% MeOH in 
CHCl3 to give 10 fractions. Fractions 2, 3, and 4 showed antimalarial activity.  Fraction 2 was 
subjected to silica gel gravity column chromatography using hexanes, CH2Cl2, and MeOH 
gradient as the mobile phase to yield five fractions. Subfraction 3 which showed antimalarial 
activity was further separated by preparative thin layer chromatography (PTLC) using 0.4 % 
MeOH in CHCl3 (× 3) as the developing solvent to obtain 19,20-epoxycytochalasin C (5, 85.0 
mg). Fractions 3 and 4 were also subjected to PTLC using 0.4 % MeOH in CHCl3 (× 3) as the 
developing solvent to afford 19,20-epoxycytochalasin D (6, 4 mg), and the new analogue, 18-
deoxy-19,20-epoxycytochalasin C (7, 2  mg). 
 
Compound 5 :  19,20-Epoxycytochalasin C; white amorphous powder; 
1
H, 
13
C NMR data (Table 
7.3.1) were consistent with literature values.
201
 [α]26D -13 (c 0.5, CHCl3) lit
201
 -6.8; HRESIMS 
[M + H]
 +
 m/z 524.264 (lit
201
 [M+ H]
 +
 524.2) 
 
Compound 6 :  19,20-Epoxycytochalasin D; white amorphous powder;  
1
H, and 
13
C NMR, data 
(Table 7.3.1) were consistent with literature values.
202
 [α]26D -113 (c 0.085, CHCl3) lit
202
 -228; 
HRESIMS [M + H]
 +
 m/z 524.283 (lit
202
 [M+ H]
 +
 524.2) 
 
Compound 7 :  18-Deoxy-19,20-epoxycytochalasin C; white amorphous powder; 
1
H and 
13
C 
NMR (see Table 7.3.1.) [α]26D -2.4 (c 0.09, CHCl3); HRESIMS [M + H]
 +
 m/z 508.2703 (calcd 
for [C24H33NO4 + H]
 +  
508.2620) 
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7.5.4. Biological Assay 
 
7.5.4.1. Antiplasmodial Assay  
 
In vitro antiplasmodial activity was determined as described earlier.
69
 
 
7.5.4.2. Phytotoxic Assay 
 
 The bioassay for phytotoxicity was carried out as described
70
 by Dayan and coworkers. 
 
 
7.5.4.3. Cytotoxicity Assay 
 
In vitro cytotoxicity was determined against a panel of mammalian cells as described
76
 earlier.  
 
7.5.4.4. In Vivo Antimalarial Assay 
 
In vivo antimalarial activity was determined as described in Chapter 4 (4.5.7).  
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SECTION 7.4: ANTIMALARIALS FROM BOTRYOSPHAERIA DOTHIDEA 
 
7.4.1. Summary 
 
The culture broth extract of Botryosphaeria dothidea showed antimalarial and phytotoxic 
activities. Bioactivity-guided fractionation of this extract afforded a mixture of two known 
phytotoxins, sapinopyridiones (8a) and flavipucine (8b), one inactive -alkyl-,-unsturated--
lactam (9), and three antiplasmodial -alkyl--lactam derivatives (10-12).   
 
7.4.2. Introduction 
 
Botryosphaeria dothidea was isolated from seeds collected from cultivated Torreya 
taxifolia trees that included plants with disease symptoms. This fungus is a member of the family 
Botryosphaeriaceae (Botryosphaeriales, Ascomycetes) which includes species of telemorph and 
anamorph stages of Diplodia, Botryosphaeria, Fusicoccum, Dothiorella, Lasiodiplodia, and 
Sphaeropsis.
205
 Botryosphaeria is the teleomorph (sexual) stage of the anamorph (asexual) genus 
Sphaeropsis. Chemical investigation of Sphaeropsis sapinea has been reported
206
 by Evidente et 
al.. S. sapinea is known
206
 to be identical to B. dothidea. S. sapinea, also known as Diplodia 
pinea, is the causative agent for shoot blight and canker diseases of pines and other conifers.
208
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Several phytotoxins, sapinopyridione,
206
 sphaeropsidins,
209-213
 sapinofuranones,
214
 
sphaeropsidones,
215
 and dimedone methyl ethers
215
  have been reported from  S. sapinea  isolated 
from conifers.  Most of the fungi of this family are known
205
 as endophytes and/or latent 
pathogens and cause diseases with the onset of environmental stress factors due to climate 
changes. This is the first report of the isolation of a fungus producing compounds capable of 
severe plant pathogenicity from the seeds of T. taxifolia. 
 
 
 
 
Figure 7.4.1.   PDA plate of B. dothidea 
 
Bioassay-guided fractionation of an EtOAc extract of the potato dextrose broth of B. 
dothidea resulted in the isolation of a mixture of the known closely related phytotoxins, 
sapinopyridiones (8a)
206, 216
  and flavipucine (8b),
216, 217
 and four new -alkyl --lactam 
derivatives (9-12). Three of these (10-12) showed potent, selective antiplasmodial activity.  
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7.4.3. Results and Discussion 
 
 Analysis
68
 of 18S rDNA of the fungus gave 100 % sequence identities to B. dothidea. 
An EtOAc extract of B. dothidea culture broth was fractionated by silica gel column 
chromatography followed by Sephadex LH-20 gel filtration (MeOH) and repeated  reversed- 
phase HPLC ( MeOH-H2O) to afford a mixture of two known phytotoxins,
216
 sapinopyridione 
(8a) and flavipucine (8b), and four related new compounds (9-12).  Structure elucidation of 
sapinopyridione (8a) and flavipucine (8b) was carried out by comparing the spectroscopic data 
with reported data.
206, 217
  
 
Compound 9 was isolated as a brown amorphous solid, and its molecular formula was 
determined as C22H29NO5 by HRESIMS. The 
1
H (Figure 7.4.2) and 
13
C NMR (Figure 7.4.3) 
spectra of 9 (Table 7.4.1) indicated the presence of 22 carbons resonances that consisted of eight 
quaternary, six methine, two methylene, and six methyl carbons. Analysis  of 
1
H and 
13
C NMR 
data of 9 indicated that it was an α-alkyl-α,β-unsaturated-γ-lactam derivative, related to 
epolactaene
218
 (Figure 7.4.4). Comparison of the 
1
H and 
13
C NMR data of these compounds 
showed that they had the same side chain but differed in the 2-pyrrolidone ring. These 
differences were attributable to the replacement of the epoxide and the hydroxy groups in the 2-
pyrrolidone ring of epolactaene by a double bond and methoxy group, respectively, in 9. In the 
HMBC spectrum of 9 (Figure 7.4.5),  observed cross-peaks of H-1 (δH 1.72)  with C-2 (δC 139.9) 
and C-3 (δC 130.3); H-2 (δH 6.96)  with C-3 (δC 130.3) and C-19 (δC 167.8);  H-4 (δH 5.98) with 
C-21 (δC 14.3), C-19 (δC 167.8), and C-2 (δC 139.9); H-21 with C-6 (δC 135.6) and C-4 (δC 112.1);  
H-8 (δH 2.35) with C-6 (δC 135.6), C-7 (δC 128.2), C-9 (δC 30.1), and C-10 (δC 150.0); and H-22 
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(δH 1.82) with C-10 (δC 150.0) and C-6 (δC 192.1) confirmed the structure of the side chain. 
Further, HMBC correlations of the -OCH3 singlet at δH 3.18 with C-15 (δC 139.9), the 18-CH3 
singlet at δH 1.61 with C-15 (δC 89.23) and C-14 (δC 149.5), and the H-14 olefinic proton singlet 
at δH 6.83 with C-17 (δC 168.3) confirmed the structure of the 2-pyrrolidone moiety and its link to 
the side chain.  Similarly, a methyl triplet (δH 1.89) at C-22 showed correlations with C-12 (δC 
191.4) and C-10 (δC 148.6), and other COSY (Figure 7.4.6) and HMBC (Figure 7.4.7) 
correlations supported this structure (Figure 7.4.8). The configuration of the olefinic  bond 
between C-6 and C-7 was determined to be E (trans) by the coupling constant (J = 15.6 Hz). Due 
to the lack of NOESY or ROESY data, the configuration of the remaining double bonds could 
not been determined. However, ROESY data indicated that olifinic bonds between C-2 and C-3, 
C-4 and C-5, and C-10 and C-11 in compound 10 were in E configuration (vide infra). Since 
compounds 9 and 10 presumably share a common biosynthetic origin these bonds in compound 9 
also have the same configurations. 
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Figure 7.4.2. 
1
H NMR spectrum of 9 
 
 
 
Figure 7.4.3. 
13
C  NMR spectrum of 9 
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  Figure 7.4.4. Structurally related compounds  
 
 
   
epolactaene     fusarin C 
 
   
  fusarin A      fusarin D   
  
   
  fusarin F      luciactaene 
 
   
  NG-391      PI-091 
 
 
              
Figure 7.45 Structurally reported similar compounds  
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Figure 7.4.5. COSY spectrum of 9 
 
Figure 7.4.6. HMBC spectrum of 9 
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Figure 7.4.7.  HMBC ( ) and COSY ( ) correlation of 9 
  
The antimalarial fraction of the extract was found to be a mixture of three minor 
diastereomers (10-12) which was separated by preparative HPLC. Owing to lack of sufficient 
material and the apparent instability of compounds, only tentative structures could be proposed 
for these compounds. 
Compound 10 gave the molecular formula, C24H33NO7, by HRESIMS. Its NMR spectra 
showed resonances due to the same side chain as 9, and COSY and HMBC data provided 
confirmatory evidence (Figures 7.4.9–7.4.22). Comparison of the remaining resonances with 
those of 9 indicated the absence of the olefinic bond and the methoxy group in the 2-pyrrolidone 
ring and the presence of three oxygenated carbons due to a glycerol moiety.  
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Figure 7.4.8.  Structure of compounds isolated from B.dothidea
 
 
sapinopyridione (8a)                           flavipucine (8b) 
 
 
9 
 
10-12 
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Table 7.4.1. 
1
H and 
13
C NMR data of compounds 9-12 in CDCl3-Methanol-d4 
 
Position 
Epolactaene 9 10 11 12 
δC
b δH 
a 
(J in Hz) δC
b δH 
a 
(J in Hz) δC
b δH 
a 
(J in Hz) δC
b δH 
a 
(J in Hz) δC
b δH 
a 
(J in Hz) 
1 16.0 1.72, dd, 1.2, 7.3 15.9 1.72, d, 7.1 15.8 1.55, d, 6.9 15.7 1.62, d, 7.1 15.8 1.56, d, 9.5 
2 140.9 6.93, dq, 1.0, 7.3 139.9 6.93, q, 7.1 140.1 6.70, q, 10.0 140.0 6.85, q, 7.1 140.1 6.80, m 
3 131.9 
 
130.3 
 
130.5 
 
130.3 
 
130.4 
 4 123.7 5.94, br s 123.1 5.97, br s 122.6 5.76, s 122.6 5.83,s 122.6 5.77,s 
5 139.6 
 
137.6 
 
138.0 
 
138.1 
 
137.9 
 6 136.6 6.27, d, 15.6 135.6 6.23, d, 15.6 135.0 6.1, d, 15.6 134.9 6.15, d, 15.4 134.9 6.15, d, 15.7 
7 129.7 
5.77, dt, 15.6, 
7.8 128.2 
5.68, dt, 15.2, 
6.6 128.8 
5.60, dt, 15.4, 
6.9 128.7 
5.65, dt, 15.6, 
7.2 128.8 5.56, m 
8 32.6 2.35, m 31.5 2.30, m 31.6 2.20, m 31.5 2.26, m 31.5 2.20, m 
9 30.1 2.47, m 28.4 2.40, m 29.4 2.30, m 29.4 2.35, m 29.4 2.30, m 
10 150.0 7.01, dt, 1.0, 7.3 148.6 6.56, t, 6.4 146.4 6.59, t, 4.6 146.8 6.67, t, 6.1 147.3 6.61,m 
11 137.2 
 
137.8 
 
138.8 
 
137.9 
 
137.9 
 12 192.1 
 
191.4 
 
196.2 
 
195.9 
 
195.2 
 
1
8
8
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a1
H NMR spectra recorded at 600 MHz. 
b13
C NMR spectra recorded at 100 MHz. 
 
13 63.9 
 
139.1 
 
50.0 3.21, s  49.28 3.28,s 49.15 3.23,s 
14 66.1 3.98, s 149.5 6.83, s 76.5 4.29, s 77.0 4.7, s 77.3 4.07, s 
15 84.8 
 
89.2 
 
83.9 
 
83.1 
 
85.2 
 17 172.2 
 
168.3 
 
168.3 
 
168.3 
 
168.3 
 18 22.2 1.51, s 24.4 1.61, s 20.3 1.46, s 20.2 1.52, s 20.2 1.47, s 
19 169.6 
 
167.8 
 
168.3 
 
168.3 
 
168.3 
 20 52.4 3.71, s 51.9 3.74, s 51.9 3.55, s 51.8 3.62, s 51.9 3.57, s 
21 14.6 1.61, d, 1.3 14.3 1.62, s, 3.4 14.3 1.45, s 14.2 1.51, s 14.3 1.45, s 
22 11.1 1.82, s 11.1 1.89, s 11.5 1.67, s 11.6 1.62, s 11.4 1.63, s 
23 
    
60.6 3.48, m 61.5 3.64, m 61.6 
3.46, m 
(overlap)  
24 
    
70.4 3.65, m 68.3 
3.73, m 
(overlap) 68.3 
3.70, m  
(overlap) 
25 
    
61.9 3.40, d, 3.08 61.8 3.54, m 61.8 
3.80  
(overlap) 
1
8
9
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Figure 7.4.9.  
1
H NMR spectrum of 10 
 
 
Figure 7.4.10.  
13
C NMR spectrum of 10  
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Figure 7.4.11.  COSY spectrum of 10 
 
Figure 7.4.12. HMBC spectrum of 10 
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Figure 7.4.13.  ROESY spectrum of 10 
 
 
Figure 7.4.14.  
1
H NMR spectrum of 11 
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Figure 7.4.15. 
13
C NMR spectrum of 11  
 
 
Figure 7.4.16. COSY spectrum of 11 
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Figure 7.4.17. HMBC spectrum of 11 
 
 
 
Figure 7.4.18. 
1
H NMR spectrum of 12 
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Figure 7.4.19. 
13
C NMR spectrum of 12 
 
 
Figure 7.4.20.  COSY spectrum of 12 
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Figure 7.4.21. HMBC spectrum of 12 
 
The COSY (Figure 7.4.11) and HMBC (Figure 7.4.12) spectra of 10 showed, 
respectively, two oxymethylenes (δH 3.40 and 3.48) coupled with a methine multiplet (δH 3.65) 
and a methylene doublet (δH 3.40) correlating with C-23 (δC 60.6) and C-24 (δC 70.4), confirming 
the presence of a glycerol moiety. In the HMBC spectrum, H-14 of the 2-pyrrolidone ring had a 
cross peak with one of the oxygenated methylenes of glycerol, indicating one of its linkages. 
Based on the molecular formula C24H33NO7, this compound has an additional index of 
deficiency. The polarity of 10-12 was comparable to that of 9 indicating that additional hydroxy 
groups were functionalized. Even though no other cross peaks between the glycerol moiety and 
the 2-pyrrolidone ring were visible in the HMBC spectrum due to high noise levels, it was 
probable that the second oxygenated methylene group of the former was linked to C-15 of the 
latter. The tentative structure of 10 and its COSY and HMBC correlations are shown in Figure 
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7.4.22. Large coupling (J = 15.6 Hz) between H-6 and H-7 showed that the olefin bond between 
C-6 and C-7 was in E (trans) configuration. ROESY correlations, as shown in the Figure 7.4.23 
indicated the E configuration for the other double bonds in the side chain and cis orientation for 
two cyclic rings.  
HRESIMS data confirmed that compounds 11 and 12 had the same molecular formula, 
C24H33NO7 as that of 10.  NMR analysis showed that these compounds had identical side chains 
and the same gross structure. The addition of the glycerol moiety to the 2-pyrrolidone ring 
creates four stereogenic centers. Thus, these compounds 10-12 are likely diastereomeric as far as 
C-13, C-14, C-15, and C-24 are concerned? However, complete structure elucidation of these 
compounds was not possible due to lack of sufficient material.
  
  
Mass spectra, calculated for C21H26NO4, of compounds 10-12 had base peaks at m/z = 
355.1784. This fragment could form from the parent due to the loss of glycerol as shown in the 
Figure 7.4.24, further supporting the proposed structures. Compound 9 may be the biosynthetic 
precursor of these compounds.  
 
 
 
Figure 7.4.22.  HMBC ( ) and COSY ( ) correlations of 10 
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Figure 7.4.23.  ROESY (  ) correlations of 10 
 
Several compounds (Figure 7.4.4) structurally related to compounds 9-12 have been 
isolated and their biological activities have been studied. Epolactaene,
218
 isolated from 
Penicillum sp. has been shown to promote  neurite outgrowth and arrest the cell cycle at the 
G0/G1 phase in a human neuroblastoma cell line. In addition, Osada and coworkers reported
219
 
the ability of  epolactaene to bind human Heat shock protein (Hsp60) and inhibit the Hsp60 
chaperone activity that is involved in apoptosis, immunoregulatory function, and cell spreading; 
however, epolataene is known
220
 to be labile as it contains a conjugated triene moiety and an 
epoxy group which is activated by two oxo groups. Several fusarins have been isolated from 
Fusarium moniliforme,
221, 222
 and  Nectria coccinea.
217 
Of these compounds, fusarin C has been 
identified as a mutagen, and one of the compounds responsible for the toxicity associated with F. 
moniliforme has been found in contaminated food.
223, 224
 Luciactaene, a cell cycle inhibitor in 
p53-transfected cancer cells, and NG-391 have been reported from different Fusarium sp.
225
 A 
number of analogues of  the platelet aggregation inhibitor, PI-091, isolated from Paecilomyces 
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sp.,
226
 have been synthesized and their biological activities have been reported.
219
 Their 
biological activity is most likely due to the presence of reactive functional groups such as α, β-
unsaturated carbonyl, epoxide, and hemiaminal carbonyl, which could react with biological 
nucleophiles such as the sulfhydryl functionality of cysteine.
219
    
Sapinopyridione (Figure 7.4.8) has been reported from S. sapinea, the anamorph 
(asexual) genus of B. dothidea.
206
 (+)- and (-)-flavipucine (Figure 7.4.8) has been reported from 
plant pathogenic fungi Macrophoma sp.
216
 and  Phoma sp.
217
 respectively. 
 The fraction containing compounds 10-12 showed strong antiplasmodial activity (<1.17 
nM) with no cytotoxicity to Vero cells (Table 7.4.2). The lack of material prevented further 
biological studies on these compounds. However, due to instability and the toxicity reported for 
this class of compounds, they would not serve as potential antimalarial agents. 
Compound 9, sapinopyridione, and flavipucine were inactive in antiplasmodial assays. 
The mixture of sapinopyridione and flavipucine showed weak to moderate cytotoxicity (Table 
7.4.4). The mixture of sapinopyridione and flavipucine was highly phytotoxic to both monocots 
and dicots (Table 7.4.3). Phytotoxic activity of sapinopyridione and flavipucine  has been 
studied, and the oxirane ring and the oxo group in the aliphatic side chain have been determined 
to be  prerequisites for this acivity.
80
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Chemical formula C24H34NO7 [M+H]
 +
  Chemical formula C21H26NO4 [M+H]
 +
  
Exact mass m/z = 448.2335    Exact mass m/z = 356.1862 
 
Figure 7.4.24. Mass fragmentation of compounds 10-12 and their common base peak  
 
7.4.4. Biological Activities 
 
Table 7.4.2.  Antiplasmodial activity of 8-12 
 
 
 
Compound 
 Chloroquine-
sensitive (D6)-
clone  
Chloroquine-
resistant (W2)-clone  
Cytotoxicity  
to Vero cells  
IC50 nM S. I. IC50 nM  S. I. IC50 nM  
Mixture of two sapinopyridione 
(8a) and flavipucine (8b)   
NA  NA  NC 
9 NA  NA  NC 
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10-12 <1.17 >9 <1.17 >9 NC 
chloroquine
a
  0.03 496.6 0.31 48.1 NC 
artemisinin
a
  0.02 845 0.01 1690 NC 
 
a 
Positive controls  
IC50 = concentration casusing 50% growth inhibition  
NC, not cytotoxic  
NA, not active  
S. I. (selectivity index) = IC50 for cytotoxicity/IC50 for antiplasmodial activity  
 
  Table 7.4.3. Phytotoxic activity of 8-11 
 
Compound  Lettuce Bentgrass 
Mixture of two sapinopyridione 
(8a) and flavipucine (8b)   5 5 
9 NT NT 
10-11 NT NT 
 
Ranking based on  scale of ο to 5  
0 = no effect  
5 = no growth  
Solvent used, 10% acetone  
Concentration used, 1 mg/mL 
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Table 7.4.4. Cytotoxic activity [IC50 (µM)] of 8-12 
  
Compound SK-MEL KB BT-549 SK-OV-3 LLC-PK11 
Mixture of two 
sapinopyridione (8a) and 
flavipucine (8b)   5.05 21.9 20.3 6.7 7.6 
9 NT NT NT NT NT 
10-12 NT NT NT NT NT 
doxorubicin
a
  1.29 2.12 1.83 1.47 1.28 
 
NA: not active at the highest test concentration of 10 µg/mL.  
a 
Positive control.  
IC50 = concentration casusing 50% growth inhibition  
SK-MEL = human malignant melanoma  
KB  = human epidermal carcinoma  
BT-549 = human breast carcinoma (ductal)  
SK-OV-3 = human ovary carcinoma  
LLC-PK11 =  pig kidney epithelial  
 
7.4.5. Experimental 
7.4.5.1. General 
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Carried out as previously described in the section 7.1.4.1. 
 
7.4.5.2. Isolation of the Fungus from T. taxifolia  
 
 
The fungus was isolated from the infected seeds collected from a cultivated T. taxifolia 
plants. Infected seeds of T. taxifolia Arnott were furnished by Dr. Edward Croom,
 
Croomia, 
1509, Smallwood Dr., Oxford, MS, and isolation of fungi from those was performed by Dr. Luis 
Rosa, NCNPR, University of Mississippi. 
 
7.4.5.3. Fermentation, Extraction, and Purification 
 
Botryosphaeria dothidea was cultured in 80 conical flasks (1 L) containing 500 mL of 
Potato Dextrose Broth and incubated at 27
 ο
C for 14 days on an orbital shaker at 100 rpm. The 
mycelium was separated by filtration, and the broth was extracted with EtOAc (× 3). The EtOAc 
extract was evaporated to give a black residue (3.15 g).  
The EtOAc extract (3 g) was chromatographed over  silica gel and eluted with a gradient 
of hexanes, CH2Cl2, and MeOH to yield 15 fractions. Fractions which showed antimalarial 
activity were combined (550 mg) and chromatographed over Sephadex LH-20 and eluted with 
MeOH to give 12 fractions. A white precipitate observed in subfraction 11 was separated and 
washed with Et2O to yield a mixture (1:3) of sapinopyridione (8a) and flavipucine (8b).  
Subfractions 6-10, which showed antimalarial activity, were combined (160 mg) and further 
separated using a C18 reversed-phase semi-preparative HPLC column eluting with MeOH-H2O 
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(1:4), at a flow rate of 3.0 mL/min, to give eight fractions.  Sub-fraction 4, which showed no 
antimalarial activity, was further purified by Sephadex LH-20 gel filtration with MeOH (100%) 
to give a new compound (9, < 1.5 mg).   
Subfractions 5-7, which showed potent antimalarial activity, were further purified by 
using C18 reversed-phase analytical HPLC chromatography and eluted with MeOH-H2O (1:4) at 
a flow rate of 1.5 mL/min, to give three minor compounds 10 (1.0 mg), 11 (1.0 mg), and 12 
(<1.0mg).  
 
   A mixture (1:3) of sapinopyridione (8a) and flavipucin (8b); white amorphous powder;
 1
H and 
13
C NMR, and HRESIMS were compared with the literature data.
206, 217 
 
 
Compound 9: epolactaene; HRESIMS [M + H]
 +
 m/z 388.2184 (calcd for [C24H33NO4 + H]
 +
 
388.2124), 
1
H and 
13
C NMR data: see Table 7.4.1 
 
Compound 10: HRESIMS [M + H]
 +
 m/z 448.2268 (calcd for [C24H33NO4 + H]
 + 
448.2335), 
1
H 
and 
13
C NMR data: see Table 7.4.1 
 
Compound 11: HRESIMS [M + H]
 +
 m/z 448.2268 (calcd for [C24H33NO4 + H]
 + 
448.2335), 1H 
and 13C NMR data: please see Table 7.4.1 
 
Compound 12: HRESIMS [M + H]
 +
 m/z 448.2247 (calcd for [C24H33NO4 + H]
 + 
448.2335), 
1
H 
and 
13
C NMR data: see Table 7.4.1 
 
 205 
 
7.4.5.4. Biological Assay 
 
Antiplasmodial,
69
  phytotoxic,
70
 and cytotoxicity
76
 assays were carried out as previously 
described. 
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